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A novel methacrylate based nanogel system has been designed and developed for drug 
delivery applications. Methacrylates are optimal tuneable materials in terms of polarity, 
with combination of hydrophobic and hydrophilic moieties. Synthesis of these nanogels 
(NGs) was achieved via high dilution radical polymerisation using 2-(tert-
butylamino)ethyl methacrylate (tBAEMA) as functional monomer, methacrylic acid 
(MAA) or ethylene glycol methyl ether methacrylate (EGMMA)  as co-monomer  and 
N,N′-methylenebis(acrylamide) (MBA) as cross-linker. Fabricated nanoparticles (NPs) 
were shown to possess water solubility higher than 2 mg/mL and diameter ranging from 
5 to 20 nm (depending on nanogels’ composition) as confirmed by either dynamic light 
scattering (DLS) and transmission electron microscopy (TEM). Moreover, nanogels 
produced have shown the ability to be employed as Pickering-Ramsden emulsion 
stabiliser. Their reduced size together with their emulsion capabilities make these 
nanoparticles a promising system for drug delivery, in particular taking into account 
skin as administration route. The size is in fact small enough to favour their penetration 
through the stratum corneum. Furthermore, in the view of their ability to form 
emulsions, nanogels could be used both as drug carrier and emulsifier in a final 
pharmaceutical formulation. NGs proved to be able to incorporate both small molecule 
such as fenoprofen (an anti-inflammatory non-steroidal drug) and big macromolecule 
such as siRNA. Cytotoxicity and cell metabolism were also evaluated by transfecting 
normal human dermal fibroblasts (NHDF), keratinocytes (HaCaT) and HeLa cells with 
nanogels. Data showed that nanoparticles did not affect viability, cells’ morphology 
and adenosine triphosphate (ATP) levels up to high concentration of 100 μg/mL. In 
addition, preliminary studies indicated the ability of the nanogels to internalise and 
release their payload inside cells. In conclusion, the results confirmed that this novel 
system possesses all the desired characteristics to be used as a promising platform for 
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 Drug Delivery System 
 
1.1.1 Overview and desirable properties 
 
Drug discovery intended as the use of natural extracts, goes back to the early stages of 
human civilization. [1] Foundations of modern chemistry and physics were laid between 
the end 1800s and the beginning of 1900s. This was the time when synthetic bioactive 
compounds were introduced and pharmaceutical companies were founded. [1, 2] At the 
beginning of the previous century it was paramount to discover and develop new drugs 
capable to suppress most of the human diseases that were, until then, incurable. 
Sulfanilamides (prepared by P. Gelmo and investigated by J. Domagk J. Tréfouël, T. 
Tréfouël, F. Nitti and D. Bovet) and penicillin, discovered by A. Fleming and further 
studied by H. Florey and E. B. Chain, are among the most famous example of drug 
identified and then produced at industrial scale [1]. Although drug discovery is still 
progressing, from 1960-70, thanks to pioneering work carried out by J. Folkman, T. 
Higuchi, A. Zaffroni and A. Michaels the pharmaceutical industry moved the attention 
towards the development of new ways of drug administration that would be able to 
optimise the pharmacological properties of already known bioactive compounds. [3, 4] 
Pharmacological activity of a molecule, alone, is often not enough to induce safe and 
reliable therapeutic effects. Peptide therapeutics, for instance, cannot be administered 
orally due to their poor stability and weak resistance against enzymatic degradation. [5, 
6] There are several desirable characteristics that a drug should possess in order to be 
employed in the treatment of a disease: the ability to maintain a concentration in the 
body as stable as possible and within the therapeutic window (Figure 1.1); the capacity 
to selectively target a specific district of the human body; the resistance against 
environmental condition (such as the acidity inside the stomach) that could lead to the 
premature degradation of the drug before the induction of the final effect; possess an 
adequate speed of action according to the disease that is intended to address and the 
power to respond to particular stimuli just to name few. 




Fig. 1.1 Schematic explanation of drug concentration fluctuation in the body over 
time and possible effects. 
 
In order to enhance erratic properties of investigational drugs, pharmaceutical 
industries employ what is called a drug delivery system (DDS). 
DDS is a way of administering a pharmaceutical compound to achieve a therapeutic 
effect in humans or animals. [7] The purpose of a DDS is to alter drug pharmacokinetics 
and to act indirectly on its pharmacodynamics. DDS can potentially provide several 
advantages. Among them:  
 Promote drug solubility and stability. 
 Protect the drug from the external environment. 
 Increase patient compliance through the introduction of a new route of 
administration (for instance from injection to oral administration), lowering 
numbers of administrations, reduction of side effects, covering unpleasant 
smells, colours and taste of a free drug. 
 Site targeting and side effect avoidance. Some drugs express a therapeutic effect 
on specific organs while, at the same time, they show toxic or adverse effects 
on others. 
 Stabilising the drug release rate and avoid any side effects related to drug level 
fluctuation.  [8,9] 
The major carriers for drug delivery available today can be divided into two groups: 
prodrug and drug encapsulating systems.  
Giorgio Chianello PhD Thesis Chapter 1 
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A prodrug is a pharmacologically inactive medication that is designed to be activated 
after enzymatic or chemical reaction inside the body. The drug is therefore chemically 
modified in order to optimise its ADME (administration, distribution, metabolism and 
excretion) profile. The results are: the increase in drug solubility, as more than 30% of 
drugs show poor hydrophilicity; facilitate permeability across physiological 
membranes and introduce site targeting, by the addition of a targeting moiety linked to 
the drug through a spacer, as visually explained in the example below (Fig. 1.2). [10]  
 
Fig. 1.2 Schematic showing targeted prodrug. 
Although prodrugs offer several advantages there are few downsides that limit their 
application. First of all not all the drug can be chemically modified in the desired way; 
some of them for instance are not able to endure the reaction’s conditions needed for 
the chemical modification, while some others do not possess the required functional 
groups that are essential for further modification. Furthermore, sometimes the chemical 
modification or linkage of the therapeutic compound to a carrier is not sufficient to 
protect the drug from the harshness of the external environment. Lastly, genetic 
polymorphisms or age-related physiological changes may vary the pharmacokinetics of 
the prodrug. [10] 
In order to overcome all the above mentioned limitations, drugs can be embedded inside 
particles or the cavity of a three-dimensional structure. This approach in fact allows the 
fabrication and subsequent chemical modification of a final system without direct 
interaction with the drug, at least during initial studies. Once the system is fully 
Giorgio Chianello PhD Thesis Chapter 1 
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synthesised, characterised and tested, the drug can then be uploaded inside. Another 
important feature is the possibility to tune the drug release rate by modifying the 
chemistry of the drug encapsulating systems, a property that cannot be achieved by a 
prodrug. Moreover, drug encapsulating systems can be designed in order to respond to 
multiple biomedical relevant changes such as pH or temperature as well as enzymatic 
cleavage at the same time, without the need of drug chemical modification.  
When the development of a new DDS is being considered, it is important to remember 
that, in addition to the therapeutic improvement, DDS should also possess as many of 
the following characteristics as possible: 
 Biocompatibility, probably one of the most important requirement for a DDS. 
 Biodegradability.  
 Absence or reduced toxicity.  
 Low cost.  
 Ease of synthesis, in terms of equipment, labour and manufacturing time 
needed.   
 High raw materials availability, possibly from multiple sources/providers.  
 Absence of flavour, a desirable property when taking into account oral 
administration for example. 
 Absence of unpleasant colours.  
However, it is also necessary to specify that the desired properties of a DDS also depend 
on the route of drug administration and targeted disease. 
 
1.1.2 Route of drug administrations: overview and 
comparison 
 
Drug administration can be classified into two groups according to either the 
localisation of the final pharmaceutical effect or the route of drug administration. In the 
first case it is possible to identify two subcategories: 1) local, when the drug exerts its 
therapeutic effect in the area of application or in a specific compartment of the human 
body; 2) systemic, when the bioactive compound produces a generalised effect in 
multiple or all body apparatuses. The second group can be further subdivided into five 
Giorgio Chianello PhD Thesis Chapter 1 
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major routes of drug administration: parenteral, oral, pulmonary, trans-mucosal, and 
transdermal. Each of which have pros and cons. 
Parenteral, otherwise known as injection, is the fastest and more reliable way of 
administration as the drug quickly reaches the bloodstream or tissue which is 
penetrated. Injection is further categorised according to the site of needle penetration 
in: intravascular, intramuscular, intraosseous, epidural, intravitreal and subcutaneous, 
just to mention a few.  The advantages of this route are: speed of action; precision and 
accuracy; first pass effect avoidance, which is the chemical processing operated by the 
liver when a molecule is adsorbed by the gastrointestinal tract and the opportunity to 
use this route when a patient is unconscious or has his/her gastrointestinal tract 
compromised (for instance vomiting or blockage). [11] 
At the same time parenteral administration shows several disadvantages: It is invasive 
and could lead to inflammation of the tissue perforated; must be performed by trained 
personnel to avoid risk of embolism or critical tissue damage; can be painful and has 
low patient compliance due to the pain related to needle perforation or irritating 
properties of formulation administered. [11] 
Oral, or enteral, administration is generally the preferred patient administration route. 
It is non-invasive, provides ease of administration and is normally well accepted by 
patients unless showing unpleasant organoleptic properties. The latter case however can 
be easily masked using formulation excipients able to cover distasteful characteristics. 
On the other hand, this way is not suitable for formulations that are not able to resist 
the gastrointestinal environment, for patients who are either unconscious or have a 
malfunctioning gastrointestinal tract and for drugs that get immediately metabolised by 
the liver or that need to act fast, in case of emergency. [11] 
Pulmonary administration comprises all the pharmaceutical formulations administered 
through the airways. It is a relatively fast administering route, it has intermediate patient 
compliance, it can profit from an extensive exchange surface and offers first pass effect 
bypass. Although this route is being currently explored and the number of formulations 
are increasing, there are several issues that restrict its use. The number of drugs that can 
be administered through this route are still very limited, the process of formulation 
production is complicated and expensive, it requires the use of a complex and 
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sometimes expensive external device and it requires either training or experienced 
personnel to be performed. [12, 13] 
Trans-mucosal administration is the delivery of therapeutic agents across the mucous 
membrane. It includes: rectal, vaginal, and urethral delivery. Most of the DDS 
administered through this route exert local therapeutic effects with only few of them 
that can go systemic. In regards to the advantages, this route can benefit from: 
avoidance of first pass effect, avoiding harsh condition of the stomach, the possibility 
to be used on unconscious subjects and prolong residence time at the site of 
administration. However trans-mucosal administration often shows low patient 
compliance and it presents significant difference in drug adsorption profiles depending 
on mucosa condition. Furthermore, some medication can produce irritation and several 
drugs can be degraded by the environmental conditions of the body apparatuses of this 
route of administration. [14] 
Transdermal delivery involves the administration of biologically active compound 
through the skin. This route demonstrated high potential, not yet fully exploited, in 
providing an alternative to hypodermic injection and oral administration. With the latter 
it shares few properties such as high patient compliance and ease of administration. The 
skin can provide several advantages over the aforementioned routes: first pass effect 
avoidance; the capacity to exert local or systemic effect depending on DDS degree of 
penetration in the superficial or deep strati of the skin respectively; the possibility to be 
used on unconscious patients; an extensive surface of application available; the invasive 
character and the constant and controllable drug release.  [15] 
However, some physical obstacles limit its use, like penetration capacity of DDS that 
have to cross the tight junction of the skin and, as the oral route, the impossibility to 
administer therapeutic agents that are required to act immediately. [15]   Despite all the 
mentioned limitations, DDS research is rapidly progressing in order to address and 
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1.1.3 Modern DDS technology  
 
Nature and the physiological body functions already perform at a level that is close to 
perfection. All movements, sensing and body’s basal activities are the results of 
reactions that take place at the molecular level. Thanks to the tremendous advancement 
in technology, today it is possible to detect, image, manufacture and modify materials 
at the nanoscale.  Therefore, it is clear that the development of a DDS that could act at 
the same scale as biological processes would be extremely beneficial and could 
potentially open new applications. For these reasons, in the last twenty years there has 
been a growing interest and investments in nanotechnology research and in 
nanomedicine, with a particular interest in drug delivery. [16-18]   
‘‘There’s Plenty of Room at the Bottom,” Richard P. Feynman 1959. This sentence is 
considered the birth point for nanotechnology, a field of research and material 




1.2.1 Introduction, applications and advantages 
 
Nanotechnology is defined as the science that studies, produces and manipulates 
materials which have at least one dimension in the size range 1-100nm. In order to 
provide a visual explanation of this extremely reduced magnitude, scientist use to make 
a comparison with the human hair which has a diameter of 80,000nm (Figure 1.3). [19]  




Fig. 1.3 Representation of nanoscale objects. From R. A. Yokel et al. J. Occup. Med. 
Toxicol., 2011, 6, 1-27 [a]  
 
Although this is the most accepted definition, some researchers believe that 100 nm 
cut-off would exclude physiochemical behaviours that occur at a slightly larger scale. 
For instance, the plasmon-resonance, reported in literature, for 150 nm diameter gold 
nanoshells or the enhanced permeability and retention (EPR) effect that arise in the size 
range between 100-200 nm. [20] 
 
Nanotechnology is an extremely broad field of research that includes applications in 
food industry, electronics, energetic sector etc. [21-23] Nanomedicine is the application 
of nanotechnology in medical science. It comprises two main employments areas: 
diagnostics, the detection or monitoring of chemicals, diseases, biomarkers etc. and 
therapeutics the use of nanomaterials to improve and sustain therapeutic effects of 
bioactive compounds.     
Drug delivery is a segment of the nanomedicine sector which attract consistent funding 
[24]. As mentioned previously, there is currently an exceptional and rapid growth of 
research involving nanoparticles (NPs) as drug delivery systems due to their promising 
characteristics. 
For instance, one of the great assets of nanomaterials is their high surface to volume 
ratio when compared to bulk materials [25] (Figure 1.4). This provides the particles with 
a very extensive surface area of interaction between the material and the external 
environment. A fundamental consequence of the increased surface to volume ratio is 
the high loading capacity of nanoparticles resulting in a lower quantity of nanomaterial 
required to encapsulate a certain amount of drug, compared to bulk materials. This leads 
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to two main advantages:  reducing the amount of materials required for the synthesis 
and most importantly decrease the chances of side effects or toxicity associated with 
the material. Below is a visual explanation of the increment of surface to volume ratio 
related to scaling size down.  
 
 
Fig. 1.4 Surface to volume ratio explained. From Lehninger, D. Nelson; M. Cox. 
Principles of biochemistry, 2nd edition [b]  
 
As an example, a cube with a side of 1cm has a volume of 1 cm3 and a surface of 6 cm2. 
If this cube was cut into 10nm cubes, while keeping the same total volume of 1 cm3, 
the new surface area would then become 600 m2, significantly increasing the surface to 
volume ratio from 6:1 up to 6,000,000:1.  
Moreover, together with the modern advancement in biotechnology, nanomedicine 
could provide solid foundations for the development of personalised medicine systems. 
“The right patient with the right drug at the right dose at the right time” [26]. The 
development of a drug can require up to 20 years and very high costs, therefore the 
selection or modification of a suitable delivery system could provide tailoring of 
pharmacodynamics in a relatively short time and with a tremendous impact on costs.    
Furthermore, another advantage of nanomaterials is the promise of active site targeting 
by tuning the chemistry of nanoparticle or nano-devices in order to provide them with 
stimuli response capabilities or specific receptor recognition [27, 28].    
Although nanomedicine has proven to be an extremely promising research field, 
pharmaceutical industries and several research groups express concerns regarding the 
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long term effects of nanomaterials both on living beings and the environment [28-30]. It 
is in fact still unclear the fate of many NP systems in terms of biodegradability and 
accumulation in the body or the environment. Nevertheless, the advances both in terms 
of novel materials and technological instrumentations are continuously improving the 
knowledge in this area, further enhancing the potential for medical applications. 
One of the disadvantages of drug delivery is the extended timeframe needed for 
preclinical and clinical studies in order to assess safety of the materials, this of course 
applies also to nanomaterials to an even larger extent due to the additional 
characterisation tests required. This is probably the biggest limitation for the 
pharmaceutical industry since it implies higher costs and reduced revenues due to 
shorter intellectual property coverage. However, the market has already found its own 
solution to this issue by employing small and medium sized enterprises (SMEs), a 
growing business which develops the technology and then license it out to big pharma 
companies. As proven by the European Medicine Agency (EMA) annual reports, SMEs 
are playing and are expected to play a more important role in the pharmaceutical sector. 
[31]   
Nevertheless, the potential advantages provided by nanomaterials for medicine are 
attractive, therefore justifying the continuous effort and resources invested. This is also 
proven not only by the growing number of scientific publications but also by a series 
of formulations in the process approval or already approved and present in the market 
by the American Food and Drug Administration (FDA).  [32, 33] Renagel® -cross-linked 
poly allylamine hydrochloride for the control of hyperphosphatemia in adult patients 
receiving hemodialysis or peritoneal dialysis, Marqibo® -Vincristine sulfate 
encapsulated in sphingomyelin/cholesterol (60/40, molar) 100 nm liposomes for the 
treatment of adult patients with Philadelphia chromosome–negative (Ph‒) acute 
lymphoblastic leukemia and Eligard® - Leuprolide acetate incorporated in 
nanoparticles composed of biodegradable poly-DL-lactide-co-glycolide for managing 
advanced prostate cancer, just to name few [32].    
Several of the DDS systems currently under development or already available in the 
market are described in more details in the next section. 
 
 




1.2.2 Overview of existing nano drug delivery systems 
 
In the last six decades numerous DDSs have been developed in order to enhance the 
therapeutic profile of drugs [34]. As scientific literature can prove there are several 
different systems currently under development and used today. They can be classified 
in diverse ways: inorganic or organic according to their chemical composition; self-
assembled or synthesised in regards to the production process required; polymeric or 
oligomeric taking into account their basic structure lengths; natural or synthetic when 
considering the material source etc. However, three main categories can be identified 
to describe most of the DDS known: inorganic, non-polymeric and polymeric materials. 
 
1.2.2.1 Inorganic nanomaterials 
 
Inorganic nanomaterials are all those systems not based on carbon chemistry. 
Mesoporous silica and gold nanoparticles (NPs) are among the most studied and used 
inorganic systems. Herein a brief description, of the two NPs is provided. 
Mesoporous silica nanoparticles (MPSNPs) are solid materials with honeycomb-like 
structure able to adsorb large amount of molecules due to their extremely high surface 
area [35]. They are used in several applications as sensors, catalyst and drug delivery 
systems [35, 36]. Nonetheless, studies have demonstrated toxicity related to MPSNPs. [37] 
Gold nanoparticles are colloidal gold shell coated nanoparticles (Figure 1.5). They are 
currently object of a large number of studies and applications such as diagnostics, drug 
delivery, photochemistry etc. [38] However, there is a concern regarding the fate of these 
particles that still needs to be addressed. It has been proven in fact that gold 
nanoparticles deposit in the liver and spleen and although there is no evidence of short 
term side effects, their long term reactivity still needs to be studied [39]. Furthermore, 
their cost may need to be considered.   




Fig. 1.5 Transmission electron microscope (TEM) image of gold NPs. From S.-H. 
Kim et al. J. Nanomater., 2012, Article ID 504026. (OPEN ACCESS).[c]  
 
Inorganic NPs are considered stable under different temperatures and pH conditions 
however they do not generally biodegrade which may give rise to concerns for the long 
term administration. [40]  
 
1.2.2.2 Non polymeric organic nanomaterials 
 
The best known example of non-polymeric organic nanomaterials is represented by 
liposomes. These are vesicles constituted by one or more lipid bilayer with the polar 
heads of the lipid oriented toward the extravescicular solution (water in the human 
body) and the inner cavity, and the hydrophobic chains forming the bilayer (Figures 1.6 
and 1.7) [41-43]. Hydrophilic molecules can be retained in the centre of the liposomes 
while hydrophobic ones can fit within the bilayer. Their size range, between 20 nm and 
5µm, lies between micro and nano systems. They are a versatile DDS because of their 
wide size range and similarity to cells, perhaps at the same time they show limitations 
in achieving active site targeting and controllable drug release rate. [42-44] 




, 1.6 Liposomes schematic views. Where green circle represent the hydrophylic 
moyety of the lipid surfactant and the yellow chains the hydrofobic region of the 
surfactant. 
 
1.2.2.3 Polymeric nanomaterials 
 
The majority of modern drug delivery systems can be included in the category of 
polymeric materials. They are the most versatile systems as their broad chemical 
composition and architecture can give rise to numerous particles with diverse tuneable 
properties which can be tailored according to the final application. Moreover, polymers 
can also be used as coating agents for inorganic nanoparticles [40, 45; 46]. Some examples 
of polymeric materials are reported below. 
Micelles (Figure 1.7) are described as self-assembled colloidal particles, with a size 
ranging generally between 5 and 100 nm and constituted by amphiphilic polymeric 
molecules or surfactants that associate in aqueous medium to form core-shell structures. 
[47-50]   
Hydrophobic drug Hydrophilic drug 




Fig. 1.7 Schematic representation of micelles, liposomes and bilayer sheet. From D. 
Bitounis et al. ISRN Pharmaceutics, 2012, Article ID 738432. 
doi:10.5402/2012/738432 (OPEN ACCESS). [d]  
 
A surfactant is a molecule that possesses two regions, one hydrophobic and the other 
hydrophilic. Depending on the nature of the solvent the surfactant will expose the 
segment that shows affinity to the solvent on the outside and the lyophobic part on the 
inside (away from solvent) forming an inner core in order to minimise the free energy 
(Figure 1.8) [47, 48].  
 




Fig. 1.8 Difference between direct and inverse micelles. From J. Zhang et al. Chem. 
Commun., 2015, 51, 11541-11555. License Number: 3991880626562. [e]  
 
It is possible to describe two different kinds of particles: direct micelles (polar solvent) 
and inverse micelles (apolar solvents). Micelles are being extensively studied for their 
promising characteristics such as small particle size, high loading capacity, general 
biocompatibility and ability to modulate drug release kinetics which makes them 
suitable for drug delivery and image diagnostics applications. [49, 51-53] The formation of 
the micelles generally relies on non-covalent bonds and micelles are in fact generally 
considered as not static systems. In fact, the building blocks (surfactants) micelles are 
made of, can reshuffle and are in dynamic equilibrium with free surfactants. However, 
this property is not always an advantage, such as in drug delivery applications, where 
this can lead to premature drug bleeding from the particles. For this reason, a particular 
subset of micelles, characterised by stable chemical cross-linking has been developed 
and studied. [54] Micelles are the main competitor of the drug delivery system described 
in this work and could be considered a valuable alternative. However, nanogels possess 
some characteristics not achievable by micelles such as imprinting capabilities (further 
described in the following section) which provide high specificity and molecule 
recognition abilities.  
 
Giorgio Chianello PhD Thesis Chapter 1 
30 
 
Dendrimers are defined as nanosized, radially symmetric branched macromolecules 
(Figure 1.8) that are extremely homogenous with organised structures and high 
potential for drug delivery and diagnostics. [55] On the other hand, they are difficult to 
synthesise, generally expensive and do not provide enough space for drug loading. [56] 
 
 
Fig. 1.9 Schematic representation of dendrimers. From M. Sowinska et al. New 
J.Chem., 2014, 38, 2168-2203. License Number: 3934721385025 [f]  
Finally, there are nanogels, which are nanosized networks of physically or chemically 
crosslinked polymers that swell in particular solvents. Nanogel is the system object of 
this study and is further described in the following section.  
 
These are some of the main systems employed today for drug delivery. However, 
several more are currently being used or under development.  
 
1.2.3 Nanogels: properties, uses and advantages 
 
The term “nanogel” was introduced by S. V. Vinogradov and A. V. Kabanov while 
describing swollen chemically cross-linked networks of cationic and neutral branched 
polyethylene glycol-crosslinked-polyethylenimine (PEG-cl-PEI) polymers, which 
were developed for the delivery of antisense oligonucleotides [57]. Nanogels (NGs) are 
swollen nanosized networks composed of hydrophilic or amphiphilic polymer chains. 
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They are defined as nanoscale stable colloidal systems formed by physically or 
chemically cross-linked polymer networks [58, 59] (Figure 1.10). 
NGs are soft particles that show features of hydrogels and NPs at the same time. They 
are flexible, stretchable and able to swell as hydrogels and offer all the potential 
pharmacokinetics improvements of NPs. Due to their ability to swell and adsorb large 
amounts of water, NGs are generally inert and show characteristics between solids and 
fluids while their porous structure provides them with high loading capabilities. [58]  
 
 
Fig. 1.10 Schematic representation of crosslinked structure of nanogels. Polymer 
chains are drawn in blue and inter-chain crosslinking in red. Image on the right 
showing the possibility to approximate nanogels to spheres  
 
 
In the last few decades, a large number of nanogels have been developed for application 
in nanomedicine due to their promising characteristics. NGs possess high loading 
capacity, stability and responsiveness to physical changes, such as ionic strength, pH 
and temperature [61, 62]. As reported in the literature, several applications have been or 
are currently under investigation, such as NGs with catalytic activity [63] or thermo-
responsive profile [62]. Furthermore, they satisfy most of the requirements for an ideal 
drug delivery system. [64] 
NGs provide drug protection, they can avoid premature interaction between the drug 
and the human body or the external environment. In this way they can decrease side 
effects and protect the drug from premature degradation. They can be designed to 
respond to particular stimuli such as pH or temperature variation. The responsive 
characteristics of NGs can act as a passive site targeting or as a controller for the release 
rate. The latter feature is fundamental when the therapeutic window of a drug is 
particularly narrow, which means that fluctuations in drug concentration would 
probably cause side effects. NGs can show high penetration efficiency due to their 
reduced size and deformability, therefore they show high potential for penetration in all 
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districts of the human body. Moreover, they can be chemically functionalised in order 
to gain site targeting properties. This is an excellent way to reduce side effects and 
lower the amount of drug needed in order to produce the desired therapeutic effect. [60] 
Lastly, NGs show ease of synthesis which is a fundamental characteristic for industrial 
scale production of a DDS.  
There are different synthetic methodologies for the preparation of nanogels: 1) physical 
self-assembly of interactive polymers; 2) cross-linking of preformed polymers; 3) 
polymerisation of monomers in homogeneous or heterogeneous phase and 4) template-
assisted nanofabrication.  The first three methods are, in most cases, relatively 
inexpensive and simple processes while the fourth is more complex but leads to 
formation of very homogenous NPs. [65]  
Physical self-assembly of interactive polymers leads to the formation of micelle-like 
particles, therefore their stability may not be as high as chemically crosslinked particles.  
Cross-linking of preformed polymers and polymerisation of monomers (in the 
homogeneous or heterogeneous phase) are perhaps the most used synthetic techniques. 
The first approach generally produces NGs with larger pore size however does not 
allow the same property control as the latter.   
Template-assisted nanofabrication or photolithographic technique utilises a preformed 
and inert stamp that forces polymerisation into the stamp cavities, molding gels into 
defined 3D structures that can then be washed out from the support (Figure 1.11). [66]  
 
 
Fig. 1.11 The process of template assisted nanofabrication. A: pattern formation of 
vertical posts onto a silicon template. B: aqueous gelatine solution is poured to for a 
gel imprint. C: once solidified, the gel mold is peeled off. D: the mold cavities are 
filled with polymerisation mixture. E: polymerisation solvent is evaporated and the 
Giorgio Chianello PhD Thesis Chapter 1 
33 
 
mold dissolved to yield 3D constructs with shape complementary to the mold cavities. 
From G. Acharya et all J. Control. Release, 2010, 141, 314-319. License Number: 
3937560904561. [g] 
 
This approach leads to the formation of a very homogenous batch and shape of defined 
particles. However, instruments performing electron beam lithography (EBL), the 
technique used for the synthesis of the stamps, are extremely expensive (over 
$1million) and require highly skilled personnel to ensure correct operation.  
Polymerisation of monomers in the homogeneous or heterogeneous phase is therefore 
the preferred way of synthesis and it can be further divided into different techniques. 
Precipitation is one of the methods employed. It involves the dissolution of the 
monomers into a solvent where the nanogels, as soon as they are formed, are insoluble. 
Therefore, nanogels precipitate and are recovered from the solution by 
centrifugations/washes and filtration. However, this process generally requires the use 
of either toxic surfactant such as sodium dodecyl sulphate (SDS) [67, 68] or toxic solvents 
like dimethylformamide (DMF). [69]    
Heterogeneous emulsion is one of the most used techniques and can be subdivided into: 
membrane emulsification, inverse emulsion and reverse micellar methods. [70] The first 
approach involves the extrusion of one of the two phases (oil or water) through a porous 
membrane. The small, homogeneous pores allow one phase to be injected into the other 
to form small liquid droplets. The second method employs a homogenizer or a high-
speed mechanical stirrer to mix the oil and water phases to form droplets. [70] The 
reverse micellar process utilises a high concentration of surfactants able to form reverse 
micelles inside the oil phase and adsorb water in their inner core where the nanogel 
formation will take place. All these synthetic procedures include the employment of 
organic solvent or oil phases and surfactant to stabilise the emulsion droplets. These 
not only add complexity and higher cost to the synthetic environment but also introduce 
elements that may not be completely removed from the final product and therefore 
cause unpredictable effects both in terms of biocompatibility and physico-chemical 
properties of the nanogels. 
Lastly, high dilution radical polymerisation, a homogenous phase approach, is probably 
the simplest method for the synthesis of nanogels. This is the technique that was chosen 
for this work and it is explained in more details in chapter 2.    
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Further feature of NGs include their suitability to be used in imprinting procedures. 
This technique utilises a template approach that can be divided into three key steps. 
Firstly, the functional monomer(s), through physical interactions, arrange themselves 
around a template molecule. Later this complex is cross-linked during a polymerisation 
process. Finally, the removal of the template from the polymeric matrix leaves a 3-D 
cavity complementary in terms of shape and functionality to a target analyte (substrate) 
[71, 72] (Figure 1.12). 
 
Fig. 1.12 Schematic representation of imprinting process.  
 
Imprinting technology is currently studied and used for a wide range of applications 
such as sensors, catalyst, potential drug delivery system, for purification or isolation 
procedures etc. [73-75] The approach can be extremely beneficial for the development of 
DDS as imprinted nanogels can accommodate bioactive molecules in their drug 
complementary cavity with higher specificity than non-imprinted particles. Moreover, 
when considering the design of a multidrug formulations, the production of two or more 
highly specific and selective nanoparticles could allow avoidance of drug cross 
interaction, simultaneous drug administrations, improvement of patient compliance 
(due to reduced number of doses) and lowering the amount of excipients required. 
NGs are extremely versatile materials [76] that can be used not only on their own but 
also as hybrid or composite. Plasmonic, magnetic and core shell nanogels are some of 
the main examples of hybrid and composites that combine properties of different 
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systems. Extensive works from Molina et al. and Maya et al. show the large number of 
current preparations employing nanogel technology [77, 78].  Below are reported some of 
the recent formulations deduced from the before mentioned reviews.   
Drug loaded NGs Characteristics Cancer cells 







swelling/deswelling of the core, 
enhanced Doxorubicin (Dox) release at 
the endosomal pH (6.4) and release 




Transdermal delivery of anticancer 
agents, excellent skin penetration and 
retention, cationic charged nanogels 
(CCNGs) interact with negatively 






Long circulating nanoparticles (NPs), 
enhanced regression in tumour volumes 
in vivo, 50% survival rate for 9 days and 

















Simultaneous optical temperature sensing, 
cell imaging and combined chemo-
photothermal treatment. Superior Hela cells 
death when irradiated with 515nm laser 
CdSe quantum dots 
(QD) 
hydroxypropylcellulose-





Dual temperature and pH responsive, emit at 
two different fluorescence wavelengths, 
combining a pHsensitive NIR emission (741 
nm) and a less sensitive visible emission 
(592 nm) 
Table 1.2 A selection of the nanogels for imaging purposes. [78] 




Table 1.1 and 1.2 provide few examples of NGs currently under investigation while 
Table 1.3 (below) shows formulations already undergoing preclinical and clinical 
studies.  
 
Phase Hybrid NGs Application 
Preclinical 
Plasmonic@NG Cancer therapy 
Core-shell NGs Neurodegenerative disorders 
Core-shell NGs 




Bone loss disorder 
Clinical CHP Vaccines 
Table 1.3 Hybrid nanogels in preclinical and clinical phase [77] 
 
The main reasons for the versatility of nanogels are: 1) the wide spectrum of materials 
that can be used for their preparation, ranging from synthetic biopolymers such as 
hyaluronic acid or chitosan to vinyl polymers like poly-acrylamides or poly-
methacrylates [78-82] 2) the possibility of tuning their properties (such as size or rigidity) 
by modifying the percentages of building blocks and synthetic conditions. 
 Natural monomers and polymers are usually employed for their faster biodegradability 
while synthetic monomers and polymers, in particular vinyl compounds, should be 
preferred when higher stability is required.  
The work herein presented focused on the development of a novel methacrylate based 
nanogels for drug delivery purposes. For this reason, a brief introduction on 
methacrylates and their characteristics is reported in the following section.  
 





1.3.1 Current uses and applications 
 
Methacrylates are ester derivatives of metacrylic acid (Figure 1.13) and are commonly 
used in the production of polymer plastics. 
 
Fig. 1.13 Methacrylic acid left and methacrylate right 
 
 
Methacrylic acid was first obtained in 1865 by E. Frankland [83] while its first polymeric 
form was discovered in 1880 by F. Engelhorn. [84]  
Polymethylmethacrylate (known as acrylic glass) is probably the most diffused and 
used methacrylate polymer. Plexiglas, Perspex and Lucite are some of its commercial 
names. Its development is dated 1901 and credited to the German chemist O. Röhm 
who in 1933, together with Walter Bauer, branded the polymer as Plexiglas which was 
first sold by the Rohm and Hass. [85, 86] Since then it has been used in numerous 
applications such as protection glass, for orthopaedics, material for contact lenses, 
electrochemical chip supports etc. [87-89] 
A number of methacrylate based polymers are currently employed or under 
development, offering a wide range of materials with diverse characteristics and 
applications. Methacrylate based polymers are in fact used for the production of 
platform for antibodies immobilisation, molecular imprinted matrixes for filtration 
cartridges, antibacterial coating materials, molecularly imprinted sensor for food 
chemistry, hydrophobic fabrics, nanoparticles for drug delivery and nanogels just to 
name few. [90-96] Moreover methacryaltes are often used in combination with preformed 
materials as coating or functionalising agents. [97-99] 
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1.3.2 Methacrylates structure, properties and biological uses 
 
Methacrylates are optimal tuneable materials in terms of polarity, due to the modifiable 
ester group which can lead to formation of systems ranging from highly hydrophobic 
to highly hydrophilic. Also their size and steric interactions can vary according to the 
length, arrangement and chemical composition of the ester chain (Figure 1.14).   
 
Fig. 1.14 Basic chemical structure of methacrylates and few examples of ester chains. 
 
Furthermore, by modifying the ester group, the resulting material can gain numerous 
physical-chemical characteristics including the ability to respond to stimuli such as pH 
or temperature, solubility improvements or decrement, surface tension reduction or 
emulsion formation capabilities. [100-103] The latest characteristic deserves a particular 
mention as the nanogels object of this study have been found to be able to form 
Pickering-Ramsden emulsions. Those are emulsions stabilised by nanoparticles rather 
than surfactants and they are introduced and further discussed in chapter 3. Due to the 
tuneable characteristics and the vast library of chemical structures, methacrylates are 
widely employed materials for the development of drug delivery systems and for other 
biological applications.  Works in the literature report on numerous methacrylate 
particles and polymers developed for the treatment of cancer, as antimicrobial systems, 
as drug release modulator coating polymers such as EUDRAGIT ® and as dental or 
bone materials, just to name few of the various biological applications involving 
methacrylates. [100, 104-112] 
EUDRAGIT® in particular, deserves a more in depth mention due to its large use in the 
pharmaceutical industry and for its chemical structure similarity to the nanogels object 
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of this study. [113-116] A number of ester copolymers of methacrylic and acrylic acid are 
commercialised under the name of EUDRAGIT® (Figure 1.15). [113, 116]  
Fig. 1.15 Structures of main Eudragit polymers 
Eudragits are non toxic, non adsorbable and non biodegradable polymer which can 
dissolve or increase their porosity at various pH ranges according to their chemical 
structures. Because of their pH responsiveness they are often used as coating agent in 
pharmaceutical formulations in order to gain sustained release. [113]    
However, Eudragit cannot be directly compared to methacrylate based nanogels as its 
structure is linear and not cross-linked. Therefore, Eudragit does not have the capacity 
to incorporate molecules, such as conventional nanoparticles, but simply coat them. 
Eudragit is in fact used as an eccipient, coating agent or co-polymer. [114, 115, 117; 118]   
In conclusion the great potential offered by nanomaterials, in particular nanogels, 
combined with the adjustable properties of methacrylates were the leading forces that 
triggered the development of the novel methacrylate based nanogels object of this 
study. 
Before starting the description of the chemical and biological characteristics of the 
nanogels, a brief introduction of the aims and objectives of this work are given in the 
following section.  
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 Aims and Objectives 
 
The aim of this project was the synthesis of a novel methacrylate based nanogel 
characterised by reduced size, high biocompatibility and stimuli response capabilities 
for drug delivery application, in particular targeting the skin.  
The work reported in this thesis was focused on three main objectives: 
1. Synthesis and characterisation of the nanogels. 
2. In vitro toxicity and cell metabolism studies.  
3. Preliminary testing of drug upload and release.  
Each of the objectives is covered in a dedicated chapter. Here below a short outline of 
the content of each chapter is given. 
Chapter II covers the production and characterisation of novel polymeric NPs via high 
dilution radical polymerisation, the initial screening of different monomers, reaction 
conditions and monomers/cross-linker ratios. The numerous polymerisations were 
performed in order to identify best formulation in terms of solubility, size, shape and 
stimuli response. The incorporation of elsewhere synthesised fluorescent probe was 
also carried out in the view of potential in vitro and ex vivo monitoring of nanoparticles. 
Particle size was assessed both via dynamic light scattering (DLS) and transmission 
electron microscopy (TEM). This part of the project has been carried out at the School 
of Biological and Chemical Sciences, Queen Mary University of London, under the 
direct supervision of Prof. Marina Resmini. Dr. Giulia Mastroianni has to be 
acknowledged for TEM imaging.  
In chapter III the nanogel ability to form Pickering-Ramsden emulsions and their 
stimuli responsiveness were investigated. This part of the project has been carried out 
at the School of Biological and Chemical Sciences, Queen Mary University of London, 
under the direct supervision of Prof. Marina Resmini. Chapter IV focuses on the 
biological experiments in order to assess biocompatibility of the nanomaterial 
produced. Different cell lines were employed to test cytotoxicity, cellular 
morphological modification and adenosine triphosphate (ATP) cellular levels. This 
work was carried out in collaboration with Dr. Lino Ferreira, Ms Michela Comune and 
Ms Josephine Blersch at Biocant Technological Park, Cantanhede, Portugal.   
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In chapter V, preliminary data of drug encapsulation and release are discussed. This 
chapter is divided in two parts the first regards the incorporation and release of 
macromolecules of biological relevance such as siRNA, the second instead treats the 
incorporation of small conventional anti-inflammatory drugs such as fenoprofen. The 
first part of this study was carried out in collaboration with Dr. Lino Ferreira, Miss 
Michela Comune and Ms. Josephine Blersch at Biocant Technological Park, 
Cantanhede, Portugal. The second part was carried out at the School of Biological and 
Chemical Sciences, Queen Mary University of London, under the direct supervision of 
Prof. Marina Resmini.  
A brief introduction is given for each chapter in order to place the work into context 
and facilitate the reading. 
Two additional chapters are also part of this thesis: chapter VI that includes all the 
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 Nanogel preparation 
 
Nanogels (NGs), were selected as the matrix for the development of a novel drug 
delivery system. They offer several advantages as described in section 1.2.3 and can be 
employed for the tailored release of bioactive compounds throughout several routes of 
administration [1-3], however the focus of this work was transdermal delivery. Certain 
properties have to be considered when using skin as a route of administration. Several 
are the features (deformability, charge, toxicity etc.) that play a role in skin penetration 
however size and partition coefficient are perhaps the most important [4-5]. Due to the 
tight junction of the stratum corneum (the outermost layer of skin) and its high content 
of lipids, it is fundamental to employ NPs with appropriate polarity and reduced 
diameter [4]. While it is generally accepted that NPs should possess a diameter smaller 
than 40nm [6, 7] in order to penetrate through the SC, it is difficult to determine an 
optimal partition coefficient. An extremely hydrophobic entity would remain trapped 
in the lipid layers of the skin while a highly hydrophilic one (optimal for systemic 
applications) would not be able to enter due to the inability to interact with lipids. 
Therefore, it is necessary to utilise materials with intermediate properties.  
NGs are promising platform for skin delivery due to their size, flexibility and tuneable 
properties but, in order to achieve all the mentioned desired characteristic, it is essential 
to select a suitable synthetic procedure and identify the right monomers, cross-linkers 
(XLs), initiators and solvents.   
 
2.1.1 High Dilution Radical Polymerisation  
 
In section 1.2.3 several synthetic techniques used for the production of nanogels were 
described. High dilution radical polymerisation (HDRP) was selected as synthetic 
procedure taking into account simplicity of the method, homogeneous and reduced size 
NPs obtained. In addition, the extensive works carried out by several members of 
Resmini’s group [8, 9] was also considered. HDRP or solution polymerisation was first 
explored by N. Graham and A. Cameron [10]. As the name suggest it involves generation 
of radicals which can be achieved via photolysis or thermal decomposition of an 
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initiator molecule. Polymers are then formed by consecutive addition of free radicals 
building blocks.  In high dilution conditions the particle-particle interactions are 
strongly disfavoured, therefore limiting formation of larger size constructs. The solvent 
plays a fundamental role in the polymerisation due to its interactions with monomers 
and cross-linkers (XLs). A porogen with high polymer chain solvation power is 
required to prevent chain-chain interactions that could result in polymer contraction and 
collapse of aggregates. Given a set of cross-linkers, monomers and initiators, a solvent 
able to fully dissolve all the components, to ensure homogeneous condition, should be 
chosen. Furthermore, it is essential to mention that only certain monomers’ 
concentrations (CM) and building blocks ratios can be chosen to form nanogels and 
avoid macrogelation or suspension formation. For every system it is possible to 
correlate composition to nanogel/macrogel formation by plotting the media solubility 
parameter (a value that expresses the solvation power of solvents) against initial 
monomer concentrations (IMC) (Figure 2.1).  
 
Fig. 2.1: Example of plot of critical gelation concentration as function of IMC against 
solubility parameter of the solvent or solvent mixture used for polymerization. 
 
Nanogels or microgels are formed when IMC is within the critical gelation 
concentration (CGC), while CM higher than CGC would culminate in macrogelation.    
Overall HDRP offers several advantages: a) bypassing the use of surfactants with the 
consequent simplification of purification processes and reduction of compounds 
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required for the synthesis b) one pot reaction c) lower costs d) possibility to tune particle 
size and properties by altering NG composition and polymerisation conditions e) 
production of homogenous particles which require relatively short time for fabrication. 
The characteristics and advantages of using nanogels for drug delivery purposes were 
previously described in chapter 1. It is important to point out that those properties are 
dependent both on synthetic protocol and selected building blocks. In the next section 
the process and rationale behind these selections are described. 
 
2.1.2 Choice of monomers, cross-linker, initiator and 
solvents 
 
Monomers and cross-linkers are responsible for the final physico-chemical properties 
of nanogels. Therefore, their choice is fundamental for the development of the delivery 
system. Literature data clearly identify small size and balanced polarity as key features 
for successful skin penetration [4-7]. In view of these facts two formulations, one based 
on lauryl methacrylate (LMA) and one on ethylene glycol methyl methacrylate 
(EGMMA), were initially selected for further studies (Figure 2.2).  
 
          
Fig. 2.2 left: lauryl methacrylate and right: ethylene glycol methyl methacrylate 
 
The choice was driven by the different polarity of the two monomers. LMA has low 
hydrophilicity due to the long carbon chain while EGMMA has higher water solubility 
due to the ethylene glycol moiety. The initial idea was to obtain two nanogels’ 
preparations, evaluate their possible different interaction with the skin and eventually 
test combinations of the two monomers to fine tune polarity. Moreover, the two systems 
present the advantage that following ester hydrolysis a negative charge would be 
formed (Figure 2.3), providing the particles with a negative surface charge, a feature 
that is often reported to improve cell internalisation [11] and body clearance rate [12]. 




Fig. 2.3 Formation of negative charge subsequent to hydrolysis of ester bond leading 
to increased cellular uptake. 
 
In order to form the network structure, the use of a polymer chains interconnecting 
agent (cross-linker) is required, therefore both LMA and EGMMA were copolymerised 
with the widely used N,N′-methylenebis(acrylamide) (MBA) [13-15] as cross-linker. It 
was agreed to fix MBA maximum molar concentration at 20% of the total 
polymerisation mixture so that the overall methacrylate nature of the nanoparticles was 
retained. Previously reported methacrylate based nanogels or microgels employ either 
toxic aromatic XLs such as divinyl benzene (DVB) [16] or degradable ones as ethylene 
glycol diacrylate (EGDA) and derivatives [17, 18]. Herein it was proposed to utilise MBA 
as a less toxic and chemically resistant cross-linker to lower risk of toxicity and 
premature degradation of the nanogel’s network. Moreover, it is interesting to note that 
MBA is one of the smallest cross-linkers available, and this feature was expected to 
influence the size of the nanogel, leading to a compact structure and reduced particle 
size.     
              
Fig. 2.4 From left to right chemical structures of: DVB; EGDA with n=1 and R=H 
while n=2,3… and R=H or CH3 for derivatives; MBA. 
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A number of minimum requirements were identified to assess suitability of NGs for 
transdermal application: water solubility greater or equal to 1 mg/mL, due to the 
expected interaction with biological fluids (water based) and to allow further biological 
testing such as cytotoxicity analysis; reduced particle size (< 40 nm) screened via 
dynamic light scattering and polymerisation yields over 50%. 
Dimethyl sulfoxide (DMSO) and deionised water were the main solvents employed as 
polymerisation media. The first for its ability to solvate both polar and non-polar 
compounds, the latter for its capacity to form hydrogen bonding and to verify whether 
an organic solvent free (greener) approach was achievable. Two widely used initiators 
were also selected: azobisisobutyronitrile (AIBN) (Figure 2.5) to be used in DMSO 




Fig. 2.5 AIBN structure and radical generation mechanism 
 
 
Fig. 2.6 APS structure and radical generation mechanism 
 
Choice of AIBN and APS were based on proven efficacy shown on numerus researches 
reported in literature [16, 19, 20; 21]. Unfortunately, preparations based on lauryl 
methacrylate had to be discarded at an early stage of the project due to their total 
insolubility in aqueous media.   
Initially, polymerisations using EGMMA, as the functional monomer, were carried out 
in DMSO for its high solvation power and ideal Hildebrand solubility parameter that 
was previously shown within the Resmini group to lead to nanogels with low 
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polydispersity. However, the solvent was soon found to be not suitable for the 
production of methacrylate nanogels as it was leading to formation of particles poorly 
soluble in water and with large diameter (over 200 nm). Several solvent mixtures with 
different Hildebrand (solubility) parameter were then evaluated, in order to find an 
optimal environment for the synthesis of NGs. DMSO (solubility parameter δ/MPa= 
26.4) was therefore not completely abandoned and was used in conjunction with water 
at different ratios (Table 2.1). Nonetheless, even in this cases, polymerisations did not 
produce nanogels with the desired solubility and particle size.  
 
NGs EGMMA MBA AIBN CM% Solvent Yield 
MRGC 120  80% 20% 1% 0.1% W : D 9:1 82% 
MRGC 121  80% 20% 1% 0.1% W : D 8:2 52% 
MRGC 123  80% 20% 1% 0.1% W : D 4:6 45% 
MRGC 124  80% 20% 1% 0.1% W : D 2:8 40% 
Table 2.1: Summary of nanogels’ preparations in water : DMSO (W:D). Initiator 
percentage is referred to total number of double bonds in the polymerisation mixture. 
 
Results showed that polymerisation yield was decreasing as function of DMSO 
increase. Using the solubility theory, which states that materials with similar 
intermolecular attractive forces are expected to be miscible, and considering the more 
similar solubility parameter values of DMSO to methacrylate monomers (example 2-
hydroxyethyl methacrylate δ/MPa= 25) than water (δ/MPa= 48) [22-24], It was 
hypothesised that strong DMSO-methacrylates interactions could have prevented 
polymers elongation and particle formation, leading to yield decrease.  
After discarding DMSO due to the poor water solubility and large particle size of 
nanogels produced, isopropyl alcohol (IPA) was employed as replacement of DMSO, 
due to its similar Hildebrand parameter (δ/MPa= 24.9), to understand whether the 
previously mentioned hypothesis was confirmed or not. Also these attempts resulted 
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NGs EGMMA MBA APS CM% Solvent Yield 
MRGC 125  80% 20% 2% 0.5% W:IPA 5:5 20% 
MRGC 126 80% 20% 2% 0.1% W:IPA 5:5 4% 
MRGC 127  80% 20% 2% 0.5% W:IPA 4:6 18% 
MRGC 128  80% 20% 2% 0.1% W:IPA 4:6 1% 
Table 2.2: Summary of nanogels preparations in water : isopropyl alcohol (W:IPA) 
mixtures. 
 
Despite the unsuccessful polymerisations, a correlation between water percentage and 
yield obtained was identified. This was indeed the trigger that directed towards the 
selection of water as the only solvent of reaction. Water with its higher Hildebrand 
parameter (δ/MPa= 48) seemed to favour nanogel formation, probably due to a lower 
interaction with monomers which made them more available for polymer conversion. 
Therefore, if a modification of the environmental synthetic condition will be required 
in the future, for instance for the imprinting of molecules not soluble in water, solvent 
with high δ/MPa, such as short carbon chain glycols (δ/MPa= 30-35) or glycerol 
(δ/MPa= 36.2) should perhaps be considered. 
Water polymerisation of EGMMA gave rise to formation of nanogels in high yield 
(over 90%), however their solubility (< 1 mg/mL) and size (90-250 nm) were still not 
suitable for skin delivery purposes. Moreover, in agreement with the solubility theory, 
water proved to possess lower dissolution power compared to DMSO since 
preparations using CM 1% lead to macrogelation/precipitation. It should be also noted 
that the particle size was found to increase when increasing CM (Table 2.3). 
NGs APS AIBN CM% Solvent  Y Size I Size V Size N Pdi 
MRGC 
110 






































Table 2.3 Main EGMMA (80%) : MBA (20%) preparations.Y is the yield of 
polymerisation. I for intensity V for volume and N for number size distributions. All 
data are mean values of triplicate with standard deviation. 
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A number of different alternative approaches were then investigated and although not 
successful in terms of yielding the desired nanogels, these studies provided some 
interesting information regarding the polymerisation conditions and are briefly 
summarised below. 
In order to test alternative radical initiation procedures and to assess possible properties 
modification of nanogels, both thermal and ultraviolet (UV) methods were tested. UV 
is a generally faster technique useful in the presence of thermosensitive species, but at 
the same time it requires more sophisticated apparatus and cannot be employed when 
photosensitive monomers, such as fluorophores, are present in the polymerisation 
mixture. Although particle size resulted slightly smaller (≈ 70 nm by number 
distribution) the yield obtained was significantly lower (Table 2.4).     
NG Y Size I Size V Size N Pdi 


















Table 2.4 comparison between UV and thermal radical initiation. UV performed at 
room temperature in water and thermal at 70 ºC in water. Both polymersiatios 
performed in water with EGMMA (80%), MBA (20%).  2% of APS and CM 0.1%. Y 
is yield of polymerisation.  I for intensity V for volume and N for number 
distributions. Standard deviation reported as ± (mean value of triplicates) and as seen on 
DLS measurments. 
 
It was then decided to increase the percentage of cross linker as an additional attempt 
to reduce particle size, due to the formation of denser core and closer polymer chains, 
before testing new nanogels’ compositions (Table 2.5).  
NG EGMMA MBA Y Size I Size V Size N  Pdi 
MRGC 

















Table 2.5 No effect of cross-linker percentage on particle size. Both polymersiatios 
performed in water with 2% of APS and with CM 0.1%. I for intensity V for volume 
and N for number distributions. 
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However, as shown in Table 2.5, also the increment of MBA percentage did not produce 
any size contraction. It was hence chosen to employ new monomers in order to improve 
nanogels’ characteristics. 
After considering different methacrylate alternatives to overcome the poor aqueous 
solubility issue and to attempt to reduce particle size, 2-(diethylamino)ethyl 
methacrylate (DEAEMA) (Figure 2.7) was introduced as co-monomer. 
 
Fig. 2.7 DEAEMA chemical structure 
 
DEAEMA had been extensively used in the production of nanoparticles for different 
applications such as for the synthesis of drug delivery systems or bile acids adsorbents 
[17, 25-27] consequently it was considered a good candidate for NGs synthesis. 
The main reasons behind this choice were the presence of an amino group characterised 
by higher hydrophilicity and possible pH responsiveness capabilities [28]. Moreover, 
previous works by Morse et al. [20] showed that the monomer could have potentially 
provided emulsion stabilising properties. 
Combination of EGMMA, DEAEMA and MBA were therefore screened by keeping 
EGMMA : DEAEMA ratio 1:1. Results suggested that CM had to be kept under 0.5% 
in order to avoid formation of precipitate during polymerisation; DMSO was also found 
not suitable to be used as porogen for the production of nanoparticles, as in the case of 
EGMMA polymerised with MBA.  
While testing different reaction conditions, a corrrelation was identified between cross-
linker percentage and yield achieved (Table 2.6), in the range between 5 and 20% of 
cross-linker. Higher methylenebis(acrylamide) percentage was in fact leading to higher 
yield. Furthermore, nanogels produced, showed large particles size (> 300 nm by 
intensity, volume and number distribution) and poor water solubility (< 1 mg/mL) 
hence still not usable for transdermal delivery. 
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NG EGMMA MBA APS AIBN DEAEMA CM% Solvent Yield 
141 40% 20% 5% 0% 40% 0.5% Water P 
142 40% 20% 5% 0% 40% 0.1% Water 87% 
148 40% 20% 0% 5% 40% 0.1% DMSO 0% 
146 40% 20% 0% 5% 40% 1% DMSO 10% 
159 42.5% 15% 5% 0% 42.5% 0.5% Water 84%P 
160 42.5% 15% 5% 0% 42.5% 0.1% Water 57% 
155 45% 10% 5% 0% 45% 0.5% Water 77%P 
147 45% 10% 5% 0% 45% 0.1% Water 48% 
144 47.5% 5% 5% 0% 47.5% 0.5% Water 40%P 
145 47.5% 5% 5% 0% 47.5% 0.1% Water 24% 
Table 2.6 DEAEMA : EGMMA 1:1 preparations. Formation of precipitate is 
indicated with P. 
2-(diethylamino) ethyl methacrylate was therefore tested on its own and cross-linked 
with MBA (90:10) to understand the monomer contribution to nanogel’s water 
solubility. The yields obtained appeared to be low (lower than 40% with CM 1%), 
probably due to prevalent formation of short dead polymer chains and low amount of 
MBA used. The solubility (up to 1 mg/mL) instead, proved to be more suitable for the 
planned application. It was hypothesised that hydrogen bonding interaction between the 
two monomer may play a role in the formation of nanogels. When EGMMA and 
DEAEMA are placed together in the polymerisation mixture their interactions bring 
them closer, so when the polymerisation is initiated there are more chances to build 
larger polymer network which will then be retained during the purification via dialysis.  
It was then decided to increase the percentage of DEAEMA in the polymerisation 
mixture to evaluate whether solubility and particle size could have been improved. 
Therefore DEAEMA : EGMMA : MBA water polymerisation, 60:20:20, 60:25:15, 
60:30:10 and 65:30:5 were performed at various CM confirming the previously 
observed trend of cross-linker/yield correlation . Furthermore, as previously observed, 
CM had to be kept at 0.1% to avoid precipitation also in these preparations (Table 2.7). 
NG EGMMA MBA APS DAEEMA CM% Solvent  Yield 
181 20% 20% 5% 60% 0.50% Water 81%P 
184 25% 15% 5% 60% 0.50% Water 75%P 
183 30% 10% 5% 60% 0.50% Water 72%P 
151 30% 10% 5% 60% 0.1% Water 46% 
152 30% 5% 5% 65% 0.1% Water 27% 
Table 2.7 Preparations containing DEAEMA as functional monomer. Formation of 
precipitate is indicated with P.  




It is worth mentioning that 2-(diethylamino) ethyl methacrylate is reported to provide 
thermo-responsive capabilities to particles [29]. It was therefore decided to test this 
property. In order to evaluate thermoresponse of nanogels, UV thermal analysis was 
selected as analytical method and was performed on 4 different 1 mg/mL nanogel 
dispersions (Table 2.8).     
NG EGMMA MBA APS DEAEMA CM% Solvent  Yield 
143  45% 10% 5% 45% 0.5% Water 28% 
144  47.5% 5% 5% 47.5% 0.5% Water 40% 
151  30% 10% 5% 60% 0.1% Water 46% 
152  30% 5% 5% 65% 0.1% Water 27% 
Table 2.8 Summary of nanogels’ preparations tested for thermoresponsiveness. 
The concept is that by increasing the temperature, amine groups from DEAEMA 
rearrange within the nanogels’ structure moving towards the inner part of the polymeric 
network, pushing water molecules away. This leads to a decrease in nanoparticles’ 
hydrophilicity which can be visually seen as an increased turbidity of the solution. The 
turbidity increment then prevents, partially or totally, the transmittance of UV light 
from the sample to the detector. 
The point of the curve (obtained via UV scan) where the slope is at its highest, generally 
corresponding to 50% transmittance, is considered the transition temperature of the 
material. 
UV profile of nanogels, reported below, showed that MRGC 143 and MRGC 151 were 
indeed capable to respond to temperature variation. Moreover, their response 
temperature appeared to be close to body temperature (37 ºC) as seen in thermal UV 
Figures 2.8 and 2.9.  
 
Giorgio Chianello PhD Thesis Chapter 2 
63 
 
   
Fig 2.8 MRGC 143 UV thermal profile.   
 
 
Fig. 2.9 MRGC 151 UV thermal profile. 
 
In addition, results appeared to suggest that reduction of cross linker percentage led to 
shifting of thermal response towards higher temperature, not fully recorded because 
over the optimal thermal conditions for measurements in water as at a temperature 
higher than 60 ºC the solvent would start evaporating fast, potentially compromising 






























Fig.  2.11 MRGC 152 UV thermal profile 
 
Although the data provided some evidence of thermo-responsive behaviour, the desired 
increase in solubility (equal or over 1 mg/mL) expected as a result of the increase in 
percentage of DEAEMA in the mixture, was not observed. Moreover, it was noted that 
CM of 0.1% would have drastically limited the scalability of the process for potential 
industrial applications. For these reasons, DEAEMA was replaced with 2-(tert-
butylamino) ethyl methacrylate (tBAEMA) for its chemical similarity but higher 
solubility provided by the secondary amine which could form an additional hydrogen 
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Fig. 2.8 tBAEMA chemical structure (left); comparison of water hydrogen bonding 
formation with tBAEMA (centre) and DEAEMA (right).  
 
Moreover, due to different pKb values, secondary amines are stronger bases than tertiary 
leading to increased formation of positive ions more soluble in water media (Figures 
2.12 and 2.3). 
 




Fig. 2.13 DEAEMA protonation (pKa = 6.9; pKb = 7.1) 
[15] 
 
tBAEMA has been previously employed for various applications such as antimicrobial 
agents [30,31] or Pickering emulsifier [32] and was shown by previous work to be able to 
provide all the potential advantages that were expected from DEAEMA [16, 28]. 
Therefore, it was considered a good candidate for the improvement of nanoparticles’ 
properties.  
In order to evaluate the impact of the new monomer on the solubility of the 
nanoparticles, tBAEMA was first tested together with MBA but without EGMMA as 
co-monomer. A series of different polymers were prepared using a combination of 
different percentages of cross-linker and CM (Table 2.9). 
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NG MBA APS tBAEMA CM% Solvent  Yield 
167 10% 5% 90% 1% Water 47% 
165 10% 5% 90% 0.5% Water 30% 
166 10% 5% 90% 0.1% Water 29% 
173 15% 5% 85% 0.5% Water 57% 
174 15% 5% 85% 0.1% Water 43% 
168 20% 5% 80% 0.5% Water 53% 
172 20% 5% 80% 0.1% Water 58% 
Table 2.9 tBAEMA:MBA preparations. Red high lined value seemed not to follow 
the trend of yield increase due probably to material loss during nanogels’ purification 
and collection processes. However due to time constrains the preparation was not 
repeated. 
Comparison of the preparations reported on Table 2.9 with those obtained employing 
only DEAEMA suggested that tBAEMA use was leading to production of better 
nanogels as they showed  no sign of macrogelation even at CM 1% and higher solubility 
in water (>2 mg/mL). Similarly, to what was noted previously, the results suggested a 
direct correlation of CM and cross-linker percentages used with the overall yields that 
were obtained. On the other end all the polymer preparations, analysed by dynamic 
light scattering in order to evaluate particle size, were found to be over 200 nm in 
diameter. This size was deemed too large for skin penetration and therefore these 
preprations were not considered suitable.  
EGMMA was then introduced to complete the comparative study. Taking in to account 
previously tested DEAEMA based polymerisations, different tBAEMA : EGMMA : 
MBA ratios were selected and consequently tested in order to identify a potential good 
candidate for the proposed application. After screening various compositions, an 
optimal mixture constituted by 60% of tBAEMA as functional monomer, 20% of 






Giorgio Chianello PhD Thesis Chapter 2 
67 
 
NG tBAEMA EGMMA MBA  Yield Size I Size V Size N  Pdi 
























180 60% 20% 20% 76% 
34 ± 30 
nm 
9 ± 5 
nm 
6 ± 2 
nm 
0.400 








Table 2.10 Preparations containing tBAEMA as functional monomer. Optimal 
formulation highlighted in green. All polymersiatios performed in water with 5% of 
APS and with CM 0.5%. I for intensity V for volume and N for number distributions. 
 
Careful analysis of the new polymers suggested that their characteristics were better 
suited for the desired application as drug delivery system for the skin. Among the 
different preparations polymer MRGC 180 showed: yield over 75%, water solubility 
greater than 2 mg/mL and particle size in the range 5-15 nm (by number and volume 
distribution) confirmed by both dynamic light scattering (DLS) measurements and 
transmission electron microscopy (TEM) imaging (Figure 2.14) which are discussed in 
more details in the following sections. 




Fig. 2.14 TEM image (top) and triplicate overlap of DLS distribution signals by 
number (bottom) for MRGC 180 
  
In the view to investigate systems with different polarity, it was decided to prepare 
additional nanogels by replacing EGMMA with methacrylic acid (MAA) (Figure 2.15) 
to further improve hydrophilicity of the nanoparticles. 
 
 
Fig. 2.15 MAA chemical structure. 
 
Nanogels were then obtained using the previously identified composition of 60:20:20 
(tBAEMA : MAA : MBA) (Table 2.11). Their synthesis in water at CM 0.5% achieved 
a substantial yield of over 90%, water solubility higher than 5 mg/mL and particle size 
in the range 5-20nm (by number and volume distribution). 
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NG tBAEMA EGMMA MAA Y Size I Size V Size N Pdi 
180 60% 20% 0% 76% 
34 ± 30 
nm 
9 ± 5 nm 6 ± 2 nm 0.400 
196 60% 0% 20% 94% 
45 ± 30 
nm 
14 ± 9 
nm 
9 ± 3 nm 0.285 
Table 2.11 Nanogels containing tert-buthylaminoethyl methacrylate as functional 
monomer and ethylene glycol methyl ether methacrylate (EGMMA) or methacrylic 
acid (MAA) as co-monomer. Polymerisations performed in water MBA at 20% and 
CM 0.5% 
 
Along with the desired size and solubility, these nanogels were shown to possess 
additional capabilities such as pH responsiveness and emulsion stabilising properties 
which are further discussed in the following chapter.    
This work represents the first attempt to synthesize nanogels using tBAEMA as 
functional monomer in combination with EGMMA or MAA as co-monomers and MBA 
as cross-linker hence this is the first reported study for these novel nanomaterials.  
Beside the synthesis of nanoparticles with optimal characteristics for drug delivery, the 
ability to monitor them in vitro, ex vivo and in vivo provides a great benefit to further 
demonstrate the suitability of the DDS for the intended application. For this reason, it 
was proposed to incorporate a fluorescent probe into the nanogels.  
 
2.1.3 Fluorescent tag selection 
 
One of the big challenges in the development of a new drug delivery system is to 
demonstrate whether the carrier is able to be internalised inside cells or to be distributed 
within a tissue. Fluorescent labelling is a widely used technique to address these 
objectives [33, 34].  Two are the approaches used for the introduction of a fluorophore 
moiety into a delivery system: covalent and non-covalent [35-37]. The first implies the 
chemical link between the fluorescent tag and the particle, the latter instead envisages 
the adsorption of the probe into the particle via physical interactions. Although the 
second approach does not significantly modify the structure of the cargo it does not 
grant accurate quantification due to possible fluorescent leakage.  Covalent approach is 
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for this reason the best approach when certain localisation and quantification is 
requested.  
The selection of a chemically attached fluorophore, to be used as tag for nanogels, has 
to consider few key parameters: chemical similarity in order to react at a rate 
comparable to monomers used and to avoid significant alteration of the structure; 
photo-stability and minimal impact on nanoparticles properties (size, polarity, 
responsiveness etc.). Furthermore, it must be pointed out that tag incorporation planned 
in this study was aimed only for the demonstration of cell internalisation and potential 
skin penetration. Therefore, the final pharmaceutical formulation would not contain the 
probe that served exclusively as proof of concept. 
A number of different candidates were first evaluated, based on to experience 
accumulated in the group:  
a) 1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl-ethyl) acrylamide (naphtalic 
based fluorophore NBF) (Figure 2.16) previously developed and employed by 
Dr. P. Bonomi [38], former postdoctoral fellow in the Resmini team. 
 
 
Fig. 2.16 1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl-ethyl) acrylamide chemical 
structure. 
 
b) 7-[4-(Trifluoromethyl)coumarin]acrylamide (TFMCA) (Figure 2.17) reported 
in literature [39] and already tested by Dr. J. Ray, former PhD student of 
Resmini’s group. 
 
Fig. 2.17 7-[4-(trifluoromethyl)coumarin] acrylamide chemical structure. 




Both NBF and TFMCA were selected for their acrylamide polymerisable moiety which 
should possess similar reactivity to MBA. However due to their bulkiness and almost 
total insolubility in water they were soon discarded. 
Further evaluation of literature reports led to the identification of a new fluorophore, 
developed by O’Reilly et al., named 2-(2-(3,4-bis(butylthio)-2,5-dioxo-2,5-dihydro-
1H-pyrrol-1-yl)acetoxy)ethyl methacrylate {methacrylate fluorophore} (MAF) (Figure 
2.18), [33, 40-42;].  
 
Fig. 2.18 MAF chemical structure. 
 
Due to the reported high quantum yield (54%) [33] and MAF’s chemical similarity to 
monomers used, the fluorophore appeared to possess good characteristics to be 
employed as nanogels’ tag. Moreover, the maximum emission (λem ≈ 540 nm) 
[33] of 
MAF was considered an optimal value for the avoidance of fluorescence signal 
overlapping with cell nuclei’ staining agent Hoechst H33342 (λem ≈ 460) and dead cells’ 
staining dye propidium iodide (λem ≈ 620) used to evaluate cell viability profile of 
nanogels, reported in chapter 4.   
Synthesis of MAF was achieved, following the published literature procedure [40-42], in 











Fig.  2.19 MAF synthetic pathway. 
 
MAF synthesis was confirmed both by 1H-NMR and fluorimetry studies (Figure 2.20 
and 2.21). 
 




Fig. 2.20 1H-NMR of MAF 
 
Fig. 2.21 fluorescence profile of MAF in chloroform. Excitation set at λ= 417 nm. 
The analysis showed that concentrations equal or higher than 0.23mM give rise to 
fluorescent self-quenching. 
 
Following its synthesis, it was required to identify the appropriate conditions for its 
incorporation into the nanoparticles via covalent bond. Polymerisations in water were 
first carried out setting MAF percentage at 5% and using tBAEMA : EGMMA : MBA 
or tBAEMA : MAA : MBA ratios of 55:20:20. The low fluorophore percentage was 
selected to minimise the potential effect of the fluorescent tag on the nanoparticles 
properties. Despite a number of attempts, the fluorescent nanogels could not be 
obtained with the desired solubility. Some changes in the solvent solution were then 
evaluated and after testing different approaches, a mixture of water and acetone (1:1) 
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tBAEMA EGMMA MAA MAF Solvent Yield Size I Size V  Size N  
MRGC 
211 






















Table 2.12 Chemical composition, yield and diameter of fluorescent nanoparticles. 
Cross-linker percentage was set at 20% and CM at 0.5%. Polymerisation was carried 
out for 72 hours at 40 ºC. W is water and Ac is acetone. I stands for intensity, V for 
volume and N for number Dynamic light scattering (DLS) measurements. Standard deviation 
reported as ± (mean value of triplicates) and as seen on DLS measurments. 
 
 
In order to evaluate the incorporation efficiency of the fluorescent tag into the nanogels, 
UV spectroscopy was selected as analytical method over fluorescence spectroscopy due 
to its higher accuracy. Given the insolubility of nanogels in chloroform, MAF 
calibration and NGs spectra were recorded by using samples dissolved in a mixture of 
acetone : water = 7:3 which was found to be the optimal ratio in order to dissolve both 
fluorophore on its own and fluorescent labelled nanoparticles (Figures 2.22 and 2.23).  
 


















11.27    M
22.54    M
45.09    M
  0.12 mM
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The maximum fluorophore absorbance was observed at λab = 411 nm (close to the value 
of fluorescent excitation).  Therefore, absorbance values, obtained at this wavelength, 
at five different fluorophore concentrations were used to produce a calibration curve in 
order to extrapolate the molar extinction coefficient ε, using Lambert-Beer law, then 
used for the evaluation of fluorophore’s incorporation into nanogels.    
For comparative purposes, previously achieved nanogels (MRGC 180 and 196) were 
synthesised in the same solvent mixture, used for fluorescent nanoparticles production, 





tBAEMA EGMMA MAA MAF Solvent Yield Size I  Size V  Size N 
MRGC 
180 
60% 20% 0% 0% Water 76% 
34 ± 
30 nm 
9 ± 5 
nm 












12 ± 3 
nm 
















60% 0% 20% 0% Water 94% 
45 ± 
30 nm 
14 ± 9 
nm 












11 ± 2 
nm 














Table 2.13 Summary of fluorescent and non-fluorescent preparations. All 
polymerisation at CM 0.5% with MBA at 20%. Reaction time of 72 hours at 40 º C for water : 
acetone volume ratio 1:1 and at 70 º C for water preparations. I stands for intensity, V for 
volume and N for number Dynamic light scattering (DLS) measurements. Standard deviation 
reported as ± (mean value of triplicates) and as seen on DLS measurments. 
  




Fig. 2.23 UV profile of fluorescent (MRGC 209 and 211) and non-fluorescent 
(MRGC 213 and 214) nanogels dissolved in a mixture water : acetone 3:7 
 
Figure 2.23 shows the UV spectra for nanogels MRGC 209 and MRGC 211 both used 
at the same concentration of 0.5 mg/mL. Comparison of the UV spectra of the two 
fluorescently labelled nanogels with their non-fluorescent analogues (MRGC 213 and 
MRGC 214) clearly provides evidence of incorporation of the fluorescent tag into the 
polymer matrix. The difference in absorbance between the two polymers could be taken 
as evidence of variation in tag incorporation, however potential fluorophore-monomers 
interactions as a result of the different monomers present in the two polymer structures 
could also justify such differences. 
A very simple estimate of fluorescent tag incorporation was done by using the 
extinction coefficient to determine the concentration of fluorophore in the polymer, 
while the theoretical content of MAF was estimated in each case and was based on the 
assumption that all nanogel’s components (included MAF) contributed to the final yield 
proportionally to their molar percentages initially fed into the polymerisation mixture. 
MRGC 209 showed a tag incorporation of 78% while MRGC 211 higher than 100%, 
indicating that degree of probe inclusion into nanogels’ structure resulted to be 





















MRGC 213 0.5 mgmL
MRGC 214 0.5 mg/mL
MRGC 209 0.5 mg/mL
MRGC 211 0.5 mg/mL
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It is interesting to note that the yields obtained and particles size for the nanogels 
containing the fluorescent probe were found to be different from the NGs synthesised 




tBAEMA EGMMA MAA MAF Y Size II Size V V Size N N 
MRGC 
209 
55% 0% 20% 5% 69% 
78 ± 
28 nm 
58 ± 22 
nm 









11 ± 2 
nm 




55% 20% 0% 5% 51% 
116 ± 
36 nm 
97 ± 35 
nm 









12 ± 3 
nm 
10 ± 2 
nm 
Table 2.14 Chemical composition, yield and particles’ size fluorescent (MRGC 209 and 211) 
and non-fluorescent (MRGC 213 and 214) nanogels. All polymerisation at CM 0.5% with 
MBA at 20%. Reaction time of 72 hours at 40 º C in water : acetone volume ratio 1:1. I stands 
for intensity, V for volume and N for number Dynamic light scattering (DLS) measurements. 
Standard deviation reported as ± (mean value of triplicates) and as seen on DLS 
measurments. 
 
Lower yields observed could have been due to radical quenching operated by MAF 
while increased particle size was probably caused by the larger dimensions of the 
fluorophore compared to monomers.  
The larger diameter of the tagged nanogels could have significant implications in terms 
of final properties of the drug delivery system such as penetration throw the skin, cell 
internalisation and toxicity, compromising the assumption that nanoparticles labelled 
and non-labelled would behave in similar manner. Moreover, also water solubility of 
fluorescent NGs proved to be lower compared to non-fluorescent equivalents (≤ 1 
mg/mL). An obvious next step would be reducing the percentage of MAF, however due 
to time constrains these formulations were not prepared. Nevertheless, an alternative 
way to evaluate cell internalisation was identified and it is described in chapter 5.  
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2.1.4 Nanogels isolation 
 
After performing the polymerisation and before the characterisation, the nanogels need 
to be purified in order to get rid of any unreacted monomers, cross-linker and initiator 
as well as dead short polymer chains. Dialysis, over deionised water, through a cellulose 
membrane was selected as the most suitable technique. Due to the reduced size of 
nanoparticles produced the smallest commercially available membrane with molecular 
cut off of 3500 Da was employed, to avoid the loss of nanogels via diffusion. This 
method was well established within the Resmini group and was previously shown to 
work very effectively [43]  
Following the dialysis step the purified nanogels solutions were freeze dried in order to 
yield soft powders. The reasons of this treatment were: a) to calculate yield of 
polymerisation; b) to obtain a material with extended shelf life compared with a 
solution; c) work with known amount of material and d) reduce space required for 
storage.  
Nanogels were then reconstituted in the appropriate solvent in order to perform 





A number of experiments were carried out in order to gain structural information of 
the nanogels and confirm their formation over simple polymer chains.  These tests 
include infra red spectroscopy, nuclear magnetic resonance, dynamic light scattering, 
zetapotential and transmission electron microscopy. All these studies are reported in 
the individual sections below.  
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2.2.1 Fourier transform infra red (FT-IR) spectroscopy 
 
Fourier transform infra red (FT-IR) spectroscopy was employed in order to confirm the 
presence of main functional groups of the monomers within the different polymeric 
structures. 
First, each individual monomer was analysed alone to identify the characteristic peaks 
that would allow to confirm their presence in the final polylmer structure. These are 





Fig. 2.24 FT-IR of MBA. Main significant signals:  3301 cm-1 (N-H st); 1655 cm-1 
(C=O st); 1625 cm-1 (N-C=O st); 1541 cm-1 (NH Δ).  St is streaching and Δ is 
bending. 
Figure 2.24 shows signals for the stretching and bending of the secondary amide (both 
nitrogen and carbonyl) at 3301, 1655, 1625 and 1541 cm-1 which characterise N,N′-
methylenebis(acrylamide) (MBA). 
 




Fig. 2.25 FT-IR of tBAEMA. Main significant signals:  2960 cm-1 (NH st); 1717 cm-1 
(C=O st); 1159 cm-1 (C-O st). 
 
In Figure 2.25 the characterist peaks of ester and secondary amine for 2-(tert-
butylamino) ethyl methacrylate (tBAEMA) are present (2960, 1717 and 1159 cm-1).  
 
Fig. 2.26 FT-IR of EGMMA. Main significant signals: 1716 cm-1 (C=O st); 1161, 
1126 cm-1 (C-O st). 
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FT-IR spectrum of ethylene glycol methyl methacrylate (EGMMA) shows (Figure 
2.26) signals for the ester group (1716 and 1161 cm-1) as for tBAEMA but without the 
presence of the amine signal. 
 
Fig. 2.26 FT-IR of MAA. Main significant signals: 2931 cm-1 (O-H st); 1689 cm-1 
(C=O st). 
Finally, Figure 2.26 shows the characteristic broad peak for the hydroxyl/alkoxyde 
group (2931 cm-1) toghether with the carbonyl signal (1689 cm-1) of the methacrylic 
acid (MAA)  
Having identified the main functional group signals, also the six selected final 
preparations were analysed and are shown in Figures 2.27-2.32 below.   




Fig. 2.27 FT-IR of MRGC 180. Main significant signals: 3294 cm-1 (R2HH2
+ st); 2976 
cm-1 (NH free st); 1722, 1648 cm-1 (C=O st); 1544 cm-1 (NH Δ). 
 
 
Fig. 2.28 FT-IR of MRGC 196. Main significant signals: 3284 cm-1 (R2HH2
+ st); 2970 
cm-1 (NH free st); 1736, 1649 cm-1 (C=O st); 1542 cm-1 (NH Δ). 
 




Fig. 2.29 FT-IR of MRGC 214. Main significant signals: 3311 cm-1 (R2HH2
+ st); 2988 
cm-1 (NH free st); 1721, 1655 cm-1 (C=O st); 1547 cm-1 (NH Δ). 
 
 
Fig. 2.30 FT-IR of MRGC 213. Main significant signals: 3346 cm-1 (R2HH2
+ st); 2978 
cm-1 (NH free st); 1718, 1650 cm-1 (C=O st); 1550 cm-1 (NH Δ). 
 
 




Fig. 2.31 FT-IR of MRGC 209. Main significant signals: 3362 cm-1 (R2HH2
+ st); 2977 
cm-1 (NH free st); 1712, 1643 cm-1 (C=O st); 1550 cm-1 (NH Δ). 
 
 
Fig. 2.32 FT-IR of MRGC 211. Main significant signals: 3294 cm-1 (R2HH2
+ st); 2957 
cm-1 (NH free st); 1712, 1656 cm-1 (C=O st); 1534 cm-1 (NH Δ). 
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In all the polymers it is possible to identify the broad signal for the protonated amine 
(around 3300 cm-1) and the streaching of the secondary amine (around 2970 cm-1) from 
tBAEMA toghether with the ester (around 1710 cm-1) and the MBA amide (around 
1650 cm-1) signals.   
Therefore, FT-IR analysis confirmed the presence of the main functional groups within 
the polymer structure of nanogels. It is relevant to note that although it was not possible 
to resolve the peaks between 1200-1000 cm-1, the nanogels MRGC 180, 211 and 214 
showed a partial splitting of signals in this region (as seen in EGMMA) due to the 
presence of the ether group of EGMMA while MRGC 196, 209 and 213 did not show 
such splitting. 
In order to further confirm formation of polymeric structure of nanogels it was decided 
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2.2.2 Proton nuclear magnetic resonance (1H-NMR) 
 
Previosly it was mentioned that proton NMR was employed in order to to confirm 
completion of polymeristaion  
As for the FT-IR experiments, each monomer and cross-linker were dissolved in 
deuterated water and characterised (Figure 2.33)  
 
 
Fig. 2.33 1H-NMR assignment of monomers and cross-linker. Black EGMMA, Blue 
MAA, green tBAEMA and red MBA. 
 
In a fist stage the two main preparations (MRGC 213 and MRGC 214) were 
characterised via 1H-NMR (Figures 2.34 and 2.35). 
Figure 2.34 below shows the 1H-NMR characterisation for MRGC 213. 




Fig. 2.34 1H-NMR assignment of MRGC 213. Magenta MRGC 213, green tBAEMA, 
blue MAA and red MBA. 
Signals for protons attached to carbon e (4.36 and 3.90 ppm), f (3.45 and 3.23 ppm) and 
j (1.49 and 1.45 ppm) are present in two forms, this was due to presence of protonated 
and unprotonated secondary amine of tBAEMA. Moreover, there is only 0.5% trace of 
remaining double bond meaning that practically all the monomers had reacted to form 
the final cross-linked structure. Integration of peaks also reveal that monomers and 
cross-linker ratios were maintained durng polymerisation. 
Similar results were obtained for MRGC 214 and are shown in Figure 2.35 below. 




Fig. 2.35 1H-NMR assignment of MRGC 213. Magenta MRGC 214, black EGMMA, 
green tBAEMA and red MBA. 
 
The chemical differences between MRGC 213 and 214 can be easily visualised in 
Figure 2.35 (signals l and m). In the first case MAA was employed as co-monomer 
while in the latter EGMMA was used. The extra signals of the 4 protons of the ethyl 
groups of EGMMA for MRGC 214 (protons attached to carbons l and m) are found at 
3.75 pmm (2 protons from carbon l) and hidden within the signal of the 2 protons 
connected to carbon f which belong to the tBAEMA monomer.  
Further studies involved the analyses of the fluorescent nanogels (MRGC 209 and 
MRGC 211). These analyses showed very similar chemical shift and spectra compared 
to non fluorescent nanoparticles and can be visually correlated from Figure 2.36.  
 




Fig. 2.36 1H-NMR assignment of fluorescent and non fluorescent nanogels. Blue 
MRGC 214, Magenta MRGC 211, yellow MRGC 209 and red MRGC 213. 
It is important to note that due to the reduced percentage of fluorophore (5 %) and the 
reduced solubility of fluorescent nanogels (≤ 1 mg/mL) the signals of the fluorophore 
could not be detected. 
The data obtained by NMR, all related to the polymers isolated following dialysis, 
confirmed that no monomers could be identified in the isolated nanoparticles. In the 
case of the non-fluorescent polymers this was further supported by a very high chemical 
yield of polymerisation, over 80%, while for the fluorescent polymers this was lower, 
as previously reported. Having confirmed the completion of reaction and formation of 
nanogels the next step was to analyse their particle size, solution stability and 
morphology via dynamic light scattering, transmission electron microscopy and 








2.2.3 Dynamic Light Scattering and Zeta Potential 
 
Previous sections of this chapter highlighted the importance of size for skin penetration. 
Therefore, a careful evaluation of the particle size was an important part of this work. 
Dynamic light scattering (DLS), also known as Photon Correlation Spectroscopy 
(PCS), is a widely used technique for the measurement of nanoparticles’ average 
diameter in solution [20, 21; 32]. DLS instruments estimate hydrodynamic diameter by 
correlating random Brownian motion with time-dependent variation in the light 
scattering intensity arising from particles in solution [44, 45].   
The instrument records average size using 3 different methods: 
 Intensity: the contribution of each particle in the distribution relates to the 
intensity of light scattered by the particle. Bigger particles produce higher 
intensity peaks  
 Volume: the contribution of each particle in the distribution relates to its 
volume, therefore a larger volume will give higher contribution to the analysis. 
This is useful from a commercial perspective as the distribution represents the 
sample composition in terms of its volume/mass. 
 Number: each particle is given equal weighting irrespective of its size. This is 
the most accurate measurement, especially when considering very small 
nanoparticles. [45] 
Figure 2.37 below provide a visual explanation of the differences between the three 
measurement techniques.   




Fig. 2.37 Sample consisting of equal numbers of particles with diameters of 5 nm and 




In a purely monodispersed solution, and in the absence of any large impurities such as 
dust, the intensity-size distribution, in a given DLS measurement, is most reliable.  The 
important point to note is that in the intensity versus size plot in the DLS technique, the 
types of materials giving rise to the intensity are not important. The material properties 
are accounted for only when the intensity size distribution is converted into a volume 
or number distribution plots using the Mie theory. Hence the contribution to the 
measured intensity by each particle is only taken into account in a volume-size 
distribution plot. [Malvern Instrument, UK]  
The intensity is proportional to the square of the molecular weight and in a real system, 
having a multimodal particle size distribution, the interpretation of the data in terms of 
intensity could be misleading.  This is because a very small number of aggregates or 
impurities such as dust particles can dominate the intensity distribution. The data in 
intensity, volume or number weight as a function of particle size, for example, have 
different sensitivities, 106, 103 and 1.   
For example, one million particles of 10 nm size and only one 100 nm will have peaks 
of roughly the same intensity (Figure 2.38). 




Fig. 2.38 Contribution to size distribution by intensity of particles of different 
hydrodynamic diameter. 
Gustav Mie developed an exact solution (without any need for approximation) to 
Maxwell’s electromagnetic equations for scattering from spheres. The solution is 
sensitive to smaller sizes (wide angle scatter), a different range of absorption 
characteristic, and only requires the refractive indexes of particle and bulk medium. [46] 
Mie scattering theory (Lorenz-Mie theory) is normally applied to all the intensity data. 
Now the particles cannot be considered as point sources of scattered light. Destructive 
inferences are taken into account from light originating at different parts of our solution. 
Mie theory is a complete solution of Maxwell’s equation for electromagnetic radiation 
being scattered by all the particles in a given solution. Mie scattering analysis is 
normally used and the data are then represented as a volume-size distribution. 
 
In the view of this and due to reduced hydrodynamic diameter of nanogels, size 
distribution by number and volume were considered to be a more accurate 
representasion of the nanoparticle characterists. Moreover, in order to avoid operator 
inaccuracy or erroneous data collection and to produce significant results, all the 
measurements were recorded as triplicate and samples were tested randomly twice or 
thrice on the same day and on different days.  
Results for the fluorescent and non-fluorescentformulations, summarised in Table 2.15, 









tBAEMA EGMMA MAA MAF Solvent Yield Size I Size V Size N 
MRGC 
180 




9 ± 5 
nm 












12 ± 3 
nm 























14 ± 9 
nm 












11 ± 2 
nm 

















Table 2.15 Summary of 6 preparations selected. All polymerisation at CM 0.5% with MBA at 
20%. Reaction time of 72 hours at 40 º C for water : acetone volume ratio 1:1 and at 70 º C 
for water preparations. I stands for intensity, V for volume and N for number DLS 
measurements. Standard deviation reported as ±. 
 
 




Fig. 2.39 DLS measurements of MRGC 180 by intensity volume and number (top to bottom). 
Polydisprsity index (Pdi): 0.40 
 
 





Fig. 2.40 DLS measurements of MRGC 196 by intensity volume and number (top to bottom). 
Pdi: 0.28 
 













Fig. 2.42 DLS measurements of MRGC 213 by intensity volume and number (top to bottom). 
Pdi: 0.59 
 
As briefly mentioned in section 2.1.3, no significant difference was found in particle 
size for NGs synthesised in pure water or in the 1:1 mixture of water and acetone. This 
could be easily visualised by comparing Figure 2.38, 2.39, 2.40 and 2.41.  
 
The high polydispersity index (Pdi) values of these formulations can be explained 
considering what was previously said in this section regarding DLS measurments.  
 




Fig. 2.43 DLS measurements of MRGC 209 by intensity volume and number (top to bottom). 
Pdi: 0.20 
 




Fig. 2.44 DLS measurements of MRGC 211 by intensity volume and number (top to bottom). 
Pdi: 0.10. 
 
Figures 2.42 and 2.43 showed larger hydrodynamic diameter of fluorescently labelled 
nanoparticles. In section 2.1.3 was in fact acknowledged that monomers polymerised 
in the presence of MAF resulted in formation of nanogels with lower yield and larger 
particle size. 
After measuring particle size via DLS it was also decided to assess solution stability 
via Zetapotential measuremnts. These studies are reported in the following section. 
 





DLS instruments are generally equipped with an electrical circuit that can apply current 
through a solution. This is done by using a specific cuvette equipped with metallic 
plates on each sides which are in contact with the solution of particles. When electrical 
current is applied to the sample the movement of the particles is recorded by measuring 
the fluctuation in intensity of laser light scattered by the particles and zeta potential 
values are extrapolated.  
 
Particles in solution are surrounded by charges which form two main liquid layers 
around them. The inner one, where ions are strongly bound with the particle, called the 
Stern layer and the outer diffuse region called the slipping plane where the ions are free 
to move. When a particle moves the charges within the slipping plane move together 
with it and vice versa, when an electrical potential is applied the particle is pushed by 
the ions surrounding its surface (Figure 2.45). Zeta potential (ζ potential) is the 
electrical potential difference between the Stern layer and the medium. Its value gives 
an indication of colloidal dispersion stability. Particles with zeta potential over +30 mV 
or lower than -30 mV are generally considered very stable while those with values 
comprised between -10 to +10 mV are considered unstable as they may tend to 




Fig. 2.45 Visual explanation of zeta potential R. Talero, C. Pedrajas and V. Rahhal (2013). 
Performance of Fresh Portland Cement Pastes – Determination of Some Specific Rheological 
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Parameters, Rheology - New Concepts, Applications and Methods, Associate Prof. Rajkumar 





ζ-potential data, reported on Table 2.16, were the results of triplicate analyses as for 
particle size measurements.  
 
 













60% 20% 0% 0% 
W:Ac 
1:1 
12 ± 3 
nm 
10 ± 2 
nm 




55% 20% 0% 5% 
W:Ac 
1:1 
97 ± 35 
nm 






60% 0% 20% 0% Water 
14 ± 9 
nm 





60% 0% 20% 0% 
W:Ac 
1:1 
11 ± 2 
nm 
10 ± 2 
nm 




55% 0% 20% 5% 
W:Ac 
1:1 
58 ± 22 
nm 
45 ± 13 
nm 
18 ± 3 
mV 
Table 2.16 Summary of 6 preparations selected. All polymerisation at CM 0.5% with MBA at 
20%. Reaction time of 48 hours at 40 º C for water:acetone volume ratio 1:1 and at 70 º C for 
water preparations. Standard deviation reported as ±. 
 
Focusing the attention on non-fluorescent particles, data suggested that the reaction 
environment played an important role in assembly of the polymer chains. 
Polymersitaion performed in water led to production of systems with negative ζ-
potential while water : acetone (1:1) environment produced particles characterised by 
positive ζ-potential (Table 2.17). These results were further confirmed by 
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NG tBAEMA EGMMA MAA MBA CM Solvent Zeta  
MRGC 
180 





60% 20% 0% 20% 0.5% 
W:Ac 
1:1 









60% 0% 20% 20% 0.5% 
W:Ac 
1:1 
18 ± 7 
mV 
Table 2.17 ζ-potential comparison of nanogels produced in water and in mixture water 
: acetone 1:1. 
 
Different solvent environments may induce different intermolecular interaction 
between monomers and crosslinker which resulted in diverse disposition within the 
nanogel network leading to different charge disposition around he particles. 
Although dynamic light scattering (DLS) is an extensively used procedure that provides 
reliable results, it is always good practise to confirm the data obtained with additional 
analytical techniques. Moreover, DLS alone does not provide any information 
regarding nanoparticles morphology. It was therefore decided to pair DLS 
measurements with high resolution microscopy techniques, in particular with 
transmission electron microscopy. These analyses are reported in the following section.     
 
2.2.5 Transmission Electron Microscopy  
 
Transmission electron microscopy (TEM) is an extensively used and powerful 
technique to obtain highly magnified images of materials at a scale close to atomic level 
[47-49]. A focalised electron bean is transmitted to a support where the material is cast 
and by adsorbing part of the energy the material produces a contrasted area that is 
recorded as an image by a photographic device such as a CCD camera [50, 51]. TEM was 
therefore employed to gain information of nanogels morphology and to confirm DLS 
measurements. Moreover, by comparing TEM and DLS data it is also possible to gain 
information on NPs behaviour in solution and at the solid state.    
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Below are reported images from the 6 selected nanogels’ preparations. All the images 
were taken using carbon oxide coated copper grids as support and without staining 
samples with contrast agents. The use of contrast agents was avoided due to the porous 
nature of nanogels that could lead to staining leakage which could then results in false 
positive assessments.   
Nanogel MRGC 180 was one of the first preparation analysed (Figure 2.46). Pictures 
recorded showed that at the dry state particles had a tendency to aggregate into small 
cluster of 3 to 5 particles on average. However, their individual diameter appeared to 
be in line with DLS measurements. 
 
Fig. 2.46 TEM image of MRGC 180 at 1 mg/mL, scale bar 200 nm. Provided by Dr. Giulia 
Mastroianni. 
 
Also NG MRGC 214 showed a similar cluster behaviour even though the number of 
particles was found to be higher and the individual particles could be more easily 
resolved (Figure 2.47). 




Fig. 2.47 TEM image of MRGC 214 at 1 mg/mL, scale bar 100 nm. Provided by Dr. Giulia 
Mastroianni. 
As noted in previously performed DLS analyses, particle size of fluorescent nanogels 
appeared to be larger compared to non-labelled ones (MRGC 180 and MRGC 214), this 
can be seen by comparing Figure 2.45 and 2.46 with the image below (Figure 2.48). 
 
Fig. 2.48 TEM image of MRGC 211 at 1 mg/mL, scale bar 200 nm. Provided by Dr. 
Giulia Mastroianni. 
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Similar to MRGC180 and MRGC214 formation of cluster, in the dry state, were also 
observed for MRGC 196 (Figure 2.49). However, in this case clusters formed appeared 
to be constituted by a larger number of particles and characterised by high density.  
 
Fig. 2.49 TEM image of MRGC 196 at 1 mg/mL, scale bar 100 nm. Provided by Dr. 
Giulia Mastroianni 
Nevertheless, this aggregation behaviour could potentially be limited using different 
techniques or a combination of them. Sonicating the water solution containing the 
nanogels for longer than 2 minutes (time used for the analysis herein reported) before 
casting onto TEM grids as well as reducing nanoparticles concentration could be good 
approaches to resolve clustering. Another way would be the employment of different 
drying methods. Solutions cast onto grids were in fact dried by first removing water 
excess by placing filter paper perpendicularly on the side of the grids. Then they were 
allowed to dry for few minutes at normal temperature and pressure conditions, although 
drying could have also been achieved with the aid of air or nitrogen flow or under 
vacuum. The casting procedure, described before, was previously developed and used 
by the group for acrylamide based nanogels. However, the nanoparicles in this study 
may have needed a different casting technique to optimise particles separation that due 
to time and resources constrains could not be performed on all nanogels. 
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A solution of MRGC 214 was therefore prepared by applying a combination of the 
previously mentioned propositions, in order to prove that clusters imaged were indeed 
particles’ aggregates and to demonstrate the possibility to disaggregate these nanogels 
clumps. Sonication time was increased from 2 to 10 minutes and nanoparticles 
concentration decreased from 1 to 0.25 mg per mL. This new protocol resulted 
successful, in fact, although in the image below it can still be seen a small percentage 




Fig. 2.50 TEM image of MRGC 214 at 0.25 mg/mL, scale bar 200 nm. Sonicated for 
10 minutes. Provided by Dr. Giulia Mastroianni 
 
Another method, based on a reported technique [52], for the avoidance of drying artefacts 
was tested simultaneously by using a MRGC 214 solution prepared following the same 
procedure as for the solution used for image 2.50. This technique involves the use of 
bovine serum albumin (BSA), a macromolecule invisible to the TEM that is able to 
form a corona layer around particles limiting their aggregation during drying. Figure 
2.51 reported below shows the effect of BSA on a solution of MRGC 214 at a final 
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concentration of 0.5 mg per mL with BSA at a final concentration of 0.25 mg per mL 




Fig. 2.51 TEM image of MRGC 214 at 0.5mg/mL plus BSA at 0.25 mg/mL, scale bar 
200 nm. Sonicated for 10 minutes. Provided by Dr. Giulia Mastroianni 
 
MRGC 213 together with MRGC 209 showed the best results in terms of particles 
separations (Figure 2.52 and 2.53) without the need to use any of the techniques 
previously described to resolve MRGC 214 clustering.  




Fig. 2.52 TEM image of MRGC 213 at 1 mg/mL, scale bar 100 nm. Provided by Dr. 
Giulia Mastroianni 
 
Fig. 2.53 TEM image of MRGC 209 at 1 mg/mL, scale bar 500 nm. Provided by Dr. 
Giulia Mastroianni 
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As seen from DLS measurements and as well as previously noted for MRGC 211, 
particle size of labelled nanogel MRGC 209 was confirmed to be in the range 70-
100nm, which was significantly larger than non-fluorescent nanoparticles. 
In conclusion TEM images confirmed results obtained with dynamic light scattering 
technique. Moreover, it was shown that nanogels produced in acetone: water (1:1) 
mixture were characterised by more homogenous and shape defined structures. In 
particular nanoparticles containing methacrylic acid as co-monomer (MRGC 209 and 
MRGC 213) did not show signs of particles’ clustering, probably due to their higher 
solubility in water.   
Given the requirements for skin delivery MRGC 213 and MRGC 214 were selected as 
the best candidates for transdermal application and further tested to assess their 




In this chapter the work towards the development of new nanogels with the ideal 
characteristics to be suitable for dermal drug delivery was described. In particular, the 
features that were being targeted were: small particle size, lower than 40nm, and good 
water solubility (equal or greater than 2 mg/mL). 
A very significant part of the work was the identification of suitable monomers to be 
included in the polymer formulation. Nanogel production attempts included the use of 
tert-buthylamminoethyl methacrylate (tBAEMA), ethylene glycol methyl ether 
methacrylate (EGMMA), diethylamminoethyl methacrylate (DEAEMA) and 
methacrylic acid (MAA) as monomers and N,N’-methylenebis(acrylamide) (MBA) as 
crosslinker. 
After considerable work on screening polymerisations, nanoparticles containing tert-
buthylamminoethyl methacrylate as functional monomer and either ethylene glycol 
methyl ether methacrylate or methacrylic acid as co-monomers were identified as the 
most suitable formulations 
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In particular, nanogels. MRGC 213 and MRGC 214, best fitted the before mentioned 
requirements They were constituted by a molar ratio 60% of tBAEMA, 20% of MBA 
and 20% of either MAA or EGMMA respectively. These nanoparticles were 
synthesised in a mixture water acetone (1:1 v/v), under nitrogen atmosphere, via high 
dilution radical polymerisation (CM 0.5%) and in the presence of APS, as initiator, set 
at a molar concentration of 5% of the overall monomers and cross-linker double 
bounds. The nanogels were characterised via FT-IR, H-NMR, DLS, Zetapotential 
measurement and TEM microscopy showing size lower than 20 nm and solubility 
greater than 3 mg/mL.   
In section 2.1.2 was mentioned the use of tert-buthylamino ethyl methacrylate 
(tBAEMA) to confer emulsion capabilities to nanoparticles. In the view of this, 
nanogels were tested in order to evaluate their emulsion stabilising characteristics. 
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 Overview, advantages and applications 
 
Pickering emulsion are emulsions stabilised by particles rather than surfactants. [1] They 
were named after S. U. Pickering who first described the phenomenon in 1907 [2] 
although W. Ramsden firstly observed it in 1903. [3] Emulsion are largely employed and 
still express great potential in various sectors such as pharmaceutical, cosmetic, food, 
agricultural and petroleum industries. [4-6] Apart from industrial applications, there are 
also many examples of natural Pickering emulsions in foods like milk, mayonnaise and 
dairy cream. [7] Emulsion stabilisation via particles shows some differences and offers 
several advantages over conventional surfactants: surface active molecules are well 
known to generate tissue irritation and cell damages reducing their usability for bio-
medical applications [8]; particle-particle interactions and lateral capillary forces 
provide higher mechanical strength and rigidity to the interface compared to normal 
surfactants [9]; due to higher energy barrier required to desorb from the interface 
particles do not undergo fast absorption-desorption as tensioactive molecules [8];  
particles can be designed to respond to stimuli and reversibly or irreversibly destabilise 
the emulsion after environmental changes [10]; lastly surfactants are genarally more 
difficult to  recover from any given system than particles.   
Given such advantages, the nanogels obtained in this work were also evaluated for 
emulsion forming capabilities that would provide an additional advantage for the 
application as dermal drug delivery systems. Many formulations for transdermal 
application are administered in form of ointment which are basically emulsions. 
Therefore, nanoparticles described in this work could be potentially employed both as 
a drug carrier and as emulsion adjuvant in a final pharmaceutical application.  
Before presenting the results obtained regarding emulsion stabilisation, it is important 









 Soft particles against hard particles 
 
When considering emulsions stabilised by particles it is important to acknowledge the 
distinct properties between hard and so called soft particles. For instance, titanium 
oxide particles are one type of rigid particles employed in the stabilisation of emulsions 
[11] while micro and nanogels are examples of soft particles due to their capacity to 
deform [12].   
The deformability and ability to respond to stimuli are key parameters that are 
responsible for the diversity between soft and hard particles. The first has a significant 
impact in enhancing droplets accommodation and increasing inter-particles interactions 
given by possible particle-particle interpenetration [12]. The latter instead provides 
additional properties to the system as the emulsion can be destabilised on demand by 
tuning environmental conditions (for instance pH or temperature) [13].   
The improved characteristics of nanogels over hard particles make them an excellent 
platform for the development of responsive materials for drug delivery. 
In the next paragraph preliminary emulsion stabilisation properties of the nanogels, 
herein discussed, will be presented. 
 
 Emulsion preliminary studies 
 
Emulsions are complex systems with many variables that play a role in their formation 
and stability. Oil phase selected, chemical nature and concentration of the emulsifier as 
well as environmental conditions (pH, ionic strength, temperature etc.) can affect the 
emulsion. In order to fully understand the effect of each individual parameter extensive 
studies are required. However, this was not the object of this work. Nevertheless, some 
initial studies were performed in order to identify compatible oil phases and carry out 
preliminary studies on stimuli responsiveness of emulsions and nanogel concentration 
effect on emulsion formation.  
The selection of the oil phase is probably the most critical point of emulsion studies. 
The formation and properties of the emulsion depends on the chemical interaction 




between the emulsifier and the oil phase [14]. Without interaction between the oil phase 
and the nanoparticles the emulsion would not form. Initially the idea was to evaluate 
oil phases with different polarity to identify the phase with better affinity to nanogels 
produced. Therefore, heptane, ndodecane, paraffin oil, methyl myristate (MM), octanol 
(OC) and oleic acid (OA) were selected as suitable candidates for testing (Figure 3.1). 
The incompatibility with totally apolar oils was proven at an early stage. In view of this 
fact heptane, n-dodecane and paraffin oil were discarded due to the nanogels’s inability 
to form emulsion in their presence.  
 
Fig. 3.1 chemical structure of oil phases used. Liquid paraffin is not herein displayed 
due to its multicomponent nature.  
 
While the previously mentioned apolar phases did not form emulsions, methyl 
myristate appeared to possess intermediate characteristics. Figure 3.2 shows that 
emulsions were formed but after few seconds (< 15) they started separating from the 
centre.    
 
Fig. 3.2comparison between water / oleic acid (left) and water / methyl myristate 
(right) systems. Vial on the right shows phase separation taking place from the centre 
of the emulsion. 




Both the polar octanol and oleic acid led to formation of emulsions. Oleic acid in 
particular was selected as the optimal oil in terms of compatibility with nanogels but 
also considering its properties. Oleic acid is a natural occurring unsaturated fatty acid 
found in olive oil, several vegetables and adipose tissue of various animals. It is widely 
used as excipient in pharmaceutical formulations [15] containing bioactive compounds 
for the treatment of cardiac malfunctioning (Diltiazem), epilepsy or mental disorders 
(Carbmazepine) and as gastro protectant (Omeoprazole) to name a few [16].  
One of the first studies conducted on emulsion was mixing volumes ranging from 0.5 
to 1 mL of 1mg/mL aqueous solutions of nanogels with increasing amounts of oil 
phases ranging from 0.1mL up to double the initial volume of water phase used. The 
reason for this experiment was to assess optimal ratios between the phases. In the case 
of octanol the optimum ratio of water to oil was found to be 10:4. Oleic acid instead 
would form stable emulsions at various ratios (from 10:2 up to 10:15), however it was 
decided to fix phase’s ratio at 1:1 or 1:0.5 (water:oil) as those systems seemed to 
produce the best emulsion performance.  
As a proof of concept fluorescent labelled nanogels (MRGC 209 MRGC 211) were also 
tested and showed to be able to form emulsions (Figure 3.3). However, they were not 
analysed any further as this was beyond the scope of this work. 
   
Fig. 3.3 Water/oleic acid systems of MRGC 211 and MRGC 209 before agitation 
(left) and after agitation (right) at 2500 rpm for 1 minute. 
 
tBAEMA responsiveness to pH variation was previously referenced (section 2.1.2). For 
this reason, it was decided to confirm this property by testing emulsion stability in 
acidic, neutral and basic conditions. It is relevant to note that the pH was set both by 
using buffer solutions or dissolving the nanoparticles in either hydrochloric acid (HCl) 




0.01M or sodium hydroxide (NaOH) 0.01M water solutions. The latter method offers 
the advantage of avoiding the interference of buffer salts, which could sit at the interface 
and therefore modify emulsion properties. On the other hand, the use of buffer solutions 
produces a system that better mimics the biological environment. 
It was found that in acidic and neutral condition the nanogels were able to form stable 
emulsion while in basic condition the emulsions were disrupted or partially inverted. 
Figure 3.4 below shows the effect, on the emulsion stability, after adding a few drops 
of NaOH 0.1M to an emulsion consisting of a nanogels’ solution of 1 mg in 1mL of 
0.01M HCl in water plus 1 mL of oleic acid (for a final nanogel’s concentration 
0.5mg/mL). 
              
Fig. 3.4 Left: MRGC 180 1 mg in 1 mL of HCl 0.01M water solution (pH 4) plus 1 
mL of oleic acid 1 hour after emulsion formation. Right: nanogels emulsion 10 
minutes following addition of few drops of NaOH 0.1M (pH 12). 
 
This behaviour can be easily explained as follow. Protonated secondary amines have a 
pKa in the range between 10 and 12, therefore their conjugated bases possess a pKb 
ranging from 2 to 4. This implies that tBAEMA can be considered a medium-weak base 
and therefore, in neutral and in basic conditions the extent of its protonation is moderate 
to low. On the contrary, in acidic conditions, due to the higher hydronium ion 
concentration the equilibrium is shifted towards the protonated species (Figure 3.5).  
The increase or reduction of positive charges, as a result of protonation-deprotonations 
of the amino groups from tBAEMA, leads to modification of the hydrophilic lipophilic 
balance (HLB) of nanogels resulting in either disruption (as previously seen in the case 
of MRGC 180) or inversion of the emulsion (Figures 3.6 and 3.7). 
 





Fig. 3.5 Protonation of tBAEMA 
 
     
Fig. 3.6 0.5 mL of oleic acid plus 1 mL of MRGC 213 at 1 mg/mL 0.01M NaOH 
(left) or 0.01M HCl (right) water solution, 1 hour after agitation. 
 
 
Fig. 3.7 0.5 mL of oleic acid plus 1 mL of MRGC 214 at 1 mg/mL 0.01M NaOH 
(left) or 0.01M HCl (right) water solution, 1 hour after agitation. 
 
Overall MRGC 213 was shown to be the best preparation for the stabilisation of 
emulsions due to the presence of carboxylic acid groups (methacrylic acid) which 
conferred higher hydrophilicity and therefore greater interaction with the water phase. 
Although transdermal delivery was selected as possible route of administrations for 
NGs, their pH responsive profile would be suitable also for oral administration. In the 
acid conditions of mouth and stomach the emulsion could potentially remain stable 
while breaking up in the intestine due to its basic environment.  




The beahaviour of emulsion in buffer solutions proved to be different compared to HCl 
and NaOH pH adjusted solutions. While in a neutral enviroment the nanoparticles 
formed stable emulsions both in phosphate buffer solution (PBS) and in deionised water 
(Figures 3.8 and 3.9), basic conditions of pH 9.2, obtained through the use of 
carbonate/bicarbonate buffer, did not lead to emulsion inversion (Figure 3.6, 3.7 and 
3.8) or breakage but to formation of an emulsion similar to those formed in neutral and 
acidic conditions (Figure 3.10). However, the reason for this behaviour,  was not 




Fig. 3.8 0.5 mL of oleic acid plus 1 mL of MRGC 213 at at 1 mg/mL of aqueous citric 
acid buffer at pH 4 (left); phospate buffer solution at ph 7.4 (center) and 0.01M NaOH 
(right) 15 minutes after emulsion formation. 
 
 
Fig. 3.9 0.5 mL of oleic acid plus 1 mL of a 1 mg/mL solution of MRGC 213 in 
deionised water. 
 





Fig. 3.10 0.5 mL of oleic acid plus 1mL of MRGC 213 at 1 mg/mL of aqueous citric 
acid/citrate buffer at pH 4 (left); phospate buffer at ph 7.4 (center) and 
carbonate/bicarbonate buffer at pH 9.2 (right) 15 minutes after emulsion formation. 
 
With regards to the emulsions produced in acidic conditions at pH 4, achieved via the 
use of citric acid/citrate buffer, it should be noted that while their formation and short 
term (4 hours) stability was found to be similar to the emulsion adjusted with 
hydrochloric acid (Figures 3.7, 3.9 and 3.11), on the long term (< 24 hours) they proved 
not to be stable (Figure 3.11).  
 
 
Fig. 3.11 0.5mL of oleic acid plus MRGC 213 1 mL at1 mg/mL of aqueous citric 
acid/citrate buffer at pH 4 (left); phospate buffer at ph 7.4 (center) and 
carbonate/bicrbonate buffer at pH 9.2 (right) one month after emulsion formation. 
 
The bulky structure of citrate (Figure 3.12) compared to phosphates or carbonates could 
have caused the instability of the emulsion. In fact, phosphate and carbonate anions can 
bind with tBAEMA, through ionic interactions, while leaving the surface of the 
nanogels available for interactions with the oil and water phases. On the other hand, 
citrate, due to its tridentate and larger structure, could completely cover the 




nanoparticles’ surface offering highly hydrophilic moieties which would prevent 
interactions with the oil phase.  
 
Fig. 3.12 Chemical structure of citrare (left) and tert-butylamino ethyl methacrylate 
within the nanogel’s structure 
 
These results seemed to indicate that selection of buffer solution played an important 
role on emulsion stability. Therefore, more in depth analyses will be required to fully 
comprehend mechanisms and elements driving the emulsion formation and stability, 
that due to time constrains could not be carried out. 
 
In order to obtain more data on the ability of the nanogels to favour the formation of 
emulsions it was decided to investigate the impact of nanogel concentration. The 
images in Figure 3.13 show different samples of nanogels with concentrations ranging 
from 1mg/mL to 5 mg/mL before emulsion formation (A) and after the homogenisation 
(B). It was demonstrated that an increment in nanoparticle concentration led to larger 
emulsion volumes (Figure 3.13 B). From image B it can be easily observed that the 
emulsion phase is significantly increasing and the height of the emulsion is becoming 
more significant with increase in concentration.  
     
Fig. 3.13 Nanogels at increasing concentration, ranging from 1 to 5 mg/mL, before 
agitation (left). Emulsion formation after agitation at 2500 rpm for 1 minute. Red 
marks indicate level of phase’s separation plane before agitation (right). 
 
A B 




While macroscopic emulsion stability (over one month) could be assessed with naked 
eye. It was proposed to employ optical microscopy to confirm microscopic stability and 
to visualise behaviour of the emulsions (Figure 3.14).  
  
Fig. 3.14 Stability of oleic acid : water emulsions: MRGC 213. Left, emulsion 
prepared few minutes before analysis. Right, same emulsion after one week. Scale bar 
53 µm. Images recorded with the support of Dr. Katarzyna Zielinska. 
Figure 3.14 and 3.15 (below) show no significant difference in droplet size and 
morphology between emulsions freshly prepared and emulsions 1 week after formation 
confirming emulsion stability under both macroscopic and microscopic perspective. 
 
  
Fig. 3.15 Stability of oleic acid : water emulsions: MRGC 214. Left, emulsion 
prepared few minutes before analysis. Right, same emulsion after one week. Scale bar 
53 µm. Images recorded with the support of Dr. Katarzyna Zielinska. 
 
It is important to note that as soon as the emulsions are casted and spread on top of the glass 
for microscopy analysis, the emulsions quickly start to break therefore, the test has to be run 
promptly. The smallest droplets seen in the pictures represent the real emulsion droplets while 
the larger ones are the result of emulsion breakage due to collapsation of small droplets to form 




large clusters. Comparing Figure 3.14 with 3.15 it can be noted that the smallest droplets (1-5 
µm) possess similar size however, the pictures appear very different. This is due to the fact that 
emulsions formed by MRGC 214 break faster than those formed with MRGC 213. As the 
emulsions are water in oil this can be easily explained by the presence of extra charges (MAA) 
and higher acqueous solubility of MRGC 213 which can produce stronger interaction with the 




In conclusion MRGC 213 and MRGC 214nanoparticles were shown  to be able to form 
stable Pickering emulsions which could be broken, following pH modifications. 
These properties further expand the capabilities of these novel methacrylate based NGs. 
However additional test will have to be performed in order to fully understand the 
behaviour of the nanoparticles in more complex systems such as biological fluids or 
cell media.  
After nanogels synthesis and the evaluation of their Pickering-Ramsden emulsion 
formation capabilities, the focus was moved on the evaluation of the biological 
properties of the nanoparticles in order to assess their suitability for drug delivery 



















1. Y. Chevalier; M. A. Bolzinger. Emulsions stabilized with solid 
nanoparticles: Pickering emulsions. Colloids and Surfaces A: Physicochem. 
Eng. Aspects, 2013, 439, 23-34. 
2. S.U. Pickering. Emulsions. J. Chem. Soc., Trans., 1907, 91, 2001-2021. 
3. W. Ramsden. Proc. Roy. Soc., 1903, 72, 156-164. 
4. R. J. G. Lopetinsky, J. H. Masliyah; Z. Xu. Solids-Stabilized Emulsions: A 
Review.  In: B. P. Binks, T. S. Horozov editors. Colloidal particles at liquid 
interfaces. Cambridge: Cambridge University Press, 2006, 186-224. 
5. J. Tang, P. J. Quinlan; K. C. Tam. Stimuli-responsive Pickering emulsions: 
recent advances and potential applications. Soft Matter, 2015, 11, 3512-
3529. 
6. E. Dickinson. Food emulsions and foams: Stabilization by particles. Curr. 
Opin. Colloid. In., 2010, 15, 40-49. 
7. B. P. Binks; T. S. Horozov. Colloidal particles at liquid interfaces: an 
introduction. In: B. P. Binks, T. S. Horozov editors. Colloidal particles at 
liquid interfaces. Cambridge: Cambridge University Press, 2006, 1-73. 
8. A. Schrade, K. Landfestera; U. Ziener. Pickering-type stabilized 
nanoparticles by heterophase polymerization. Chem. Soc. Rev., 2013, 42, 
6823-6839. 
9. K. D. Danov; P. A. Kralchevsky. Capillary forces between particles at a 
liquid interface: General theoretical approach and interactions between 
capillary multipoles. Adv. Colloid. Interfac., 2010, 154, 91-103. 
10. S. Fujii, E. S. Read, B. P. Binks; S. P. Armes. Stimulus-Responsive 
Emulsifiers Based on Nanocomposite Microgel Particles. Adv. Mater., 
2005, 17, 1014-1018. 
11. T. Chen, P. J. Colver; S. A. F. Bon. Organic–Inorganic Hybrid Hollow 
Spheres Prepared from TiO2-Stabilized Pickering Emulsion Polymerization. 
Adv. Mater. 2007, 19, 2286-2289. 
12. M. Destribats, V. Lapeyre, M. Wolfs, E. Sellier, F. Leal-Calderon, V. 
Ravaine; V. Schmitt. Soft microgels as Pickering emulsion stabilisers: role 
of particle deformability. Soft Matter, 2011, 7, 7689-7698. 
13. S. Wiese, Y. Tsvetkova, N. J. E. Daleiden, A. C. Spieß; W. Richtering. 
Microgel stabilized emulsions: Breaking on demand. Colloid. Surface A, 
2016, 495, 193-199. 
14. E. S. Read, S. Fujii, J. I. Amalvy, D. P. Randall; S. P. Armes. Effect of 
Varying the Oil Phase on the Behavior of pH-Responsive Latex-Based 




Emulsifiers: Demulsification versus Transitional Phase Inversion. 
Langmuir, 2004, 20, 7422-7429. 
15. R. G. Strickley. Solubilizing Excipients in Oral and Injectable Formulations. 
Pharmaceut. Res., 2004, 21, 201-230. 




































































The biological works carried out and presented in this chapter and in chapter 4 are the 
result of a secondment, lasted for a total period of 2 months, at the Technological Park 
of Cantanhede in Portugal, under the co-supervision of Dr. L. Ferreira and with the 
collaboration of his research team, in particular Miss J. Blersch and Dr M. Comune. 
This was part of the European funded PhD program, initial training network (ITN) 
NANODRUG, undertaken by the candidate presenting this thesis.   
Chapter two described the nanogels (NGs) under a material stand point. It is important 
to place the drug delivery system (DDS) in to the context of its intended application. 
Therefore, after a brief introduction on the skin (selected as route of administration), 
this chapter presents the biological properties of NGs in terms of cell cytotoxicity and 
trafficking.  
The dermal delivery route was chosen, for this project, for its great potential which have 
not been yet fully exploited [1]. This was further strengthened by a number of 
collaborations available within the Resmini’s research group via NANODRUG, the 
European Marie Curie ITN that supported financially this study.  
 
4.1.1 Skin as route of administration 
 
The skin is the most extensive and accessible organ of the body (Figure 4.1). Its main 
functions are: defending the body from the external environment, regulating the 
temperature, controlling the output of water and the sensation [2, 3].  
 




Fig. 4.1 Structure and cellular components of the skin in mice and humans. From 
M. Pasparakis et al. Nat Rev. Immunol., 2014, 14, 289-301.   License Number: 
3962990247987.[a].  
It is constituted by three layers: epidermis, dermis and hypodermis. Epidermis, the 
external layer, consists of five individual layers: the stratum germinativum (basal layer), 
stratum spinosum, stratum granulosum, stratum lucidum (found in thick skin) and 
stratum corneum (SC) the outermost layer (Figure 3.2). Cells of this layer are: 
keratinocytes, dendritic melanocytes, Langerhans cells and tactile Merkel cells.  
Moving towards the surface keratinocytes differentiate and slowly undergo apoptosis, 
lose the nucleus, grow in size, get flatter, start to adhere each other and become less and 
less hydrated.  Epidermis has the function to protect the body from external 
environment in particular the SC has the major defensive function. In this layer 
keratinocytes are called corneocytes, they are highly keratinized, with a hexagonal 
shape and organised in cluster. The macrostructure of the SC is generally described 
with the brick and mortar model, where the corneocytes are the bricks and the lipidic 
matrix (secreted at the stratum granulosum–stratum corneum interface) around them is 
the mortar. [3-5] 




Fig. 4.2 Detailed structure of epidermis. From M. A. Farage et al. Cutan. Ocul. 
Toxicol.,2007, 26, 343-357. Permission granted free of charge from Taylor & 
Francis for thesis use. [b]   
 
Dermis, the intermediate layer, is a highly vascularised tissue that is responsible for 
bringing nutrients to the epidermis and clearing the skin from metabolic products and 
permeated compounds. This is the target layer for drugs that are required to be 
administered systemically.  [3-5] 
Hypodermis, the deepest layer, is a tissue rich in collagen and fat, which has the 
function to insulate the body, protect from external shock and offers support to the outer 
layers and it does not play any role in dermal drug delivery. [3, 4] 
There are three routes to skin permeation: two trans-epidermal (intracellular and 
intercellular) and one transapendageal (transport of drugs through hair follicles and 
sweat glands) which are shown in Figure 4.3. Although transapendageal route can be 
used in order to administer large and polar compounds it has a minor impact due to the 
relatively small area (around 0.1% of the total skin surface). On the other end 
administration via both intracellular and intercellular routes is limited by the size of the 
drug delivery system.  




Fig. 4.3 Schematic for the routes of skin penetration. From J. J. Escobar-Chávez et 
al. Ali Demir Sezer (Ed.), InTech, 2012 DOI: 10.5772/50314. (OPEN ACCESS) [c] 
 
It has been hypothesised that only particles with a size lower than 40 nm may permeate 
through the epidermis [6, 7]. Moreover, other factors have to be taken into account for 
the development of transdermal drug delivery system (TDDS) such as: pH, partition 
coefficient, level of skin hydration, thickness and condition of the specific area of skin 
treated. [2-4] 
Dermal drug delivery offers several advantages compared to oral and parental 
administration: 
 Both topical and systemic drug delivery can be achieved. 
 pH influence and harsh condition of gastro-intestinal tract is avoided. 
 The first pass effect (hepatic metabolism) is bypassed. 
 An easy way of access is provided. 
 It is a non-invasive approach. 
 Patient compliance gets improved. [2-4] 
 Several are the drugs, for topical treatment, that can be administered through 
the skin some example may be: anaesthetics such as Lidocaine or Benzocaine, 
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antifungal such as Miconazole or Ketoconazole, anti-inflammatory such as 
Ketoprofen or Diclofenac etc. 
Despite the potential advantages that drug delivery can offer there are still a number of 
issues that need to be addressed in order to fully understand all the possible applications 
and limitations. 
Before presenting the results obtained, an overview of cell lines and biological assays 
used in this study are described in order to justify the experimental work that was 
undertaken to demonstrate NGs suitability for transdermal application.  
 
4.1.2 Skin cell lines 
 
In order to evaluate the potential of these novel methacrylate based nanogels, described 
in chapter two, as a drug delivery system (DDS) for dermal administration, the first step 
involved the study of how the nanoparticles would interact with cells.   
Cytotoxicity, cellular metabolism alteration and cell internalisation (described in the 
following chapter) are the most important parameters that need to be investigated in 
order to demonstrate the suitability of the nanogels for further pharmacological 
employment.  
The selection of cells should always consider the final application of the DDS tested. 
In this case the anatomy of the skin, which is constituted by 4 main cell lines, was taken 
into account. Cells of the tissue are: keratinocytes (major component), fibroblast 
(connective tissue), Langerhans (immune system) and melanocytes (pigment producing 
cells) [8, 9]. In the view of this fact, immortalised human keratinocytes (HaCaT) and 
normal dermal human fibroblast (NDHF) were selected as model cells.  
Before starting to describe the cell lines chosen and the data collected, it is important 
to briefly describe the techniques selected for the biological analysis of the nanogels.   
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4.1.3 Cytotoxicity and metabolism tests 
 
Variations of cell viability and metabolic molecules concentration are important 
guidelines to understand the effects of a given entity to the normal biological 
functioning of cell cultures and allow to make preliminary consideration on the entity’s 
safety and usability. In this study, in particular, the interest lied on the biocompatibility 
of the nanogels, essential requirement for pharmacological applications. 
There are numerous tests available that could be used to evaluate cytotoxicity together 
with a variety of markers for the assessment of metabolic homeostasis of cells.   
Cell toxicity can be determined by: 1) analysis of morphological changes in the cell 
structure; 2) assessment of cell membrane integrity measured by using dyes that enter 
cells only when they are dead or that are actively up taken by living cells; 3) alteration 
of cell growth and 4) metabolic alteration which can be as well correlated to cell 
toxicity. [10] 
Profiting of the collaboration and expertise of Dr. Lino Ferreira and its team from 
Biocant Technological Park in Cantanhede, Portugal, it was decided to employ two 
widely used techniques in order to evaluate nanoprticles’ biocompatibility: the 
propidium iodide and the adenosine triphosphate (ATP) levels assays, which are 
described in the following sections. 
 
4.1.3.1 Propidium iodide assay 
 
Propidium iodide (PI) (Figure 4.4) is a red fluorescent dye that intercalates into the 
DNA and does not permeate through membranes in viable cells [11].  
 




Fig. 4.4 Chemical structure of propidium iodide 
 
Due to its characteristics it is used to identify dead cells by fluorometric analysis of 
cells’ nuclei. When a cell dies, its nucleus membrane integrity gets compromised and 
becomes permeable to PI that is then free to bind nucleic material [12].  PI assay is more 
reliable than tests which are based on dyes actively taken up by viable cells such as 
Almar Blue (resazurin). This is due to several factors: 1) different cell lines may have 
different dye absorption rate making a comparison between them rather difficult; 2) 
interaction between entity tested and resazurin or use of same cell internalisation 
pathway could lead to false positive or negative and 3) cell metabolism modification 
could have an impact on dye internalisation not necessarily related to cell viability [13]. 
Although its advantages, PI has few limitations. Since it binds both DNA and RNA it 
could produce false positive when binding free nucleic acid material [14]. Moreover, 
conventional PI tests employs flow cytometry or microscopy [14-16] which can present 
disadvantages like the need to sacrifice part of the cell culture, risk of cell integrity loss 
and lower throughput [17]. To overcome this issues the PI assays, presented later in this 
chapter, were performed coupling PI and Hoechst 33342 (H33342) cell nuclei staining 
[18] (Figure 4.5) with high content analysis (HSA). HSA is an accurate and reliable 
technique widely used for drug delivery applications, which combines molecular tools 
of cell biology with automated high-resolution microscopy and automated analysis [19]. 
It is important to point out that while PI does not penetrate inside viable cells, Hoechst 
33342 is always able to permeate cell membranes. 
 




Fig. 4.5 Chemical structure of Hoechst 33342 
 
In order to evaluate cytotoxicity, cell line cultures were incubated, at 37 ºC under 5% 
CO2 atmosphere, together with increasing concentration of nanogels (ranging from 10 
to 400 µg/mL) and monitored at different time points (4 and 24 hours mainly) by PI 
incorporation. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) of fetal bovine serum and 1% (v/v) 
penicillin/streptomycin and incubated with Hoechst 33342 and PI, for 15 minutes, prior 
imaging. 
The analyses were performed using an InCell analyser, a high content screening 
microscope which can imaged entire cell plates in relatively short amount of time.   
The microscope can simultaneously image different fluorescent channels together with 
the brightfield (optical microscopy). Moreover, the instrument provides a large amount 
of data easy to process and allows the combination of channels for a more accurate 
analysis and the possibility to extrapolate more information regarding the cell culture.   
Via software it is then possible to implement a segmentation around the nuclei using 
the Hoechst 33342 channel (stain binding the cell nuclei). This means that the software 
will then be able to count cells and identify dead ones by overlapping H33342 with PI 
channels (Figure 4.6). This is further explained in section 4.2.1. 
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Fig. 4.6 Images recorded with the inCell analyser. From left to right: propidium 
iodide channel, Hoechst 33342 channel and merged. 
 
It was previously mentioned that, together with the PI assay, adenosine triphosphate 
levels were also evaluated to provide additional information regarding cell metabolism 
and viability. This technique is described in the following section. 
 
4.1.3.2 Adenosine triphosphate (ATP) assay 
 
Adenosine triphosphate (ATP) is the energy currency of living organisms’ cells [20, 21]. 
Its quantification is used as a technique to evaluate metabolic activity of cells and can 
be correlated to cytotoxicity [21-23].  
In order to evaluate ATP variation, cells were seeded on 96 wells plates and incubated, 
at 37 ºC under 5% CO2 atmosphere, together with increasing concentration of NGs and 
analysed at different time points (4 and 24 hours mainly) after being treated with 
CellTiter-Glo® luminescent kit. The assay consists in the lysis of cells and the 
measurement of fluorescence intensity resulting from the binding between ATP 
molecules and luciferase [23]. As for PI assays, cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) of fetal bovine 
serum and 1% (v/v) penicillin/streptomycin. PI and ATP assays involve different 
procedures and apparatuses.  While in the case of PI the cell culture plate is directly 
analysed at the InCell analyser, ATP levels are measured via a fluorescence plate reader 
that analyses the fluorescence of the cell media, containing the cell lysate, transfered 
Cy3 channel for PI Merged Cy3 and H33342 H33342 channel 
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on  cell plates which are not transparent but completely white to ensure accurate 
fluorescence readout.  
These measurements were recorded by using a microplate reader that determines the 
total fluorescence of each well of the culture plate.  
After the overview on skin organisation and biological assays selected, the following 
section describes the cell lines employed in this work and the results obtained. 
 
 Cell Studies 
 
Before starting to discuss the biological results, the nanogel formulations evaluated in 
this work are presented in the Table below (Table 4.1). This should provide the reader 
a faster correlation of the data presented in this chapter with the chemical composition 
of the nanoparticles. 
 
NG tBAEMA EGMMA MAA MAF MBA CM% Solvent Yield 
Size 
N  
209 55% 0% 20% 5% 20% 0.5% W:Ac 1:1 69% 
70 
±5nm 
211 55% 20% 0% 5% 20% 0.5% W:Ac 1:1 51% 
70 
±5nm 
213 60% 0% 20% 0% 20% 0.5% W:Ac 1:1 91% 
6 
±3nm 
214 60% 20% 0% 0% 20% 0.5% W:Ac 1:1 86% 
9 
±3nm 
Table 4.1 Summary of preparations selected for biological assays. Experimental 
codes (MRGC) are reported in the first column 
 
4.2.1 Immortalised human keratinocytes (HaCaT)  
 
HaCaT cells (Figure 4.7) are immortalised human keratinocytes. The first attempt to 
promote their spontaneous transformation from normal human skin keratinocytes was 
achieved by Azzarone et all. In 1976 and later improved by Baden et all. in 1987 and 
Boukamp et all. in 1988 [24]. The cells are extensively used to understand the epidermal 
Giorgio Chianello PhD Thesis Chapter 4 
140 
 
functioning, as model for skin treatment testing and to perform toxicological studies on 
particles [25-29]. Their wide use is due to their ease of propagation and almost normal 
phenotype [30]. On the contrary non-immortalised keratinocytes are more complex to 
maintain in culture and are not suitable for long term investigation as they rapidly die 
[30].   
 
Fig. 4.7 HaCaT cell line culture where nuclei are stained with 4',6-diamidin-2-
fenilindolo (HOECHST 3342). Image recorded by Ms. Josephine Blersch and 
obtained by using an InCell analyser.  
 
Before describing the biological results obtained it is important to note that each 
individual data reported or shown in the pictures, in this chapter, were extrapolated by 
calculating the mean value of triplicates. Furthermore, the assays were repeated on 
different dates to minimise experimental error and in some cases performed by different 
users to increase randomisation and obtain more significant data.  
As previously mentioned cytotoxicity of nanogel in this cell line was assessed using the 
propidium iodide assay. Upon exposure of HaCaT cell cultures to increasing 
concentrations of nanogels, ranging from 10 up to 400 µg/mL, no cytotoxicity was 
observed up to 24 hours incubation (Figures 4.8 and 4.9). Moreover, very low standard 
deviation (SD) < 1% was observed confirming consistency of results obtained. The 
concentration range was based on literature research [31-36] and suggestions provided by 
Dr. Ferreira’s group, targeting higher concentrations of nanoparticles in order to induce 
a toxic effect. As observed in literature, the effect on cell viability of nanoparticles is 
often observed at concentration lower than 400 µg/mL.  A further test on nanogel 
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cytotoxicity could have been an increase in nanogel concentration in order to identify 
the toxicity starting point. However, particles concentration higher than 400 µg/mL 
would never be used in vivo. Therefore, these experiments were not performed as they 















































Fig. 4.8 Cytotoxicity of nanogels in HaCaT cells after 4 hours incubation reported as 















































Fig. 4.9 Cytotoxicity of nanogels in HaCaT cells after 24 hours incubation reported as 
a mean value of triplicates plus the standard deviation (SD). 




To assess nanoparticles cytotoxicity HaCaT cells were incubated in the presence of 
nanogels. After 4 and 24 hours incubation the cell media was removed and replaced 
with fresh medium containing Hoechst 33342 and PI and the entire plate was screened 
at the InCell analyser. Cell viability was then calculated using the Hoechst 33342 
channel to create a mask layer (Figure 4.10) able to measure number of cell by counting 
cells’ nuclei. This layer was then overlapped with the PI channel to determine the 
number of dead cells. Cells with 10% overlap of PI and H33342 stains were considered 
positive to cell toxicity (dead cells) and substracted to overall number of nuceli 
previously counted. The overlapping allowed avoidance of false positive resulting from 
binding between propidium iodide and free DNA or RNA in the medium. All results 
obtained for cells treated with nanogels were correlated with a control of untreated cells 
cultured in normal media and not exposed to nanogels.   
 
Fig. 4.10 Example of segmentation implemented on Hoechst 33342 channel. 
To further confirm and expand viability data obtained with PI assay, visual analyses of 
cellular morphology modifications were carried out also to assess possible effects not 
immediately detectable with PI assay. Figure 4.11 and 4.12 below show the comparison 
between control cells and cell incubated for 24 hours with both MRGC 213 and 214, at 
the maximum concentration (400 µg/mL). The images show no morphological 
differences between cells incubated with or without NGs. Furthermore, no variation of 
cell growth was observed (cell density). This result provides an additional evidence the 
NGs were nontoxic, in HaCaT cells, under the condition tested. 
 




Fig. 4.11 Control cells (untreated) on the left and cells incubated with MRGC 213 at 
400 µg/mL on the right, after 24 hours  
 
  
Fig. 4.12 Control cells on the left and cells incubated with MRGC 214 400 at µg/mL 
on the right after 24 hours  
 
ATP levels assays were then performed in order to understand the metabolic behaviour 
of cells in the presence of NGs and to further confirm biocompatibility of NPs (Figures 
4.13 and 4.14).   
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HaCaT, ATP levels 4hours


































Fig. 4.13 ATP levels relative to control in HaCaT cells incubated for 4 hours with 
various concentration of NGs reported as a mean value of triplicates plus the standard 
deviation (SD). 
 
Hacat ATP levels 24hours


































Fig. 4.14 ATP levels relative to control in HaCaT cells incubated for 24 hours with 
various concentration of NGs reported as a mean value of triplicates plus the standard 
deviation (SD). 




After the incubation of cells, in 96 well plates for 4 and 24 hours, half of the cell medium 
was removed and replaced with CellTiter-Glo® kit which induce complete lysis of 
cells with consequent release of ATP able to bind with luciferase and therefore emit 
yellow fluorescence. The yellow fluorescent medium was then transfered in a new 
opaque white 96 well plate and screened using a microplate reader equipped with a 
fluorimeter. Intensity readings were normalised to the control (untreated cells) and 
baselined using cell media plus CellTiter-Glo® kit as value 0.    
While figures 4.13 and 4.14 display ATP levels data in a condensed way, Figure 4.15 
below show in a more clear manner the ATP level variation for each individual nanogel.  
HaCat, MRGC 209 ATP levels 4 and 24h


































HaCat, MRGC 211 ATP levels 4 and 24h



































HaCat, MRGC 213 ATP levels 4 and 24h


































HaCat, MRGC 214 ATP levels 4 and 24h



































Fig. 4.15 ATP levels relative to control in HaCaT cells incubated for 4 and 24 hours 
with various concentration of NGs reported as mean value of triplicates plus the 
standard deviation (SD). 
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Slightly higher (in the range of 2-8%) ATP levels in cells treated for instance with 
MRGC 213 may indicate interactions between nanogels and cell components that may 
trigger ATP synthesis. However, with the experiments performed it was not possible to 
identify the real cause of this positive variation which is anyway of a very small extent. 
Results obtained demonstrated no significant and within experimental error variations 
in ATP concentrations (in the range of ± 5% relative to control cells) in cells treated 
with NGs up to 24 hours supporting previous findings. Standard deviation of each 
nanogel concentration was also found low (≤ 3%) further confiming data consistency. 
It is important to note that generally higher values of SD are observed in ATP assays 
compared to PI assays due to the higher complexicty of the first which involve the extra 
step of medium transfer leading to higher variability.  
It should also be considered that HaCaT cells are generally quite resistant to stress and 
exogenous compounds. As an example of this resistance, A. Schmidtt et al. were able 
to develop an HaCat cell line resistant to the extremely toxic sulphur mustard. [37] 
Therefore, in order to confirm nanogel biocompatibility and to obtain results with 
higher consistency it was decided to extend and repeat the same analyses on a more 
sensitive cell line, fibroblast. 
 
4.2.2 Normal dermal human fibroblast (NDHF) 
 
Fibroblast (Figure 4.16) are long, flat, and star-shaped cells extensively distributed in 
the connective tissue and are responsible for the secretion of fibres in the extracellular 
matrix (ECM) [38-40]. They are involved in wound healing, the regulation of epithelial 
differentiation and inflammation [40]. 




Fig. 4.16 Fibroblast cell line culture where nuclei are stained with 4',6-diamidin-2-
fenilindolo (HOECHST 3342). Image recorded by Miss Josephine Blersch and 
obtained by using an InCell analyser.  
 
Incubation of fibroblast with MRGC 209, 211 and 213, for 24 hours, at concentration 
up to 400 µg/mL did not indicate any reduction of cell viability however incubation 
with MRGC 214 showed small signs of cellular death for concentration equal and 
higher than 200 µg/mL (Figures 4.17 and 4.18). Also in this case a low SD < 1% was 
observed demonstrating high data consistency. 
As for HaCaT cell line, PI assay was performed for the assessment of cytotoxicity in 
fibrobalst following the same protocol as for HaCaT cells with the only difference of 
seeding concentration. NDHF were in fact seeded at a density of 5103 cells (due to 
their larger size) while immortalised keratinocytes at 2104 cells.  
















































Fig. 4.17 Cytotoxicity of NGs in Fibroblast after 4 hours incubation reported as a 















































Fig. 4.18 Cytotoxicity of NGs in Fibroblast after 24 hours incubation reported as a 
mean value of triplicates plus the standard deviation (SD). 
 
In the previous paragraph the strength and chemical resistance of HaCaT was 
mentioned, which make them not the most reliable cell line in the estimation of 
cytotoxicity. On the contrary fibroblasts can provide a more accurate view on viability 
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due to their higher sensitivity. Moreover, NDHF are expressed in almost all the tissues 
of human body making them an excellent model for a general toxicological study.  
In addition, fibroblasts are more suitable for shape and growth variation analysis than 
HaCaT cells, as they are bigger in size, possess slower division rate and are generally 
more sensitive to external compounds. Therefore, as for HaCaT cells, a visual 
investigation on NDHF was performed to individuate a correlation between PI assay 
data and the eventual morphological and growth rate changes (Figures 4.19-4.21)  
 
  
Fig. 4.19 Control cells on the left and cells incubated with MRGC 213 at 400 µg/mL 
on the right, after 24 hours  
  
Fig. 4.20 Control cells on the left and cells incubated with MRGC 214 at 200 µg/mL 
on the right, after 24 hours  




Fig. 4.21 Control cells on the left and cells incubated with MRGC 214 at 400 µg/mL 
on the right, after 24 hours  
 
Figure 4.19-4.21 confirmed results obtained with PI assays. While there was no effect 
on morphology and cell viability for MRGC 213, in the case of MRGC 214 it is clear 
that organisational changes and reduction in cell growth were occurring starting from a 
concentration of 200 µg/mL and to a greater extent at 400µg/mL. However, these were 
considered high concentrations and realistically cells would never be exposed to this 
amount of NGs in vivo.  
ATP levels were then evaluated by employing the same protocol used for immortalised 
keratinocytes and with seeding density at 5103 cells as for PI assay.  
Adenosine trisphosphate assay confirmed results achieved with cytotoxicity and 
morphological analyses (Figures 4.22 and 4.23). MRGC 214 at 400µg/mL in particular 
produced a significant decrease in ATP levels, suggesting irreversible effects on 
cellular homeostasis. As the cells dies their energy production decreases giustifying the 
lower levels of ATP observed.  
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Fibroblast, ATP levels 4 hours


































Fig. 4.22 ATP levels relative to control in NDHF incubated for 4 hours with various 
concentration of NGs reported as mean value of triplicates plus the standard deviation 
(SD). 
Fibroblast, ATP levels 24 hours


































Fig. 4.23 ATP levels relative to control in NDHF incubated for 24 hours with various 
concentration of NGs reported as mean value of triplicates plus the standard deviation 
(SD). 
 
As for HaCaT cells, Figures 4.22 and 4.23 are condensed ATP levels graphs of data 
while Figure 4.24 below show in a more clear manner the ATP level variation for each 
individual nanogel. 




Fibroblast, MRGC 209 ATP levels 4 and 24h

































Fibroblast, MRGC 211 ATP levels 4 and 24h


































Fibroblast, MRGC 213 ATP levels 4 and 24h

































Fibroblast, MRGC 214 ATP levels 4 and 24h


































Fig. 4.24 ATP levels relative to control in NDHF incubated for 4 and 24 hours with 
various concentration of NGs reported as mean value of triplicates plus the standard 
deviation (SD). 
 
These novel methacrylate based nanogels proved not to affect cell viability, after 24 
hours incubation, up to a concentration 100 µg/mL both on NDHF and HaCaT cell lines 
herein tested and up to 400 µg/mL in HaCaT. Furthermore, no morphological or 
metabolic variation were observed after cell exposure to nanoparticle, for 24 hours, up 
to 100 µg/mL in fibroblast and up to 400 µg/ml in immortalised keratinocytes, in 
agreement with cytotoxicity results.  Replicates, randomisation together with the fact 
that all the three analyses were confirming the same results, were promising findings 
that laid solid foundations for the further development of this novel drug delivery 
system, which then involved the testing of pharmaceutically active molecules loading 
and releasing capabilities of nanogels, described in chapter four.  
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Having demonstrated the nanoparticles suitability for transdermal delivery 
applications, the focus was then directed toward the assessment of cellular 
internalisation of nanogels and their drug delivery capabilities, in particular 
understanding the possibility to use the nanoparticles as a vehicle for gene therapy.  
Therefore, a third cell line was included in this work to test siRNA release ability of 
nanoparticles and at the same time confirm their uptake by cells.  
The cell line selected was a genetically modified HeLa, expressing green fluorescent 
protein (GFP), able to switch the fluorescence off upon treatment with short interfering 
RNA (siRNA) specific for GFP’s gene. Because an additional cell line was used 
cytotoxicity studies were performed also on HeLa cells and are presented in the next 
paragraph. The internalisation and siRNA release studies are instead described in depth 
in chapter four in order to maintain more defined structure and content of each chapter. 
 
4.2.3 HeLa cells 
 
HeLa are an established cell line originating from cervical carcinoma of a patient named 
Henrietta Lacks (Figure 4.25) [41]. They are among the most widely used cell lines for 
biological studies [42-45].  Furthermore their use have lead to the discovery of a vaccine 
for polio and the award of various Nobel prises [42].  
 
 
Fig. 4.25 HeLa cell line culture where nuclei are stained with Hoechst 3342. Image 
recorded by Miss Josephine Blersch and obtained by using an InCell analyser.  




Propidium iodide assay was carried out in order to test cell viability on HeLa cell 
cultures seeded at a cellular density of 5104. As for immortalised keratinocytes, 
nanogels did not show significant cytotoxicity after 24 hours incubation, with the 
exception of MRGC 214 at a concentration of 400 µg/mL which showed slight 











































Fig. 4.26 Cytotoxicity of NGs in HeLa cells after 24 hours incubation reported as 
mean value of triplicates plus the standard deviation (SD). 
 
In this case toxicological assessment was not performed on cells incubated for 4 hours 
due to time and resources constrains. Although the minor decrease of viability observed 
for MRGC 214, visual comparison between control cells and HeLa incubated in the 
presence of nanogel did not show any morphological or cellular density differences 
(Figure 4.27 and 4.28) 
 




Fig. 4.27 Control cells on the left and cells incubated with MRGC 213 at 400 µg/mL 




Fig. 4.28 Control cells on the left and cells incubated with MRGC 214 at 400 µg/mL 
on the right, after 24 hours  
 
In depth cell viability studies were carried out in NDHF and HaCaT cells, therefore 
ATP levels assay was not performed on HeLa cells as beyond the scope of this study. 
 
 





In conclusion nanogels proved to be non-toxic, after 24 hours incubation, up to a 
concentration of 100 µg/mL in all the cell lines herein tested and up to 400 µg/mL both 
in HaCaT and HeLa cell lines. The results were confirmed by morphological studies, 
cell viability and ATP levels assays and further strengthened by data consistency 
achieved (low SD) These promising results were considered essential for the further 
development of this novel methacrylate based nanogel for drug delivery applications.  
Therefore, after assessing the biocompatibility on different dermal and not dermal cell 
lines, the next step was to assess the capability of nanogels to upload and realease both 
small conventional drugs and macromolecule of biological significance like RNA in 
order to verify their functional capability to be employed in drug delivery. These 
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Chapter V: Drug 





























Chapter 3 illustrated the promising biological properties of the methacrylate based 
nanogels (NGs) that have been obtained. In particular, nanogels transfected into cells 
at concentrations up 100 µg/mL did not induce any cytotoxicity in fibroblasts, HaCat 
and Hela cells. Furthermore, the nanoparticles in the concentrations ranging from 10 to 
100 µg/mL did not show any evidence of inducing cellular morphology or growth 
variations and did not lead to disruption of normal cell metabolism, measured via 
quantification of adenosine triphosphate (ATP) levels. Following the cell studies the 
next step focused on the evaluation of the properties of the nanogels in terms of drug 
uploading and release.  
Table 5.1, shown below, summarises the chemical composition of the NGs used for 
these studies in order to facilitate correlation between chemical structure and data 
herein reported. 
 
NG tBAEMA EGMMA MAA MBA CM% Solvent Yield Size  
213 60% 0% 20% 20% 0.5% W:Ac 5:5 91% 6 ±3nm 
214 60% 20% 0% 20% 0.5% W:Ac 5:5 86% 9 ±3nm 
Table 5.1 Experimental details of the polymer preparations that were used for this 
part of the work, together with data regarding chemical yield of the polymerisation 
and particle size (by number) determined by DLS with 1mg/mL polymer solution in 
water. Chemical composition of the polymerisation mixtures is given as molar 
percentage. tBAEMA is tert-butyl amino ethyl methacrylate, EGMMA is ethylene 
glycol methyl methacrylate, MAA is methacrylic acid and MBA is methylene bis-
acrylamide 
 
In order to expand the range of applicability of the methacrylate based nanogels, it was 
decided to test the ability of nanoparticles to encapsulate large macromolecules as well 
as small drug molecules. In particular as a result of collaborations of the Resmini’s 
group with other research teams, siRNA was identified as a suitable macromolecule 
candidate, while the anti-inflammatory fenoprofen was chosen as small compound. 
While the latter provides an indication of the nanogel suitability for the delivery of 
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conventional therapeutics, siRNA incorporation may extend the nanoparticles’ 
pharmaceutical employment in the promising field of gene therapy.  
This chapter is therefore divided into two main parts: the first one describes siRNA 
incorporation and release studies while the second one focuses on the encapsulation 
efficiency of the naogels in the uploading of the small molecule fenoprofen.    
 
 Large biologically active molecules, siRNA 
delivery 
 
The biological experiments described in this section are the result of a 2 months 
secondment that was undertaken by the candidate presenting this thesis at the Biocant 
Technological Park of Cantanhede in Portugal, under the co-supervision of Dr. L. 
Ferreira and with the collaboration of his research team, in particular Ms. J. Blersch and 
Ms. M. Comune. The candidate himself obtained all the data presented in this section.  
Short interfering RNA (siRNA), also known as small interfering RNA or silencing 
RNA is a 20-25 nucleic acids chain, arranged to form a double stranded RNA, that 
reduces gene transcription by either directly suppressing transcription (transcriptional 
gene silencing [TGS]) or by promoting sequence-specific messenger RNA (mRNA) 
degradation process (posttranscriptional gene silencing [PTGS]) [1] (Figure 5.1). 
  
 




Fig. 5.1 Scheme of siRNA carrier mediated internalisation and gene silencing.  From: 
P. Resnier et al. Biomaterials, 2013, 34, 6429-6443. License Number: 
3970170454005. [a] 
 
Since its discovery in the late 1990s an increasing number of RNA-based therapies have 
been developed and are currently undergoing clinical trials, significantly expanding the 
pharmacological spectrum of conventional drugs, as in principle all the genes can be 
silenced [2].  Short interfering RNA is in fact being tested for the treatment of cancer, 
HIV, cardiovascular diseases, ocular treatment, hypercholesterolaemia etc. [3-7] 
Although siRNA has great therapeutic potential, its usability is limited by several 
factors: the low stability in vivo caused by the presence of ribonucleases (enzymes that 
degrades RNA) both in the serum and in cells; the inability to cross cellular membranes 
due to siRNA’s negative charge; the triggering of an immune response and the high 
glomerular permeability of siRNA which leads to fast kidneys’ excretion rate. [3, 8, 9] 
RNA chemical modification was the initial strategy employed, in the first years 
following the siRNA discovery, in order to avoid ribonucleases degradation and 
elimination by the immune system [10, 11]. However, this approach was not sufficient to 
achieve targeted delivery and overcome most of the biological barriers [3]. Today there 
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are two main approaches used for nucleic acid delivery: viral and non-viral methods. 
Viral vectors are genetic material extracted from viruses where a therapeutic gene is 
inserted, replacing those coding for pathogenic viral proteins, while the genetic 
sequences responsible for viral replication are kept [12]. A vast library of viral vectors, 
including gammaretrovirus, lentivirus and adenovirus to name few, is currently under 
investigation with the most successful ones already undergoing clinical trials. [12-13] 
Despite the high efficiency of viral vectors, this approach has its own limitations. Viral 
vectors are expensive and difficult to produce. Furthermore, concerns have been raised 
regarding their oncogenic, immunogenic and inflammatory potential effects [10, 13-15]. 
Non-viral methods include both the use of nanoparticles as vectors for genetic material 
and physical methods such as ultrasound or electroporation gene administration [13]. 
Although the efficiency of non-viral approaches is still not as high as for viral vectors, 
their wide range of characteristics and tuneable properties together with lower cost, 
absence or reduced immunogenic and carcinogenic power, makes them a promising 
alternative for gene delivery [8, 13-14]. 
In recent years a large number of non-viral carriers for siRNA delivery have been 
reported. Some examples are gold or lipid nanoparticles, polymers synthesised via 
reversible addition-fragmentation chain transfer (RAFT) polymerisation and nanogels 
[16-21]. Advantages of using nanogels for drug delivery were discussed in chapter 1 and 
2 together with the potential and limitations of transdermal delivery described in 
chapter 3. It must be however mentioned that topical skin administration of siRNA 
offers potential applications in the modulation of genes responsible for various 
cutaneous or subcutaneous disorders such as psoriasis, pachyonychia congenital, 
rheumatoid arthritis etc. [22] 
When considering a suitable carrier for siRNA delivery, the negative charge and 
chemical composition of the RNA interference strand have to be taken into account 
(Figure 5.2). Positive charged particles are in fact employed for successful RNA 
complexation [23-25]. 
 




Fig. 5.2 Chemical structure of nucleic bases and basic unit of RNA. 
 
The chemical structures of the methacrylate based nanogel’s functional groups (Figure 
5.3), the nucleic acid bases and the RNA strand (Figure 5.2) allow several ionic and 
electrostatic interactions between the two entities.  
 
 
Fig. 5.3 Chemical structures of NGs’ functional groups. Clockwise: tert-butyl amino 
ethyl methacrylate (tBAEMA), methacrylic acid (MAA), ethylene glycol methyl 
methacrylate (EGMMA) and methylene bis-acrylamide (MBA) 
 
A few examples of these interactions are shown in Figure 5.4 shown below. 
 
 





Fig. 5.4 Examples of electrostatic interactions between functional groups and nucleic 
acid bases together with ionic interactions between NGs and RNA strand. R is the rest 
of the RNA filament. 
 
The great potential of siRNA for transdermal delivery and the affinity between 
silencing RNA and nanogels’ chemical structures were the premises for testing siRNA 
encapsulation and release capability of the nanogels.   
In order to confirm the ability of the nanopartocles to successfully bind and deliver 
siRNA inside the cells, therefore avoiding the premature degradation of the RNA, it 
was decided to employ a model constituted by genetically modified HeLa cell 
expressing green fluorescent protein (GFP) in combination with a siRNA specific for 
the knock down of GFP (GFP Duplex I). HeLa GFP is a well-established biological cell 
model for the evaluation of gene expression and for visualisation purposes [26-28]. The 
details of the HeLa GFP assay are reported later in this chapter. 
The first step in the evaluation of siRNA incorporation and release was the 
complexation of GFP Duplex I with the nanogels. 
 
5.2.1 siRNA (GFP Duplex I) complexation 
 
To promote electrostatic interactions between nanoparticles (NPs) and siRNA, MRGC 
213 and MRGC 214 were suspended in sterile molecular grade, nuclease free, water 
together with GFP Duplex I and GFP Duplex I fluorescently labelled with cyanine 5 
(CY5) (Figure 5.5) at a mass ratio NG : siRNA of 25:1.  
 





Fig. 5.5 Chemical structure of basic cyanine 5. 
 
The labelling of GFP Duplex I with CY5 served as a way to visually localise the siRNA 
during cellular imaging and to evaluate the degree of complexation of siRNA with the 
nanogels.  
The complexation efficiency was determined indirectly by measuring the CY5 residual 
fluorescence in the supernatant of the centrifuged solution of NG : siRNA complexes. 
The protocol was based on the assumption that unbounded siRNA would have remained 
in solution while heavier complexes would have precipitated.  The values obtained were 
subtracted from fluorescence intensity of standard solutions of CY5 tagged siRNA 
previously measured. Furthermore, the fluorescence intensity of a solution of NGs in 
water non-complexed with RNA interference was used as baseline for the analysis of 
GFP Duplex I-CY5 complexed nanogels.  
MRGC 213 and MRGC 214 were both shown to possess high loading efficiency, 
99.4%±0.2. These data were calculated as mean values of triplicates.  Although the 
results may seem high, several other studies, reported in literature, show the 
achievement of similar siRNA uploading efficiency in nanogels as well as for other 
nanoparticles such as liposomes. [23, 29-30] Furthermore the almost identical 
complexation efficiency achieved by the two different nanogel formulations seemed to 
suggest that the ionic interaction between the positive charges of tBAEMA with the 
negatively charged RNA strand plays the key role in the complexation. After this study 
the next step focused on cell transfection. 
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5.2.2 Cell transfection 
 
HeLa cells were transfected with increasing concentration of nanogels ranging from 20 
to 100 µg/mL. The three concentrations used (20, 50 and 100) were selected taking into 
account results obtained while testing cytotoxicity and cell metabolism as described in 
chapter 4, which showed no sign of toxicity, cell morphology changes and adenosine 
triphosphate fluctuations. 
In order to prepare the cells for transfection with the nanogels : siRNA complexes, 
HeLa GFP cells were seeded 24 hours prior to transfection and cultured in full medium 
consisting of DMEM (without phenol red) containing 5% fetal bovine serum (FBS), 
penicillin-streptomycin (PenStrep) and Blasticidin. Phenol red confers a red color to 
the medium. This visually facilitates pipetting into the well plates. However, this color 
could also interfere with the red fluorescence of CY5. For this reason, it was decided to 
employ phenol red free medium. After the pre-transfection, the medium was replaced 
with fresh one containing nanogel-siRNA complexes or Lipofectamine RNAiMAX (a 
transfection vector) for the control cells, in order to compare cells exposed to similar 
conditions. The transfection was performed in starvation medium consisting of DMEM 
only, for 4 hours. The starvation medium was characterized by the absence of the 
essential proteins contained in FBS. This particular medium was used to mimic stress 
condition of cells (the target of nanoparticles employed for drug delivery) and to further 
promote the internalization of the nanogels. 
After 4 hours of transfection, additional medium was added to the cells to give a final 
FBS concentration of 2.5%, reduced from the standard 5%, to decelerate cellular 
proliferation and avoid 100% cell confluency. These conditions were maintained for 48 
hours. When 100% cell confluency is reached there is no more growing space for cells. 
Therefore, new cells, resulting from cellular division, replace old cells leading to their 
detachment from the wells’ walls. When the cells detach from the walls of the well they 
undergo cellular death. In these conditions it becomes difficult to evaluate cell toxicity 
by comparing control cells with nanogel transfected ones, as it would be impossible to 
discriminate between the cell deaths associated with 100% confluency and the eventual 
cytotoxicity caused by the nanoparticles. 
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5.2.3 HeLa GFP knock down  
 
Following 48 hours incubation with nanogels, HeLa GFP cells were stained with 
propidium iodide (PI) and Hoechst H33342 (nuclei staining) to assess cell viability, as 
reported in chapter 4. Dead cells, with compromised cell membrane, were stained by 
both Hoechst H33342 and PI, while live cells were stained only by Hoechst H33342.  
 
Fig. 5.6 Cytotoxicity of NGs in HeLa GFP cells after 48 hours transfection. Reported 
as a mean value of triplicate plus the standard deviation (SD). All values are relative 
to control cells not treated with nanogels. 
 
Data (shown in Figure 5.6) demonstrated no signs of cytotoxicity for HeLa GFP at 
concentrations ranging from 20 to 100 µg/mL, after 48 hours transfection with 
nanogels.  
Together with cell viability, assessment of the fluorescence intensity of the channel for 
CY5 was measured, using high content imaging paired with the automated fluorescence 
microscope, to evaluate siRNA internalisation into cells. As seen in Figure 5.7 intensity 




































Fig. 5.7 CY5 channel fluorescence intensity in cells. Reported as a mean value of 
triplicate plus the standard deviation 
 
The results provided further evidence that the different chemical composition of 
nanogels did not affect significantly the percentage of siRNA complexation and 
confirmed that interaction between tBAEMA with siRNA strand provided the highest 
contribution for the complexation. 
 
However, these data of CY5 fluorescence intensity alone were not enough to confirm 
nanogel internalisation and siRNA release, as fluorescence intensity increase could 
have been due, exclusively, to the presence of loaded NGs in the medium, not 
necessarily internalised inside cells. However, this first result was taken as further 
confirmation that the nanogels were complexed with siRNA.  
Microscope imaging provided additional indications of nanogel internalisation as an 
intense red fluorescence, produced by CY5 (attached to siRNA), was observed in the 



























































Fig. 5.8 HeLa GFP 48 hours after transfection with MRGC 213 – GFP Duplex I/CY5 
100 µg/mL. Cell nuclei stained with Hoechst H33342. Image recorded by Ms. 
Josephine Blersch and obtained by using an InCell analyser. 
 
Furthermore, the final evidence of successful nanoparticles’ internalization and siRNA 
release was provided by the analysis of green fluorescence reduction, as a result of GFP 
knock down operated by GFP Duplex I (Figure 5.9). The inability of “naked” silencing 
RNA to enter the cells and withstand ribonucleases biodegradation was already 
mentioned in this chapter (section 5.1). As a result, the gene silencing effect can only 
be explained by the ability of the novel methacrylate based nanogels to act as carriers 
for the siRNA intracellular delivery.  




Fig. 5.9 Percentage of GFP knock down, relative to control cells, induced by MRGC 
213 and 214 complexed with GFP Duplex I-CY5. Reported as a mean value of 
triplicates plus the standard deviation 
 
GFP knock down was evaluated by comparing overall well fluorescence of the control 
HeLa GFP cells with nanogel transfected cells. All data were reported as mean values 
of triplicates however due to time constrains this experiment was performed only once. 
Preliminary results seemed to indicate that MRGC 213 induced a green fluorescent 
protein knock down of 32% ±4 which was independent from nanogel-GFP Duplex 
I/CY5 complex concentrations, ranging from 20 to 100 µg/mL; on the other hand 
MRGC 214 produced a GFP silencing effect going from 8 ±3 to 28% ±3 and 
proportional to the concentration of nanogel-siRNA complexes used to transfect HeLa 
GFP cells (Figure 5.9). It was hypothesised that the different chemical composition 
between MRGC 213 and 214 may have played a role in the endocytic pathway and 
siRNA release profile of the nanogels.   
Endocytosis is an energy dependent process used by cells to internalise biomolecules, 
ions, signalling molecules and it is also the major route of nanoparticles’ cellular access 
[31, 32]. The purposes of the process are the acquisition of nutrients, the defence against 
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endocytic mechanisms, such as phagocytosis, macropinocytois clathrin-dependent and 
independent etc. (Figure 5.10), they all involve the invaginations of the cellular 
membrane resulting in the formation of vesicles called endosomes [34, 35].  
 
Fig. 5.10 Representation of endocytosis pathways. From G. J. Doherty et al. Annu. 
Rev. Biochem., 2009, 78, 857-902. (OPEN PERMISSION for thesis/dissertation)[b] 
 
Endosomes undergo a maturation process that can be divided in 4 key stages (Figure 
5.11): 1) early endosomes (EE) are the cell compartments immediately after they 
receive the cargo from the extracellular environment; 2) late endosome (LE) are more 
mature vesicles, where the pH ranges from 6 to 4.9 and that progress toward spherical 
shape; 3) LE then grows in size by fusing with other endosome and 4) endosomes fuse 
with lysosome forming endolysosome which are vesicles where their content gets 
degraded by enzymes. 
 




Fig. 5.11 Schematic for endosome/lysosome system (MT= microtubules, TGN= 
trans-Golgi network). From J. Huotari et al. EMBO J., 2011, 30, 3481-3500. (License 
Number: 3926480288417). [c] 
 
In order to exert its biological activity, siRNA needs to be released in the cytosplasm 
[36]. To achieve cytosol release, the nanoparticles need to be able to escape endosome 
pathway as it would eventually lead to their digestion inside the endolysosome (Figure 
5.12). There are several mechanisms of endosomal escape [36, 37]. However, in the case 
of particles rich in proton acceptor groups (such as the amino group of tert-butylamino 
ethyl methacrylate) the so called proton sponge effect is the main mechanism of 
endosomal escape. Essentially the protonation of nanoparticles leads to a flow of H+, 
Cl− and water inside the endosomes, resulting in osmotic swelling and endosome burst. 
[37] 




Fig 5.12 Schematic of nanoparticles’ endocytosis and exocytosis pathways 
(MVBs, multivesicular bodies). From N. Oh et al..  Int. J. Nanomedicine, 2014, 9 
(1), 51-63. (Order License Id: 3926421408563). [d] 
 
In view of these facts, it was hypothesised that MRGC 213, due to the presence of 
additional proton acceptor groups (methacrylic acid moieties), could have escaped 
endosome at an earlier stage than MRGC 214. Therefore, even the lowest MRGC 213 
–siRNA complex concentration of 20 µg/mL was sufficient to obtain the maximum 
GFP knockdown value of around 30 %, probably the highest gene silencing achievable 
with the siRNA employed. However as previously mentioned this experiment was 
performed only once thus this hypothesis will require further experiments in order to 
be confirmed, but due to time constrains additional analyses could not be performed.  
Visual evidences of green fluorescent protein knock down were also shown by 
fluorescent microscopy imaging (Figures 5.13-5.18). Figure 5.13 and 5.14, below, are 
images from the control cells, characterised by intense green fluorescence (Figure 5.13) 
and absence of red CY5 signal (Figure 5.14). 




Fig. 5.13-5.14 Left: HeLa GFP 48 hours after incubation with Lipofectamine 
RNAiMAX. Cell nuclei stained with Hoechst H33342. Merged of CY5, Hoechst 
H33342 and green channels. Right: CY5 channel. Image recorded by Ms. Josephine 
Blersch and obtained by using an InCell analyser. 
 
Images of HeLa GFP transfected with NGs-GFP Duplex I/CY5 (Figures 5.15-5.18) 
showed instead decrease of green fluorescence and intense red signal visible both in the 
merged channels images (Figure 5.15 and 5.17) and in the CY5 channel (Figures 5.16 
and 5.18).  
  
Fig. 5.15-5.16 Left: HeLa GFP 48 hours after transfection with MRGC 213 – GFP 
Duplex I/CY5 100 µg/mL. Cell nuclei stained with Hoechst H33342. Merged of CY5, 
Hoechst H33342 and green channels. Right: CY5 channel. Image recorded by Ms. 
Josephine Blersch and obtained by using an InCell analyser. 




Fig. 5.17-5.18 Left: HeLa GFP 48 hours after transfection with MRGC 214 – GFP 
Duplex I/CY5 100 µg/mL. Cell nuclei stained with Hoechst H33342. Merged of CY5, 
Hoechst H33342 and green channels. Right: CY5 channel. Image recorded by Ms. 
Josephine Blersch and obtained by using an InCell analyser. 
 
Although higher GFP knock down has been elsewhere achieved [38], also thank to 
formulation improvements [39] or with the use of high efficiency viral vector [40], the 
results herein presented are comparable, in terms of GFP knock down percentage, to 
previously reported works. [39, 41]  
HeLa GFP cannot be considered a disease model, therefore additional studies will be 
required for the implementation of these nanoparticles for drug delivery purposes. 
Nevertheless, the proven ability of nanogels to enter the cells and release their payload 
provided good basis for the further development of the system. 
In the next section the ability of methacrylate based nanogels to incorporate and release 
conventional small drugs is presented.  
 
 Drug uploading of small molecule 
 
Following the promising results of cytotoxicity, cell metabolism, nanogels cellular 
internalisation and siRNA release (chapter 3 and 4), it was decided to test encapsulation 
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and release capability of nanogels for small molecules to assess their usability for more 
conventional pharmaceutical applications.  
When evaluating possible drug candidates to be tested for incorporation, the focus was 
directed towards anti-inflammatory drugs that could be used also for the treatment of 
skin disease. In the past years, flufenamic acid was frequently used as model drug 
within the Resmini’s group, therefore it was initially considered [42]. However due to 
the availability of a chondrocytes model for rheumatoid arthritis via a recent 
collaboration with Prof M. Perretti and its research team from Queen Mary University 
of London, fenoprofen was selected as a more suitable molecule as it was already 
employed in the treatment of rheumatoid arthritis. 
Before presenting the results regarding the loading and release of fenoprofen a brief 
introduction on the drug and rheumatoid arthritis is given in the following section.  
 
5.3.1 Rheumatoid arthritis and fenoprofen  
 
Rheumatoid arthritis (RA) is a chronic inflammatory disease which affects cartilages 
and bones of the joints. [43] It is a common condition that affects around 1% of the adult 
population in the developed world, with higher incidence in woman [44-45]. RA is 
triggered by both genetic (predominantly) and environmental risk factors such as 
smoking, the diet, socioeconomic status etc. [43-44]. Several are the treatments employed 
today. They can be divided in: 1) non pharmaceutical involving surgery; 2) 
pharmaceutical including non-steroidal anti-inflammatory drugs (NSAIDs) like 
fenoprofen, analgesics and corticosteroids paired with chemical disease-modifying 
anti-rheumatic drugs (DMARDs) such as methotrexate and 3) biological consisting of 
tumor necrosis factor (TNF) and interleukin (IL) antagonists, B and T cells blocker, 
stem cells and gene therapy. [43-44] 
Despite the large number of therapeutic approaches that are investigated, an ideal 
therapy has yet to be identified, as all the previously mentioned strategies are either 
under development or associated with moderate to high toxic effects [43-44].The use of 
NSAIDs remains the main treatment of choice for RA, with careful consideration of the 
side effects.  
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Fenoprofen (Figure 5.19) is a non-steroidal anti-inflammatory drug (NSAID), also 
analgesic, which is used to treat arthritic conditions and pain [46-47]. 
 
 
Fig. 5.19 Chemical structure of fenoprofen 
 
It is administered orally and it’s commonly associated with headache, drowsiness, 
dizziness, heartburn, constipation, dyspepsia, myalgia, nausea, vomiting etc. [46-47] 
Furthermore, long-term NSAIDs therapies are well known to induce severe 
gastrointestinal, renal, and cardiovascular toxicity when administered for the treatment 
of chronic diseases. [48] This is due to their poor water solubility resulting in reduced 
bioavailability, thus requiring high doses which then cause the side effects [49]. In the 
view of this, the topical and local therapeutic effect achieved via transdermal delivery 
could potentially avoid the side effect associated with NSAIDs.   
It was therefore proposed to employ methacrylate based nanogels as potential carrier 
for fenoprofen with the final purpose of improving the therapeutic profile of the drug.  
The drug incorporation protocol, the evaluation of encapsulation efficiency and loading 
capacity are reported in the following section. 
 
5.3.2 Drug uploading, encapsulation efficiency and drug 
release 
 
Particles which are not formed via self-assembly are generally uploaded with drugs, 
after their synthesis has been completed. Post polymerisation drug encapsulation can 
be achieved in different ways such as:  
 simple drug impregnation by dissolution of both drug and nanoparticles into the 
same solvent followed by sonication or stirring in order to accelerate and force 
interactions 
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  emulsion solvent evaporation method, where an hydrophobic drug is dissolved 
together with the nanoparticles in a volatile non-miscible organic solvent then 
dispersed into water containing surfactants and homogenised via sonication or 
fast agitation letting the organic solvent evaporate 
  the thin layer evaporation method, the technique selected in this work which is 
described later in this paragraph   
 spray drying of either one solutions containing both nanoparticles and drug or 
two separate solutions mixed together, to name few. [50-52]  
This latter technique consists in the fast drying of solution droplets extruded at high 
speed into a cyclone chamber were dry air is circulating through [50]. While spray drying 
offers the advantage of scalability it is also associated with high cost. [50]  
Emulsion evaporation incorporation techniques are widely employed however their use 
is limited to hydrophobic drugs and to drugs and particles which are soluble in the same 
organic solvent. Moreover, the use of surfactants requires further purification processes 
and increase complexity and cost of the system [50]. Simple drug impregnation instead 
is limited by the use of a solvent able to dissolve both drug and NPs at the same time 
and able to allow interaction between the two.  
In order to overcome all the limitations previously discussed, it was decided to use a 
combination between the simple drug impregnation and the emulsion solvent 
evaporation methods. This technique was called thin layer evaporation method. 
Essentially nanogel (MRGC 213) and the drug were added to a volatile organic solvent 
(acetone) in which the drug was soluble but not the nanogel. Then the mixture was 
sonicated for a few minutes and left under stirring in order to let nanoparticles and drug 
interact. The solvent was then removed by rotary evaporation to produce a thin layer of 
particles and drugs on the wall of the flask containing the mixture. Finally, the film was 
re-suspended in high pressure liquid chromatography (HPLC) grade water where the 
nanoparticles were soluble while the drug was only partially soluble. HPLC grade water 
was used since drug encapsulation efficiency was evaluated by employing high pressure 
liquid chromatography coupled with UV detection, using modifications of HPLC 
analytical methods reported in literature [53-54].  The water mixture was left under stirring 
for a few minutes in order to fully dissolve the remaining film and to homogenise the 
system. After the stirring, the mixture was left resting for few minutes in order to allow 
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insoluble fenoprofen to deposit at the bottom of the vessel. The top portion of the 
mixture was filtered through 0.45µm syringe filters an injected at the HPLC. Another 
portion was instead transferred in a centrifuge Eppendorf equipped with a 
polyethersulfone (PES) membrane placed in the middle of the tube and centrifuged 
(Figure 5.20).  
 
Fig. 5.20 Representation of centrifugal filter equipped with PES membrane 
 
These two procedures were used to compare two different purification techniques. They 
were in facts used to remove any insoluble fenoprofen and disaggregate any possible 
dispersed nanogels’ clusters not visible to the naked eye. During centrifugation the 
nanogel-drug suspension was forced through the membrane. Insoluble drug (larger than 
membrane’s molecular cut-off) remained trapped on to the cellulose membrane while 
soluble and adsorbed drug were passing in the acceptor compartment of the Eppendorf. 
The content of the acceptor compartment was then injected showing comparable results 
to injection of filtrate.  HPLC grade water was also added into the donor compartment 
in order to re-dissolve the fenoprofen left and then filtered through 0.45µm syringe 
filters prior HPLC injection. Although MRGC 213 nanogel was used, the experiment 
was named MRGC 219 in order to avoid confusion. 
Previously the partial water solubility of fenoprofen was mentioned, therefore the drug 
alone, without the presence of nanonogels, was treated by using the same procedure 
carried out for MRGC 219 in order to discriminate the amount of fenoprofen dissolved 
in water from the one uploaded into nanogels.  
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Fenoprofen elution time, between 12.5 and 13 minutes (Figure 5.21), was achieved by 
using a mobile phase constituted by acetonitrile : water containing 0.5% acetic acid in 
a volume ratio of 1:1.  
 
 
Fig. 5.21 Chromatographic signal of co-dispersed nanogels and fenoprofen filtrate. 
Two parameters regarding quantification of drug uploading into the nanogels were 
evaluated: 1)  the encapsulation efficiency which is the percentage of drug uploaded 
onto the nanoparticles in respect to the total amount of drug used in the experiment, this 
provides indications on how efficient are the conditions used for drug incorporation and 
the amount of drug loss 2) the loading capacity which is a percentage that express the 
maximum amount of drug that a given mass of nanoparticle is able to carry.  
Knowing the fenoprofen amount fed into the mixture, the encapsulation efficiency was 
then assessed by fitting the data of HPLC injections into the equation of a calibration 
curve previously obtained and adjusting these values by subtracting the amount of drug 
dissolved in water. Via calculations (Equations 5.1 and 5.2), encapsulation efficiency 
was found to be 56% ±1 and loading capacity, 84% ±7, was achieved. [55] This latter 
value was found to be comparable with nanogel uploading capacity attained via similar 
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𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
weight of drug into nanogels
weight of drug fed initially
𝑥100 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%) =
weight of drug into nanogels
weight of nanogels fed initially
𝑥100 
Equation 5.1 and 5.2 
 
The release profile of the fenoprofen-loaded nanogels was obtained by dissolving the 
loaded nanoparticles in phosphate buffer (PBS pH 7.4), transferring the solution in 
dialysis cassette (M.W. cut off 5 KDa) and dyalising it against PBS (pH 7.4) at 37º C 
to mimic body temperature (Figure 5.22).   
 
 
Fig. 5.22 Release profile of fenoprofen from nanogel MRGC 213 at 37º C in PBS (pH 
7.4). 
Release of fenoprofen was monitored over 24 hours by collecting fenoprofen-loaded 
nanogel solution aliquots at differen time points. Results obtained showed almost full 
drug release (86 % ± 3 %) within 10 hours.  
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Dialysis was selected as release evaluation technique due to its well established and 
diffuse use. [58-60] At present only few studies on fenoprofen release from drug delivery 
systems were identified in literature. Available literature evaluates the drug release 
kinetics of fenoprofen from drug delivery systems, which share few similarities with 
nanogels object of this study, such as modified chitosan polymers, chewing gum tablets 
and prodrugs. [61-63] For this reason, an exact and direct comparison may not be possible. 
Moreover, it is important to note that fenoprofen release profile varies depending not 
only on polymers or particles chemical composition but also on the environment 
conditions, such as temperature or buffer solutions, used to carry out the release 
evaluation. [61-63] However, combining fenoprofen release studies available [61-63] with 
drug release profiles achieved with nanogels, [64, 65] it was possible to make a 
comparison with the results herein obtained. In particular doxorubicin release studies 
from pullulan based and polymethacrylic acid based nanogels, performed by K. Na et 
al. and Y.-J. Pan et al. respectively, [64, 65] showed that in certain conditions release 
profiles were comparable to the one shown in Figure 5.23 in terms of time frame and 




In conclusion, preliminary data suggest that methacrylates based nanogels were suitable 
for incorporation and release of both small conventional pharmaceutical compounds 
and large bio-macromolecules. Although more analysis will need to be performed 
before the safe employment of these nanogels in drug delivery, these promising findings 
provided an excellent platform for the further development of these nanoparticles.  
Before providing conclusions and discuss possible future developments of this nanogel 
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6.1.1 Chemicals reagents 
 
Ammonium persulfate, tert-buthylamminoethyl methacrylate (tBAEMA), N,N’-
methylenebis(acrylamide) (MBA), ethylene glycol methyl ether methacrylate 
(EGMMA), diethylamminoethyl methacrylate (DEAEMA), methacrylic acid (MAA), 
bromoacetyl chloride, 2-hydroxyethyl methacrylate, 2,3-dibromomaleimide, 
tetrabutylammonium iodide, 1-butanethiol, oleic acid, methyl myristate,  esterase from 
porcine liver and fenoprofen calcium salt hydrate were purchased from Sigma Aldrich. 
High pressure liquid chromatography (HPLC) grade water, HPLC grade acetone, 
HPLC grade acetonitrile, HPLC grade methanol, anhydrous dimethyl sulfoxide 
(DMSO), ethyl acetate, petroleum ether, acetic acid, 1-octanol, paraffin oil, 
hydrochloric acid 35%, potassium chloride, citric acid monohydrate, citrate dehydrate, 
sodium hydrogen phosphate, potassium dihydrogen phosphate, sodium bicarbonate and 
sodium carbonate were obtained from VWR. 
Sodium hydroxide and sodium chloride were acquired from Fisher scientific. 
Nitrogen (oxygen free) gas was purchased from BOC gases. 
Deuterium oxide (D2O), deuterated chloroform (CDCl3), deuterated DMSO 
((CD3)2SO) from Goss Scientific. 
 
6.1.2 Biological reagents 
 
Normal dermal human fibroblasts (NDHF) and penicillin/streptomycin were obtained 
from Lonza; HaCaT keratinocyte cell line from CLS service; Dulbecco’s modified 
Eagle’s medium (DMEM), Hoechst H33342, HeLa (non GFP) and propidium iodide 
from Sigma Aldrich; sterile molecular grade, nuclease free water from 5prime; fetal 
bovine serum and DMEM (without Phenol Red) from Gibco; GFP Duplex I and CY5 
tagged GFP Duplex I from GE Dharmacon; HeLaGFP cells from CellBiolabs Inc.; 
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Lipofectamine RNAiMAX from Thermo Fisher Scientific and CellTiter-Glo® 
Luminescent Cell Viability Assay from Promega. 
 
6.1.3 Additional consumables 
 
Graphene oxide support film on Lacey  carbon on 400 mesh Cu TEM grids were 
acquired from Agar scientific;  UV cuvettes high precision quartz suprasil 10 mm from 
Hellma; DLS disposable cuvettes DTS0012 and zeta potential disposable cuvettes 
DTS1060  from Malvern; PTFE-faced rubber septa and wheaton transparent glass 
bottles (various volumes) from Sigma Aldrich; acrodisc 13mm syringe filter with 
0.45µm GHP membrane, thin layer chromatography (TLC) plates TLC Silica gel 60G 
F254 20x20 cm and 500 µL centrifugal filters modified polyethersulfone (PES) 
membrane from VWR;  96 well plates from Costar; microliter syringes (various 
volumes) from Hamilton; Research plus pipettes from Eppendorf (various volumes); 
crossover forceps watchmaker 5X steel from Scientific Laboratory Supplies Limited; 
M2 minishaker vortex from IKA and dialysis tubing 3500 Da molecular weight cut-off 




Dynamic light scattering (DLS) measurements and ζ-potential measurements were 
performed using a Zetasizer NaNO ZS from Malvern equipped with a 4 mV He-Ne 
laser operating at λ= 633 nm with a detector placed at 173º angle. 
Imaging were recorded using a transmission electron microscope (TEM) Jeol JEM 
1230 operating at 80 kV equipped with camera from Morada (instrument operated by 
Dr. G. Mastroianni); Leica DMRA2 light microscope equipped with QICLICK CCD 
camera from QImaging for emulsion imaging; high content imaging for the assessment 
of cell toxicity and nanogels’ internalization was performed using the automated 
fluorescence microscope In Cell 2200 from GE Healthcare equipped with a 20x 
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objective and data analyses were then performed on the In Cell Developer software 
from GE Healthcare. 
Samples and chemicals weight was determined using a Radwag AS 60/220 R2. pH 
measurements were carried out using a MP 220 pH meter (Mettler Toledo) equipped 
with inlab micro probe (Mettler Toledo). 
Deionised water was obtained from water purifier Purelab Option (ELGA); evaporation 
processes were performed using a Buchi Rotavapor R-200 and Heidolph G1 and sample 
freeze drying was performed on a Labconco 7752060 
High performance liquid chromatography (HPLC) experiments were performed on 
Infinity series 1200 equipped with UV detector and carbon 18 HPLC column H1-5C18-
250A from Hichrom; Cary Eclipse fluorescence spectrophotometer and Cary 100 UV-
VIS spectrophotometer from Agilent Technologies, both equipped with a thermostat, 
were used for fluorescence and UV analyses respectively.  
FT-IR analyses were performed using a Perkin Elmer Spectrum 100. 
1H-NMR (400 MHz) spectra were recorded using a Bruker 400 MHz instrument and 
analysed using MestReNova software.  
1H-NMR peak multiplicity was reported as seen on NMR spectra and as follow: s 
(singlet), br (broad), d (doublet), t (triplet), q (quartet), quin (quintet), sex (sextet), m 
(multiplet), NMR chemical shift (δ) was reported in part per million (ppm) and J 




6.3.1 Synthesis of nanogels in dymethylsulfoxide, water and 
mixtures of solvents. 
 
A classic NGs synthesis was performed as follow: monomers, cross-linker, initiator and 
fluorophore (in some cases) were all placed into a wheaton bottle. The solvent was 
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poured into the flask which was then sealed with PTFE-faced rubber septa. Through 
the use of a vacuum/nitrogen line, 3 cycles of vacuum, each one followed by a nitrogen 
(oxygen free) cycle, were applied to the polymerisation mixture until no gas bubbling 
was observed. The process served to remove all traces of oxygen which act as radical 
scavenger. After the vacuum/nitrogen cycle the whaeton bottle was placed in a 
sonicating bath for 30 second and then in a oven with the temperature set at 70 ºC for a 
time ranging from 6 to 48 hours. 
The volume required for the nanogel polymerisation together with the moles of initiator 
employed, given a certain mass concentration (CM) and initiator percentage, were 
calculated using the following equations: 
𝑺𝒐𝒍𝒗𝒆𝒏𝒕 𝒗𝒐𝒍𝒖𝒎𝒆 𝒓𝒆𝒒𝒖𝒊𝒓𝒆𝒅 (𝑳) =




Equation 6.1 MSmons is the mass of monomers and MScl is the mass of crosslinker. 
 
𝑴𝒐𝒍𝒆𝒔 𝒊𝒏𝒊𝒕𝒊𝒂𝒕𝒐𝒓 𝒓𝒆𝒒𝒖𝒊𝒓𝒆𝒅 =
(Nmons + 2𝑥Ncl) 𝑥 %𝑖𝑛𝑖𝑡𝑖𝑎𝑡𝑜𝑟
100
 
Equation 6.2 Nmons are the number of moles of monomers and Ncl are the number 
of moles of crosslinker. 
 
 
When solvent mixtures were employed the density value used were calculated 
according to the contribution of each solvent by using the following equation. 
 
𝑆𝑜𝑙𝑣. 𝑚𝑖𝑥 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 = (% 𝑆𝑜𝑙𝑣. 𝐴 𝑥 𝑑𝑒𝑛. 𝑆𝑜𝑙𝑣. 𝐴) + (% 𝑆𝑜𝑙𝑣. 𝐵 𝑥 𝑑𝑒𝑛𝑠. 𝑆𝑜𝑙𝑣. 𝐵) + ⋯ 
Equation6.3 Solv. is solvent and dens. is density. 
Nanogels MRGC 213 and MRGC 214 were found to be the most promising 








6.3.2 Synthesis of MRGC 213 
 
Commercially available tert-buthylamminoethyl methacrylate (91.4 mg, 0.49 mmol), 
N,N’-methylenebis(acrylamide) (24.7 mg, 0.16 mmol),  methacrylic acid (13.8 mg, 
0.16 mmol) and ammonium persulfate (11.0 mg, 0.05 mmol) were placed into a 
wheaton bottle and dissolved in 28.9 mL of a mixture water : acetone in a ratio 1:1 (v/v) 
to obtain a final CM of 0.5%. The bottle was then sealed with a PTFE-faced rubber 
septa. To avoid evaporation of acetone, due to its low boiling point, the bottle was 
placed into ice, let cool down for 2 minutes and vacuum was applied for only 5 seconds. 
With the bottle kept in to the ice bath, nitrogen (oxygen free) was bubbled through the 
solution for 10 minutes by using a long syringe needle (going through the rubber septa) 
reaching the bottom of the bottle and a short syringe needle to allow oxygen exhaustion. 
After nitrogen saturation, the solution was placed in an oil bath set at 40 ºC and left 
reacting for 72 hours. After this time the polymerisation mixture was let cool down at 
room temperature and then dialysed against deionised water to get rid of unreacted 
materials and acetone. The dialysed mixture was then freeze dried to yield 118.9 mg of 
a white soft powder (yield 91.3%). 
Synthesis of fluorescently tagged nanogels was performed following the same 
procedure herein reported, reducing the number of moles of tBAEMA by the number 
of fluorofore’s moles used. 
 
6.3.3 Synthesis of MRGC 214 
 
Commercially available tert-buthylamminoethyl methacrylate (91.4 mg, 0.49 mmol), 
N,N’-methylenebis(acrylamide) (24.7 mg, 0.16 mmol), ethylene glycol methyl ether 
methacrylate (23.5 mg, 0.16 mmol) and (11.0 mg, 0.05 mmol) were placed into a 
wheaton bottle and dissolved in 31 mL of a mixture water : acetone in a ratio v/v 1:1 to 
obtain a final CM of 0.5%.  Bottle was then sealed with a PTFE-faced rubber septa. To 
avoid evaporation of acetone, due to its low boiling point, the bottle was placed into 
ice, let cool down for 2 minutes and vacuum was applied for only 5 seconds. With the 
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bottle kept in to the ice bath, nitrogen (oxygen free) was bubbled through the solution 
for 10 minutes by using a long syringe needle (going through the rubber septa) reaching 
the bottom of the bottle and a short syringe needle to allow oxygen exhaustion. After 
nitrogen saturation, the solution was placed in an oil bath set at 40 ºC and left reacting 
for 72 hours. After this time the polymerisation mixture was let cool down at room 
temperature and then dialysed against deionised water to get rid of unreacted materials 
and acetone. The dialysed mixture was then freeze dried to yield 120.1 mg of a white 
soft powder (yield 86.0%).  
Synthesis of fluorescently tagged nanogels was performed following the same 
procedure herein reported, reducing the number of moles of tBAEMA by the number 
of fluorofore’s moles used. 
 
6.3.4 Fluorescent tag synthesis  
 
As the synthesis of the fluorescent tag was already reported, each intermediate 
compound was only characterised by 1H-NMR. [1-3] 
 





2,3-Dibromomaleimide (2.32 g, 9.10 mmol) was dissolved in diethyl ether (70 mL) and 
cooled to 0 °C in an ice bath. Butanethiol (1.68 g, 18.66 mmol) was added and stirred 
for 5 minutes. Triethylamine (1.844 g, 18.66.33 mmol) was added dropwise to the 
cooled solution. An immediate yellow colour was observed and a white precipitate. 
After the addition of trimethylamine was completed, the solution was allowed to warm 
to room temperature and left to stir for 16 hours. The reaction was monitored by thin 
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layer chromatography (TLC) Rf = 0.31 (ethyl acetate : petroleum ether, 1:9). Diethyl 
ether (70 mL) was added, and the organic solution washed with water (150 mL) and 
then brine (150 mL). The organic layer was dried over anhydrous MgSO4. The solution 
was then filtered and concentrated under vacuum to obtain a crude as an orange oil. The 
crude was purified by flash chromatography on silica gel (ethylacetate : petroleum 
ether, 1:9) to yield the product as an orange oil (0.91 g, 37 %). 1H-NMR (400 MHz, 
CDCl3) δ 7.45-7.30 (N-H, br, 1H), 3.29 (-CH2-, t, 4H, J = 7.5 Hz), 1.64 (-CH2-, quin, 
4H, J = 7.5 Hz), 1.45 (-CH2-, sex, 4H, J = 7.5 Hz), 0.93 (-CH3, t, 3H, J = 7.5 Hz). 
 





 2-Hydroxyethyl methacrylate (HEMA) (13.0 g, 0.1 mol) and triethyl amine (TEA) 
(10.9 g, 0.107 mol) were dissolved in Chloroform (300 mL) and placed in an ice bath. 
Bromoacetyl chloride (15.7 g, 0.1 mol) was then added dropwise. The mixture was let 
reach room temperature and was left stirring for 48 hours. The reaction was monitored 
by TLC Rf = 0.45 (ethyl acetate : hexane, 2:8).  The unreacted bromoacetyl chloride 
was quenched via the addition of methanol (5 mL). The solution was then stirred for 
additional 30 min. The reaction mixture was washed saturated aqueous NaHCO3 (100 
mL) and with water twice (2 × 100 mL). The organic layer was dried over anhydrous 
MgSO4, filtered and concentrated under vacuum to give a brown oil. The crude was 
further purified by flash chromatography on silica gel (ethylacetate : hexane, 2:8) to 
give a colourless oil,(10.8 g, 37%). 1H-NMR (400 MHz, CDCl3) δ 6.13 
(CHtrans=C(CH3)-COO, pseudo d, 1H,), 5.61 (CHcis=C(CH3)-COO, pseudo t, 1H), 4.45 
(-CH2-CH2-COO-CH2-Br, pseudo quin, 2H), 4.39 (-CH2-CH2-COO-CH2-Br, pseudo 
quin, 2H), 4.09 (-CH2-Br, s, 2H), 1.95 (OOC-C(CH3)=CH2, pseudo t, 3H).  
 
 









K2CO3 (228.0 mg, 1.65 mmol) and tetrabutylammonium iodide (40.6 mg, 0.11 mmol) 
were suspended in acetone (30 mL). Acetone solutions of 1 (300.0 mg, 1.10 mmol) 
(10mL) and bromoacetyl methacrylate (2) (274.3 mg, 1.10 mmol) (10 mL) were added 
to the suspension. The mixture was then stirred at room temperature for 50 h and 
monitored by TLC Rf = 0.35 (dichloromethane : petroleum ether,  3:7). After 
completion the reaction solution was filtered and the solvent removed under vacuum. 
The crude product was purified by flash chromatography on silica gel (dichloromethane 
: petroleum ether,  3:7) to yield the product as a yellow oil (280 mg, 57.4%). 1H-NMR 
(400 MHz, CDCl3) δ  6.11 (CHtrans=C(CH3)-COO, br, 1H), 5.59 (CHcis=C(CH3)-COO, 
t, 1H, J = 1.5 Hz), 4.41 (-CH2-CH2-COO-CH2-NR2, m, 2H) 4.35 (-CH2-CH2-COO-
CH2- NR2, m, 2H), 4.27 (-CH2- NR2, s, 2H), 3.30 (-CH2-, t, 4H, J = 7.5 Hz), 1.95 (OOC-
C(CH3)=CH2, t, 3H, J = 1.5 Hz), 1.64 (-CH2-, quin, 4H, J = 7.5 Hz), 1.44 (-CH2-, sex, 
4H, J = 7.5 Hz), 0.93 (-CH3, t, 3H, J = 7.5 Hz).  
 
6.3.5 General procedure for nanogel purification  
 
After polymerisation was completed, the mixture was was allowed to cool down at 
room temperature. At the same time dialysis tubing (molecular weight cut-off 3500 Da) 
were submerged into warm water and kept hydrating for around 30 minutes. The 
mixture was poured into the dyalisis bag using a glass funnel equipped with filter paper. 
The bag was then immersed in a conical flask containing deionised water and equipped 
with a magnetic flea. The water was replaced up to 6 times at increasing time intervals 
in order to allow equilibration between mixture inside the bag and water solution 
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outside it. This procedure allowed the removal of any unreacted materials, short 
polymer chains, traces of initiator and unbounded drugs from the polymerisation 
mixture prior to the isolation of nanogels by freeze drying. 
 
6.3.6 Freeze dry  
 
The content of the dialysis bag was transferred into a round bottom flask (RBF) of at 
least 3 times the volume contained in the dialysis bag using a funnel equipped with 
filter paper. The solution was then rapidly frozen by immerging the flask into liquid 
nitrogen. By holding the RBF from the neck, tilting it 45º degrees and gently turning it, 
the solution was let freezing on the wall of the RBF. This way the ice surface was 
increased leading to a faster and more even ice sublimation. After freezing, the RBF 
was connected to the freeze dryer and let dry for 12-24 hours. The nanogel powder 
obtained appeared as a fluffy white powder for non-fluorescent nanogels and yellow 
for fluorescently labelled nanoparticles.  The powder was then collected and transferred 
into glass vial for storage. The vials were sealed and kept at room temperature.     
 
6.3.7 UV thermal analyses 
 
Thermo-responsive behaviour of nanogels was assessed by monitoring UV 
transmittance percentage variations upon thermal treatment of aqueous solutions of 
NGs in the temperature range between 20 to 60 ºC. Nanogel powders (obtained after 
freeze drying) were dissolved in deionised water at a concentration of 1 mg/mL, 
sonicated for 1 minute and then transferred into 1 cm UV quartz cuvettes. The cuvettes 
were placed in a thermostat and exposed to increasing temperature, ramping up at 1 ºC 
per minutes, in the range between 20 to 60 ºC. UV readings (500 nm) were recorded 
every minute for each temperature point. 
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6.3.8 Fluorophore incorporation assessment 
 
MRGC 209 and 211 were dissolved in a mixture water : acetone 3:7 (v/v) at a 
concentration of 0.5 mg/mL. The solutions were transferred into 1 cm quarts UV 
cuvettes, equilibrated at 25 ºC and their absorbance, in the wavelength range between 
200 and 800 nm (1nm resolution), was recorded. The maximum absorbance values, 
achieved at 411 nm, were then fitted into a calibration curve previously obtained and 
the incorporation efficiency was measured following the equations reported below. 
𝑴𝑨𝑭 𝒊𝒏𝒄𝒐𝒓𝒑𝒐𝒓𝒂𝒕𝒊𝒐𝒏 𝒑𝒆𝒓𝒄𝒆𝒏𝒕𝒂𝒈𝒆 =
µ𝑀 𝑜𝑓 𝑀𝐴𝐹 𝑜𝑏𝑡𝑎𝑖𝑛𝑒𝑑 𝑓𝑟𝑜𝑚 𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑖𝑜𝑛 
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑀𝐴𝐹 µ𝑀 𝑖𝑛 0.5 𝑚𝑔 𝑜𝑓 𝑁𝐺𝑠
 
Equation 6.4 used for the determination of MAF incorporation into NGs. 
Theoretical MAF concentration was previously calculated by using equations shown as 
follow (equation 6.5 and 6.6). 
𝒕𝒉𝒆𝒐. 𝑴𝑨𝑭 µ𝑴 𝒊𝒏 𝟎. 𝟓 𝒎𝒈 𝒐𝒇 𝑵𝑮𝒔 =
𝑡ℎ𝑒𝑜. 𝑀𝐴𝐹 𝑚𝑔 𝑖𝑛 0.5 𝑚𝑔 𝑜𝑓 𝑁𝐺𝑠 𝑥 1000
M. W. of MAF
 
𝒕𝒉𝒆𝒐. 𝑴𝑨𝑭 𝒎𝒈 𝒊𝒏 𝟎. 𝟓 𝒎𝒈 𝒐𝒇 𝑵𝑮𝒔 =
mg of MAF fed 𝑥 fraction yield
total mg of NGs obtained 𝑥 2
 
 
Equations 6.5 and 6.6 used to determine theoretical MAF concentration. M.W is the 
molecular weight. 
 
Calculation were based on the assumption that all nanogel’s components contributed to 
the final yield proportionally to their molar percentages initially fed into the 
polymerisation mixture. 
 
6.3.9 DLS sample preparation  
 
Nanogel powder (obtained after freeze drying) was dissolved in deionised water (or 
DMSO) at a concentration of 0.1 to 1 mg/mL. The mixture was then sonicated for 1 
minute at room temperature. With the use of a graduated 1 or 2 mL syringe, 1mL of the 
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solution was transferred on a disposable plastic cuvette after being passed through a 
0.45µm filter (in order to remove eventual dust particle or fibres). The cuvette was then 
capped and the sample size was analysed. Particle size was analysed 3 times to prevent 
analytical errors. Material method was set to polymer latex, temperature at 25 ºC and 
data were obtained by cumulated analyses of the correlation function using Stokes-
Einstein equation.  
ζ-potential samples were prepared following the same procedure but using a ζ-potential 
cuvette and without the involvement of a filtration step. 
 
6.3.10 TEM sample preparation 
 
Nanogel powder (obtained after freeze drying) was dissolved in deionised water at a 
concentration of 1 mg/mL (0.25 mg/mL for MRGC 214 second attempt). The solution 
was then sonicated for 2 minutes at room temperature (10 minutes for MRGC 214 
second attempt). Using a graduated pipette, 15µl of the solution obtained were 
deposited on to a carbon oxide coated TEM grid (held by the corner using a crossover 
forcep), forming a drop on top of the grid. After 2 minutes of interaction (in order to let 
some particle deposit onto the grid) the excess of water was removed using paper 
triangles cut out from filter paper. The triangles were placed perpendicularly to the grid 
in order to remove the water by capillarity and avoid any contaminations that could 
have resulted from the paper entering in direct contact with the surface of the grid. The 
grid was then let dry completely for 1 or 2 minutes and then stored in the grid holder 
provided by the manufacturer until it was analysed.     
The same process was employed for MRGC 214 nanogels complexed with bovine 
serum albumin (BSA) with the only exception that after sonication 0.5 mL of MRGC 
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6.3.11 Emulsion oil phase and w/o ratio selection 
 
Nanogel powder was dissolved in deionised water at a concentration of 1 mg/mL and 
then sonicated for 1 minute at room temperature. 1mL of this solution was placed in a 
4 mL tall and narrow glass vial and a mark was drawn with a marker pen to indicate the 
phase separation level. Then increasing amount of oil phase were poured into the vial 
starting from 0.1 mL going up to 2 mL. For each volume added the mixture was stirred 
on a vortex at 2500 rpm for 1 minute. Then the mixture was observed for sign of 
emulsion formation. If emulsion was not formed that mixture was discarded, otherwise 
observations were recoded (either reported in a laboratory book or by taking pictures) 
over time until the emulsion was dissolved. If emulsion appeared to be stable, the 
sample was kept for further analysis under the optical microscope.  
 
6.3.12 Emulsion pH test 
 
Five aqueous solutions with various pH were prepared: 1) 0.01M hydrochloric acid 
(HCl) in water; 2) 0.01M NaOH in water; 3) 0.1M citrate buffer solution (pH 4) 
prepared by mixing 0.1M aqueous solution of citric acid monohydrate (59 mL) with 
0.1M aqueous solution of trisodium citrate dehydrate (41 mL); 4) phosphate buffer 
saline (PBS) solution (pH 7.4) prepared by dissolving  NaCl (0.8 g), KCl (0.2 g), 
Na2HPO4 (1.44g)  and KH2PO4 (0.24g)  in deionised water (800 mL), pH was then 
adjusted with HCl and deionised water was added up to a final volume of 1 litre; 5) 
0.1M carbonate buffer (pH 9.2) prepared by mixing 0.1M aqueous solution of sodium 
bicarbonate (84 mL) with 0.1M aqueous solution of sodium carbonate (16 mL). 
Nanogel powders were dissolved in one of the five solutions previously mentioned, at 
a concentration of 1 mg/mL and then sonicated for 1 minute at room temperature. 1 mL 
of this solution was placed in a 4 mL tall and narrow glass vial and a mark was drawn 
with a marker pen to indicate the level of phase separation. Oleic acid (1 mL) was added 
and the two phases were homogenised by stirring on a vortex at 2500 rpm for 1 minute. 
Emulsion formed were monitored over time by taking picture and recording 
observations in laboratory book. 




6.3.13 Optical microscopy protocol 
 
One drop of emulsion was casted and spread onto a microscope glass by using a glass 
pipette. Pictures were then quickly recorded due to the emulsion breakage caused by 
the spreading onto the glass.  
 
6.3.14 Nanogels for cell cultures 
 
Nanogels were dissolved, at a concentration of 2 mg/mL, in cell medium constituted by 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) of fetal 
bovine serum and 1% (v/v) penicillin/streptomycin (PenStrep). The solutions were 
sonicated for 1 minute and then diluted in cell medium to obtain the 5 concentration 
used for cell transfection (10, 50, 100, 200 and 400 g/mL).   
 
6.3.15 HaCat/nanogels incubation  
 
Immortalised human keratinocytes (HaCaT) were seeded at a density of 2104 cells per 
well respectively and cultured in a 96-well plate for 24 hours (37 ºC, 5% CO2) prior to 
nanogel transfection. After 24 hours the medium was removed and the cell were 
incubated with MRGC 209, 211, 213 and 214, dissolved in culture medium at different 
concentrations (10, 50, 100, 200 and 400 g/mL). All transfections were performed 
with three technical replicates. Cell medium was constituted by Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) of fetal bovine serum and 1% 
(v/v) penicillin/streptomycin (PenStrep), as recommended by cells’ providing 
company.  After 4 and 24 hours (two different 96-well plates), CellTiter-Glo® 
luminescent cell viability assay was used to evaluate the adenosine triphosphate (ATP) 
production of the cells following the supplier’s instructions.  ATP level values were 
calculated as the mean value of triplicates normalised for the control cells and baselined 
with the auto-fluorescence of cell medium treated with CellTiter-Glo®. For propidium 
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iodide (PI) cytotoxicity assay, HaCaT cells were seeded at a density of 2104 cells per 
well in 96-well plates and cultured for 24 hours before incubation with nanogels. NPs 
suspended in culture medium at different concentrations (see above) were then added 
to cells. After 4 and 24 hours (two different 96-well plates), PI and Hoechst H33342 
both at a concentration of 1 g/mL were added to cells and incubated for 15 min at 
room temperature (RT) prior to the acquisition of images on In Cell Microscope 2200 
equipped with a 20x objective. Automated image analyses were performed on the In 
Cell Developer software provided with the instrument. Dead cells, with compromised 
cell membrane, are stained for both Hoechst H33342 and PI, while live cells stained 
only for Hoechst H33342. Cell nuclei stained with Hoechst H33342 were segmented 
and counted via software. Cell viability was calculated as the % of dead nuclei from the 
total count of nuclei normalised for the control (untreated cells). 
 
6.3.16 Fibroblast/nanogel incubation 
 
Normal dermal human fibroblasts (NDHF) were seeded at a density of 5103 cells per 
well respectively and cultured in a 96-well plate for 24 hours (37 ºC, 5% CO2) prior to 
nanogel transfection. After 24 hours the medium was removed and the cell were 
incubated with MRGC 209, 211, 213 and 214, dissolved in culture medium at different 
concentrations (10, 50, 100, 200 and 400 g/mL). All transfections were performed 
with three technical replicates. Cell medium was constituted by Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) of fetal bovine serum and 1% 
(v/v) penicillin/streptomycin (PenStrep), as recommended by cells’ providing 
company.  After 4 and 24 hours (two different 96-well plates), CellTiter-Glo® 
luminescent cell viability assay was used to evaluate the ATP production of the cells 
following the supplier’s instructions. ATP level values were calculated as the mean 
value of triplicates normalised for the control cells and baselined with the auto-
fluorescence of cell medium treated with CellTiter-Glo®. For Propidium Iodide (PI) 
cytotoxicity assay, NDHF cells were seeded at a density of 5103 cells per well in 96-
well plates and cultured for 24 hours before incubation with nanogels. NPs suspended 
in culture medium at different concentrations (see above) were then added to cells. 
After 4 and 24 hours (two different 96-well plates), PI and Hoechst H33342 both at a 
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concentration of 1 g/mL were added to cells and incubated for 15 min at room 
temperature (RT) prior to the acquisition of images on In Cell Microscope 2200 
equipped with a 20x objective. Automated image analyses were performed on the In 
Cell Developer software provided with the instrument. Dead cells, with compromised 
cell membrane, are stained for both Hoechst H33342 and PI, while live cells stained 
only for Hoechst H33342. Cell viability was calculated as the % of dead nuclei from 
the total count of nuclei normalised for the control (untreated cells). 
 
6.3.17 HeLa/nanogel incubation 
 
HeLa cells were seeded at a density of 4103 cells per well respectively and cultured in 
a 96-well plate for 24 hours (37 ºC, 5% CO2) prior nanogel transfection. After 24 hours 
the medium was removed and the cell were incubated with MRGC 209, 211, 213 and 
214, dissolved in culture medium at different concentrations (10, 50, 100, 200 and 400 
g/mL). All transfections were performed with three technical replicates. Cell medium 
was constituted by Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% (v/v) of fetal bovine serum and 1% (v/v) penicillin/streptomycin (PenStrep), as 
recommended by cells’ providing company. After 24 hours, propidium iodide (PI) 
cytotoxicity assay was performed. PI and Hoechst H33342 both at a concentration of 1 
g/mL were added to cells and incubated for 15 min at room temperature (RT) prior to 
the acquisition of images on In Cell Microscope 2200 equipped with a 20x objective. 
Automated image analyses were performed on the In Cell Developer software provided 
with the instrument. Dead cells, with compromised cell membrane, are stained for both 
Hoechst H33342 and PI, while live cells stained only for Hoechst H33342. Cell viability 
was calculated as the % of dead nuclei from the total count of nuclei normalised for the 
control (untreated cells).  
 
6.3.18 siRNA complexation 
 
To evaluate Nanogels capability to electrostatically bind siRNA, nanogels (NGs) 
MRGC 213 and MRGC 214 were complexed with siRNA against eGFP (GFP Duplex 
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I and CY5 tagged GFP Duplex I) in a mass ratio of NG:siRNA of 25:1. Therefore, NGs 
were dissolved in sterile molecular grade, nuclease free water to a concentration of 2 
mg/mL. A solution containing 40 µg/mL siRNA and 40 µg/mL CY5 tagged siRNA was 
prepared in sterile molecular grade, nuclease free water. For complexation, equal 
volumes of NGs and siRNA were added to a 1.5 mL Eppendorf tube and incubated at 
room temperature while shaking, at 250 rpm, for two hours on an orbital shaker. The 2 
mg/mL stock solution was then diluted in DMEM (without phenol red) to sample 
concentrations of 20, 50 and 100 µg/mL and directly used for cell transfection and 
determination of complexation efficiency. Complexation efficacy was determined 
indirectly from CY5 tagged siRNA after separating NPs and non-complexed siRNA by 
centrifugation (4ºC, 14000 g; 15 minutes), quantifying CY5 fluorescence in three 
replicates in the supernatant. Concentration was determined relative to a standard curve. 
 
6.3.19 HeLa GFP nanogel transfection and GFP 
knockdown  
 
HeLaGFP cells, cultured in full medium constituted by DMEM (without phenol red) 
containing FBS (10%, v/v), PenStrep (0.5%, v/v, 50 μg/mL,) and Blasticidin (10 
μg/mL), were seeded 24 hours (37 ºC, 5% CO2) prior to experiment in 96 well plates at 
a density of 4103 cells per well. HeLaGFP cells were then transfected with MRGC 
213 and 214 GFP Duplex I/CY5 complexes (20, 50, 100 µg/mL) and with 
Lipofectamine RNAiMAX (1.5 µL/mL) for the control cells in starvation medium 
constituted by DMEM (without phenol red) only. After 4 h of transfection, medium 
was added with final concentration of 2.5% FBS v/v (to decelerate growth in order for 
the cells not to overpass 100% confluency while the assay time) 0.25 % PenStrep (0.5%, 
v/v, 50 μg/mL) and Blasticidin (5 μg/mL). At 48 hours post transfection, cells were 
stained and placed in an automated incubator for further incubation and analysis by 
High Content Imaging with the automated fluorescence microscope In Cell 2200. Cell 
nuclei were stained at 48 h with Hoechst H33342 and propidium iodide (PI). Dead cells, 
with compromised cell membrane, are stained for both Hoechst H33342 and PI, while 
live cells stained only for Hoechst H33342. At 48 h four random fields per well were 
imaged on an In Cell 2200 with a 20x objective. Automated image analyses were 
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performed on the In Cell Developer software. GFP knockdown was accessed from 
mean GFP fluorescence intensity in the cytoplasm of live cells. GFP knockdown was 
expressed in percent with reference to 100% fluorescence in control conditions 
(untreated HelaGFP cells) after subtracting fluorescence background of Hela cells. Cell 
viability was calculated as the % of dead nuclei from the total count of nuclei.  
 
6.3.20 Post polymerisation drug uploading protocol 
 
MRGC 213 (10.40 mg) and fenoprofen (10.90 mg) were placed in a round bottom flask 
(RBF) equipped with a magnetic flea and 15 mL acetone were added. The dispersion 
was sonicated for 10 minutes and then left under stirring (400 rpm) for 6 hours. The 
acetone was evaporated under reduced pressure using a rotavapor until formation of 
white film around the wall of the RBF. The film was suspended in 10 mL of water and 
left stirring (360 rpm) for 2 minutes to homogenise the suspension and then let settle 
for 5 minutes in order to allow precipitation of eventual unsoluble fenoprofen. 1 mL 
from the top of the dispersion was filtered through 0.45 µm syringe and analysed with 
high pressure liquid chromatography coupled with UV detection instrument. 0.5 mL of 
the same dispersion were placed inside a 500 µL centrifugal filters equipped with a 
polyethersulfone (PES) membrane and centrifuged (13200 rpm for 15 minutes).  
The procedure described was employed for the comparison between the two 
purification techniques. However, for the evaluation of encapsulation efficiency and 
loading capacity of nanogels the conditions used were different, as it was necessary to 
work at a fenoprofen concentration over the water saturation point of the drug. 
Therefore, MRGC 213 (4.04 mg) and fenoprofen (10.05 mg) were placed in a round 
bottom flask equipped with a magnetic flea and 10 mL acetone were added. The 
dispersion was sonicated for 10 minutes and then left under stirring (400 rpm) for 6 
hours. The acetone was evaporated under reduced pressure using a rotavapor until 
formation of white film around the wall of the RBF. The film was then suspended in 4 
mL of water and left stirring (360 rpm) for 2 minutes to homogenise the suspension and 
then let settle for 5 minutes in order to allow precipitation of eventual unsoluble 
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fenoprofen. 1 mL from the top of the dispersion was filtered through 0.45 µm syringe, 
diluted by a factor of 2 and analysed at the HPLC. 
At the same time fenoprofen (9.75 mg) was placed in a round bottom flask equipped 
with a magnetic flea and 10 mL acetone were added. The solution was sonicated for 10 
minutes, then the acetone was evaporated under reduced pressure using a rotavapor 
until formation of white film around the wall of the RBF. The film was then suspended 
in 4 mL of water and left stirring (360 rpm) for 2 minutes to homogenise the suspension 
and then let settle for 5 minutes in order to allow precipitation of unsoluble fenoprofen. 
1 mL from the top of the dispersion was filtered through 0.45 µm syringe, diluted by a 
factor of 2 and analysed at the HPLC. This sample was prepared to determine amount 
of fenoprofen dissolved in water. 
 
6.3.21 Fenoprofen uploading quantification  
 
High pressure liquid chromatography coupled with UV detection was used for the 
evaluation of fenoprofen upload. The mobile phase used was constituted by 
acetonitrile/water containing 0.5% acetic acid in a volume ratio of 50:50. Flow was set 
at 1 mL/min and UV spectra were recorded at 230 nm wavelength. Column C18 used 
was kept at 25 ºC by the use of a thermostat. In these conditions the trace of fenoprofen 
had a retention time of 12.5-13 minutes.  
In order to evaluate the percentage of drug incorporated into the nanoparticles a 
calibration curve for fenoprofen was produced by using 5 different concentration points 
of fenoprofen solutions in acetone (Figure 6.1).  




Fig. 6.1 Calibration curve of fenoprofen in acetone. AU = arbitrary units. 
 
Knowing the fenoprofen amount fed into the mixtures and fitting the results, obtained 
after HPLC injections, into the equation of the calibration curve, the encapsulation 




𝑓𝑒𝑛. 𝑐𝑜𝑛𝑐.  𝑖𝑛𝑡𝑜 𝑛𝑎𝑛𝑜𝑔𝑒𝑙𝑠 
 𝑓𝑒𝑛. 𝑐𝑜𝑛𝑐. 𝑓𝑒𝑑 − 𝑓𝑒𝑛. 𝑐𝑜𝑛𝑐. 𝑖𝑛 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
𝑥100 
 
𝐟𝐞𝐧. 𝐜𝐨𝐧𝐜.  𝐢𝐧𝐭𝐨 𝐧𝐚𝐧𝐨𝐠𝐞𝐥𝐬 = 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑛𝑎𝑛𝑜𝑔𝑒𝑙𝑠 𝑝𝑙𝑢𝑠 𝑓𝑒𝑛. −𝑓𝑒𝑛. 𝑖𝑛 𝑤𝑎𝑡𝑒𝑟 
Equation 6.7 and 6.8 where fen. is fenoprofen 
 
𝑳𝒐𝒂𝒅𝒊𝒏𝒈 𝒄𝒂𝒑𝒂𝒄𝒊𝒕𝒚 % =
mass of fen. incorporated
mass of nanogel 
𝑥100 
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6.3.22 Fenoprofen release 
 
MRGC 213 and fenoprofen (mass ratio 1:2.5) were placed in a round bottom flask 
(RBF) equipped with a magnetic flea and 10 mL acetone were added. The dispersion 
was sonicated for 10 minutes and then left under stirring (400 rpm) for 6 hours. The 
acetone was evaporated under reduced pressure using a rotavapor until formation of 
white film around the wall of the RBF. The film was suspended in an amount of 
phosphate buffer (pH 7.4) necessary to achieve a nanogel concentration of 1 mg/mL 
and left stirring (360 rpm) for 2 minutes to homogenise the suspension and then let 
settle for 5 minutes in order to allow precipitation of eventual unsoluble fenoprofen. 
The superatant was then filtered through 0.45 µm syringe in order to remove precipitate 
still dispersed in the supernatant. 5 mL of the filtrate were placed in a 5.5 mL dyalisis 
cassette (3500-4000 M.W. cutoff). The cassette was then immersed in 50 mL of PBS. 
Fenoprofen release profile was evaluated by collecting aliquotes of either the solution 
inside and outside the cassette at different time points from 0 to 24 hours. The aliquots 
were then injected in to an HPLC equipped with UV detector using the same method 
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Chapter VII: Conclusion 




























The work described in this thesis focused on the development of a novel methacrylate 
based nanogel for drug delivery application. The study was divided in three main 
objectives: 1) synthesis and characterisation of the nanogels; 2) in vitro toxicity and cell 
metabolism studies and 3) preliminary evaluation of drug upload and release. 
The synthesis of nanogels was achieved via high dilution radical polymerisation using 
N,N′-methylenebis(acrylamide) (MBA) as cross-linker, azobisisobutyronitrile and 
ammonium persulfate as initiators, a selection of monomer concentration (CM)  and 
diverse methacrylates molecules, at various concentration, including: lauryl 
methacrylate (LMA), ethylene glycol methyl methacrylate (EGMMA), 2-
(diethylamino)ethyl methacrylate (DEAEMA), 2-(tert-butylamino)ethyl methacrylate 
(tBAEMA) and methacrylic acid (MAA), all used with a variety of solvent systems, 
depending on the combinations. This polymerisation technique was shown to give 
significant advantages in terms of good reproducibility, low costs and easy removal of 
unreacted materials.  
As a result of the initial studies, aiming to achieve optimal chemical composition of 
polymerisation mixtures and synthetic conditions, two preparations (MRGC 213 and 
MRGC 214) were identified as the most promising nanogels for dermal drug delivery 
applications due to their reduced particle size (ranging between 5 and 20 nm) confirmed 
both by dynamic light scattering and transmission electron microscopy; good water 
solubility (≥ 3 mg/mL) and emulsion formation capabilities.  
MRGC 213 and 214 were synthesised in a mixture of water : acetone 1:1 using 
ammonium persulfate as initiator and with a CM of 0.5%. Their chemical composition 
was tBAEMA : MAA : MBA and tBAEMA : EGMMA : MBA respectively, in a molar 
ratio of 60:20:20. In order to visually evaluate the fate of nanogels crossing the skin or 
internalising inside cells, nanoparticles covalently labelled with a fluorescent tag 
(MRGC 209 and 211) were prepared. The fluorescent nanoparticles were prepared 
using the same protocol and with similar composition as for MRGC 213 and 214, with 
the only difference being a moles reduction of 5% of tBAEMA in favour of 5% moles 
of 2-(2-(3,4-bis(butylthio)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetoxy)ethyl 
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methacrylate {methacrylate fluorophore} (MAF), for a final chemical composition of 
tBAEMA : MAA : MBA : MAF and tBAEMA : EGMMA : MBA : MAF 55:20:20:5.  
Excellent results were also obtained, in terms of nanogels’ biocompatibility, by testing 
cell cytotoxicity, cellular morphology modifications and adenosine triphosphate levels 
inside cells incubated with various concentrations of fluorescent and non-fluorescent 
nanogels (10, 20, 50, 100, 200 and 400 µg/mL).Viability and cellular morphology 
modification studies were performed on immortalised human keratinocytes (HaCaT), 
normal dermal human fibroblast (NDHF) and HeLa cells while adenosine triphosphate 
levels were carried out only on NDHF and HaCaT cells. No evidence of cell toxicity 
was observed after 24 hours incubation, up to a nanogel’s concentration of 100 µg/mL 
on NDHF and up to 400 µg/mL in HaCaT and HeLa cell lines. Furthermore, no 
morphological or metabolic (ATP levels) variations were observed after cell exposure 
to nanoparticle, for 24 hours, up to 100 µg/mL in fibroblast and up to 400 µg/mL in 
immortalised keratinocytes and HeLa cells, in agreement with cytotoxicity results. 
An important aspect, in the development of these novel nanogels for drug delivery, was 
the evaluation of the nanoparticles ability to incorporate and then release 
pharmaceutically active molecules. Two different therapeutic profiles were considered. 
The first envisaging the use of siRNA as large biomolecule to assess the nanogels’ 
suitability to be used as a vector for gene delivery and the second regarding the 
employment of fenoprofen, a non-steroidal anti-inflammatory drug (NSAID), as a more 
conventional small pharmaceutic. Silencing RNA encapsulation and release were 
evaluated by transfecting genetically modified HeLa cells, expressing green fluorescent 
protein (GFP), with nanogels complexed with a fluorescently labelled siRNA (mass 
ratio 25:1) specific for the knock down of GFP gene (siRNA Duplex I/CY5), at various 
concentration ranging from 20 to 100 µg/mL. A siRNA’s complexation efficiency of 
99% was achieved and GFP knockdown up to 30% was observed, confirming capability 
of nanoparticles to act as vector for silencing RNA release. Preliminary studies on 
fenoprofen incorporation were also performed showing an encapsulation efficiency 
over 55% and high loading capacity over 70%. These results proved the potential of 
nanogels to function as cargo for the drug.  
The time available for this project did not allow to achieve all the desired objectives, in 
particular regarding further characterisations in terms of pharmacology. In view of the 
Giorgio Chianello PhD Thesis Chapter 7 
216 
 
promising physico-chemical and biological features of these methacrylate based 
nanogels, demonstrated in this work so far, further studies are proposed for future 
development and are briefly described in the following section. 
 
 Future works and perspectives 
 
7.2.1 Materials studies 
 
More extensive polymerisation studies could be performed in order to create an 
exhaustive library of methacrylate based nanogels. Additionally, important information 
could be obtained by an in-depth polymerisation kinetic studies which could lead to 
further optimisation of nanogel synthesis. Lastly tests on physicochemical properties of 
nanogel (rheology, thermal properties, resistance to compression and traction etc.) 
could provide additional information on material characteristics and physical 
behaviour.  
 
7.2.2 Emulsion studies 
 
In order to identify a suitable formulation composition and to fully understand the 
action of nanogels at the interface, more tests need to be carried out. In regards to 
formulation composition it is essential to determine the best combination of water/oil 
phases and the optimal nanogels concentration. At the same time, it would be ideal to 
gain information on emulsion performance in function of physical-chemical changes 
such as temperature, ionic strength, presence of impurities etc. 
 
7.2.3 Small drug incorporation and release studies 
 
Following the promising results of fenoprofen incorporation it was considered to assess 
nanogels’ encapsulation efficiency using a molecularly imprinting approach of drug 
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uploading profiting from the expertise of the Resmini’s research group in the field. 
Although these experiments were planned they could not be completed due to time 
constrains.  Moreover, further analyses will be performed in order to further evaluate 
the release profile of the nanogels herein presented.  
 
7.2.4 Biological studies 
 
Additional siRNA complexation and release studies will need to be carried out in order 
to gain an exhaustive understanding of potential gene therapy applications, nanogels 
cell internalisation and content release mechanisms. Furthermore, as a results of a 
collaboration with Prof. M. Perretti and his research team, at Queen Mary university of 
London, a chondrocyte model for rheumatoid arthritis will be available to evaluate the 
ability of the nanogels to target this disease. This experiment has already received 
funding and will be performed by the candidate presenting this thesis. After 
chondrocytes analyses and implementation of siRNA delivery, the system will require 
ex vivo and in vivo testing to bring the nanogels one step closer to the development of 
a final pharmaceutical formulation. Ex vivo models comprise Franz cells equipped with 
membranes or pig skin and penetration studies on human skin obtained from surgery 
procedures, available via a partner research group led by Prof. D. Kelsell from the 
medical school of Queen Mary University of London. Possible animal models include 
zebrafish and mice, accessible via present and past collaborations with research groups 
led by Dr. C. Brennan from the school of biological and chemical of Queen Mary 
University of London (zebrafish) and Prof. V. Preat from the Univerité Cahtolique de 
Louvain, Belgium (mice). 
 
7.2.5 Further development 
 
Although an extensive amount of work still needs to be carried out before the 
pharmaceutical employment of these nanogels, the study highlighted the potential to 
use 2-(tert-butylamino)ethyl methacrylate (tBAEMA) based crosslinked nanoparticles 
as a drug delivery carrier for transdermal application. However, many more 
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applications can be taken into account not only in terms of different route of drug 
administration but also in the development of nano-emulsion synthetic environment or 
as coating agent for organic and inorganic nanoparticles. 
 
 
 
